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Abstract 
 
The stilbene polyphenol trans-resveratrol has shown to interact with several mechanisms 
that may serve to preserve or even enhance cognitive function, either directly or indirectly. 
A small, but growing body of research has found resveratrol is capable of nitric oxide 
(NO)-mediated increases to cerebral blood flow (CBF), which, in turn, serve to increase 
access to the neural metabolic substrates (oxygen & glucose). To date, research has found 
increases in CBF and oxygen extraction resulting from oral resveratrol administration, 
yet these have not been found in conjunction with improved cognitive performance in 
young, healthy samples; questioning the CBF mechanism of resveratrol as an appropriate 
means to enhance cognitive performance.  
 
Additionally, it was hypothesized that the CBF effects of resveratrol may provide 
increased utility in naturally ageing populations, as such cohorts are noted to experience 
reductions to CBF and neural oxygen metabolism; which, in turn, is an acknowledged 
contributor of age-related cognition. To link the reduced neural oxygen availability 
suffered during ageing and subsequent poorer cognitive performance, the current thesis 
also aimed to test the use of hypoxia as a representative, experimental model for the 
cognitive ageing process. The purpose of this model was to provide clear and direct 
evidence that the CBF effects of resveratrol can function to attenuate reductions to 
cognition imposed via a compromised neural fuel supply. Therefore, the four acute, 
placebo-controlled, double-blind, crossover investigations of this thesis aimed to assess 
the efficacy of the resveratrol-mediated CBF effects to engender cognitive enhancement; 
in both young and older adults. 
 
The key findings from this thesis show that there is merit to a hypoxia model of cognitive 
ageing, evidenced by clear cognitive deficits that are also commonly observed with 
ageing cohorts. Furthermore, a single dose of resveratrol showed to increase fuel 
oxidation during cognitive performance when measured via indirect calorimetry. 
However, resveratrol was unable to provide increases to CBF (when measured by Near-
Infrared Spectroscopy) or cognitive performance in hypoxia or in ageing populations. In 
fact, resveratrol was found to impair cognitive performance in the latter. The results of 
this thesis therefore do not support the argument that resveratrol can provide CBF-
mediated cognitive enhancement in healthy, young or naturally ageing samples.  
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Chapter 1 
General Introduction 
1.1 Definition, classification and synthesis of polyphenols 
1.1.1 Occurrence and synthesis of polyphenols 
Plants are immobile and must be self-nourishing, or autotrophic, to survive. Due to their 
stationary nature, plants face several challenges including the risk of nutrient deprivation, 
exposure to ultraviolet radiation and numerous environmental stressors (namely 
pathogens, competing plants and herbivores) (Bennett & Wallsgrove, 1994; Kennedy & 
Wightman, 2011). Consequently, plants synthesize a wide range of phytochemicals that 
perform key roles in enhancing survival and providing protection against environmental 
stressors. It is worth noting that these metabolites do not contribute to the plant’s primary 
physiological or metabolic functioning (such as growth or photosynthesis), but rather 
enhance the survival of the plant, and aid in its ability to overcome challenges in its 
immediate environment (Kennedy & Wightman, 2011). Thus, these phytochemicals have 
been termed ‘secondary metabolites’ (Crozier et al., 2006). The role of these compounds 
within plants has been found to include attraction of pollinators and seed-dispersing 
animals, protection against microbial infection and herbivore attack, and also as 
signalling molecules for interactions between other plants and herbivores (Pichersky & 
Gang, 2000; Kennedy, 2014). There are three main categories of secondary metabolites: 
terpenes, alkaloids and phenolics. The latter of these, will be the sole focus of this thesis.   
Phenolics are initially synthesized from shikimic acid via the shikimate pathway, 
although the acetate malonate pathways can provide components of more complex 
phenolic structures (Kennedy, 2014; pp 143). Some simple phenolic acids can be 
produced directly from shikimic acid but, in most cases, this process then proceeds with 
the essential amino acid L-phenylalanine. This is subjected to hyrdroxylation and 
methylation to form cinnamic acid, which forms the basis of all polyphenols. The 
synthesis of stilbene polyphenols occurs via the phenylpropanoid / malonate pathway. 
Initially phenylalanine, the enzyme phenylalanine ammonia lyase, transforms 
phenylalanine into cinnamic acid. Further action from 4-hydroxylase and 4-coumarate 
CoA ligase convert cinnamic acid to produce P-Coumartl-CoA (Lijavetzky et al., 2008). 
17 
 
Stilbene synthase then converts this into the building block for all stilbene polyphenols, 
including resveratrol. 
1.1.2 Classification, definition and sources of polyphenols 
Possessing a molecular weight of ≥30,000 Da (Bravo, 1998), polyphenols are an 
extensive family of phytochemicals that encompass a diverse range of further sub-
categories. By strict definition, a polyphenol is a compound that structurally contains two 
or more phenolic rings. As phenolic acids possess only one phenol ring, and therefore not 
a polyphenol, the description of these compounds will be omitted from this section. 
Polyphenols are amongst the largest group of secondary metabolites (Castellano et al., 
2012); with more than 10,000 structures now identified. Polyphenols can be divided into 
structural categories based on the number of phenol rings that they contain and the basis 
of structural elements that bind these rings (Li et al., 2014). The first categorisation of 
polyphenols is the partition of flavonoids and non-flavonoids – see Figure 1.0. The 
separation of flavonoids is indexed by their shared structure (C6–C3–C6), comprising two 
6-carbon molecule rings with a further 3-carbon molecule bridge (Kennedy & Wightman, 
2011). As Figure 1 demonstrates, this classification can be further sub-grouped into: 
flavonols (partitioned further into: flavan-3-ols and proanthocyanidins), flavones, 
flavanols (or catechins), flavanones, isoflavones and anthocyanins.  
Arguably the most common of these sub-groups is the flavanols (Crozier et al., 2006), 
found abundantly in fruit and vegetables (Aherne, & O’Brien, 2002), with notable 
examples including quercetin and myricetin. Flavones are found less commonly than 
flavonols in fruit and vegetables (Manach et al., 2004), despite their similar structure. 
Flavones such as apigenin exist in their highest quantities within fresh celery (75 mg/100 
g) and a handful of herbs, such as parsley (1484 mg/100 g fresh matter) (Hanske et al., 
2009). Flavanol catechins like epigallocatechin-3-gallate (EGCG) exist in their most 
prevalent quantities in sources such as green tea, with a standard (250 ml) brewed 
beverage containing around 50–100 mg catechins (Khan & Mukhtar, 2007; Rains et al., 
2011). Other noteworthy flavanols such as (-)-epicatechin, are found in large amounts 
(158.30 mg/100 g) within cocoa (Rothwell et al., 2013). 
Flavanones exist within in a few aromatic plants (e.g. mint), but only citrus fruits appear 
to contain quantities which could be regarded as high (El Gharras, 2009). Examples such 
as hesperidin are found in average quantities of 25.85 mg/100 ml in orange juice 
(Rothwell et al., 2013) with lemons and other citrus fruits providing somewhat smaller 
18 
 
quantities. Usually the fruit itself contains up to 5 times more than its juice, which is 
mainly due to the albedo (the white spongy film between the skin and the flesh) and the 
membranes separating the segments holding a high proportion of flavanones (El Gharras, 
2009). Isoflavones generally originate from (although not limited to) soy sources in 
relatively high concentrations (Setchell, 2000). Most notable examples include daidzein 
and glycitein, with almost all isoflavones found exclusively in legume plants (El Gharras, 
2009). Finally, anthocyanins are perhaps one of the most widespread of the flavonoids, 
which provide the blue, purple and red colour of many fruits, vegetables, and flowers (He 
& Giusti, 2010). In terms of human consumption, one of the most commonly consumed 
anthocyanins is cyanidin; with most anthocyanin food sources consisting of fruits 
(Horbowicz et al., 2008), particularly berries (up to 611 mg/100 g) (Koponen et al., 2007).  
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Figure 1.0 The main sub-groups of polyphenols with dietary examples and the average amount of content (in mg/ g /ml).  Examples, dietary 
information and chemical structures in this diagram were adapted from phenol-explorer version 3.6 (Rothwell et al., 2013).
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1.1.3 Classification and sources of resveratrol 
Figure 1 also details one non-flavonoid group, the stilbene polyphenols. These are 
particularly notable due to their similar structure to flavonoids (C6–C2–C6). The most 
commonly referenced stilbene polyphenol is the phytoalexin resveratrol (3, 4’, 5 
trihydroxystilbene), and is the polyphenol under investigation in this current PhD thesis. 
Resveratrol was first identified in the 1940’s from the roots of white hellebore (Veratrum 
grandiflorum) (Takaoka, 1940) and, later, in Japanese Knotweed (Fallopia japonica) 
(Nonomura et al., 1963). Since then, resveratrol has been found to exist in a number of 
dietary sources including nuts, berries, soy and Itadori tea; yet is most notably associated 
with its presence in red grapes and in turn, red wine (Burns et al., 2002). Resveratrol 
typically exists in two stereoiso-forms, cis or trans; with the latter being the focus of most 
research to date (Giovinazzo et al., 2012). This is potentially due to the trans-isoform 
being more biologically active than cis- (Mukherjee et al., 2010). Consequently, the 
supplementation of the trans-resveratrol isoform will be the focus of this PhD thesis (and 
will be referred to hereafter simply as ‘resveratrol’). Resveratrol has been reported to be 
found in average quantities of .27 mg/ 100 ml in alcoholic red grape wines (Rothwell et 
al., 2013) although these quantities can vary largely according to the colour, type and 
maturity of the grape. 
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1.2 Absorption and bioavailability of polyphenols 
Much has been learned about the possible mechanisms of action of polyphenols and 
potential health benefits once consumed. Yet, how polyphenols and their dietary 
glycoside forms reach their multiple intended sites of action in humans (if at all) is 
complex and multifactorial (Walle, 2004). Therefore, before outlining evidence of the 
bioactivity of polyphenols through epidemiological studies and controlled trials, it is first 
important to outline their absorption, metabolism and distribution. Assessing these factors 
is instrumental in understanding the bioavailability of polyphenols and how this impacts 
their biological activity in vivo.  
 
1.2.1 Absorption, metabolism and bioavailability of polyphenols  
It is first important to consider that even the most common polyphenols in the human diet 
are not necessarily active, with the majority being unable to be absorbed by the small 
intestine effectively. This is largely due to many dietary polyphenols being regarded as 
xenobiotic (foreign) to the human body and thus, the rapid excretion of these compounds 
is a protective mechanism aimed to prevent potential damage (Li et al., 2014). 
Polyphenols are primarily present as either esters, polymers or glycosides (D’Archivio et 
al., 2007), yet only aglycones (with the exception of a few intact glycosides) are believed 
to be absorbable by the body (Williamson & Manach, 2005). The bioavailability of 
individual polyphenols differs even though their metabolism occurs, in general, by a 
common pathway. Polyphenols must be released from their native matrix to pass through 
the intestinal barrier (Valdés et al., 2015). Thus, once orally ingested, polyphenols are 
first hydrolysed by intestinal enzymes to allow for absorption by the small intestine where 
they are subject to absorption via passive diffusion. Here, phenolics undergo extensive 
phase I metabolism (oxidation, reduction, & hydrolysis) in the jejunum and ileum of the 
small intestine. Polyphenols which are not absorbed by the small intestine (for example, 
anthocyanins), reach the large intestine where they are metabolised by the microbiota into 
a wide array of low molecular weight phenolic acids (Scalbert et al., 2002). Alternatively, 
microbial glucuronidases and sulphatases deconjugate the remaining polyphenols to 
allow for the reuptake of aglycones (Lampe, 2009; Valdés et al., 2015).  
Once the final aglycone (or its derivative) has been absorbed, it then undergoes phase II 
metabolism at an enterocyte level (Marín et al., 2015). These resulting aglycones and 
polyphenol monomers are then transported via passive diffusion (Valdés et al., 2015) 
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before metabolic detoxification processes take place in the liver; involving: methylation, 
sulfation, and glucuronidation. This restricts the potential toxic effects of polyphenols and 
enables their elimination through bile and urine; although enterohepatic reuptake 
increases the presence of polyphenols within the body (Manach et al., 2004). From here, 
polyphenol metabolites are then available to be transported into bile, urine or tissues.  
The bioavailability varies greatly between individual dietary polyphenol classes, 
potentially due to their glycosylation structure and the degree of polymerization (Manach 
et al., 2005; Pandareesh et al., 2015); impacting the rate and extent of absorption in the 
small intestine and colon (Cartea et al., 2010). Manach et al. (2005) reported that plasma 
concentrations of total metabolites ranged from 0 to 4 mol/L after an intake of 50 mg 
aglycone equivalents. Moreover, it was found that the urinary excretion values ranged 
from 0.3% to 43% of the intake, which exhibits the variability in the bioavailability of 
individual polyphenol classes. Isoflavones were found to be the best absorbed flavonoids 
with maximal plasma concentration (Cmax) values of approximately 2 mol/L. In contrast, 
proanthocyanidins, (galloylated) tea catechins and anthocyanins, were found to have the 
poorest rate of absorption of the flavonoids examined.  
 
1.2.2 Absorption, metabolism and bioavailability of resveratrol  
The stilbene resveratrol is well tolerated in both animals and humans, even in quantities 
far beyond those usually consumed in the diet (Crowell et al., 2004; Boocock et al., 2007; 
Brown et al., 2009). Due to its chemical structure, resveratrol has a low water solubility 
(<0.05 mg/ mL) and this is believed to be a key factor inhibiting its absorption in vivo 
(Gambini et al., 2015). Despite this, the oral absorption of resveratrol has been estimated 
to be relatively high in humans (approximately 75%) (Walle, 2011; Sergide et al., 2016). 
Resveratrol, in its free (aglycone) state, is taken up by the enterocytes and is conjugated 
with glucuronic acid and sulfates (Brown et al., 2009) thus decreasing circulating levels 
of free trans-resveratrol. Resveratrol undergoes rapid and extensive phase I (oxidation, 
reduction, & hydrolysis) and phase II-pass (glucuronic acid, sulfate, & 
methylconjugations) metabolism (Neves et al., 2012), which results in glucuronide 
resveratrol being the predominant form in plasma following oral dosing; equating to 
approximately 95–99% of total plasma resveratrol (Brown et al., 2009). However, it 
should be noted that metabolism of resveratrol still allows for small quantities of free 
trans-resveratrol in the plasma to be delivered to tissues and this has been found to be 
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increased with higher doses of resveratrol (Boocock et al., 2007). Despite this proportion 
being also present in the excretion of the metabolites, glucuronic and sulfate conjugates 
of resveratrol in human urine and faeces following oral consumption equates to 
approximately 71–98% (Walle et al., 2004); demonstrating that the circulating form of 
resveratrol is principally the modified metabolite (not the original aglycone) (Neves et al., 
2012).  
This rapid biotransformation means that resveratrol concentrations have been initially 
identified after around 30 minutes in humans, with plasma levels peaking after one hour 
(Walle et al., 2004). On review of the literature, peak plasma concentrations have been 
shown to occur between 30-90 minutes post oral administration in humans (Walle et al., 
2004; Vaz-da-Silva et al., 2008; Almeida et al., 2009; Kennedy et al., 2010; Sergides, et 
al., 2016), from a range of dosages (25 mg – 500 mg) with a half-life of between 1-3 
hours from a single dose (Almeida et al., 2009). In addition, due to hepatic and enteric 
recirculation, conjugated metabolites of resveratrol are reabsorbed following intestinal 
hydrolysis; resulting in a final plasma peak at approximately 6 hours post-consumption 
(Walle et al., 2004; Amri et al., 2012). Repeated resveratrol consumption has also been 
found to increase levels of circulating metabolites in comparison to single doses. For 
example, Wightman et al. (2015) found that a 28-day supplementation of 500 mg 
resveratrol resulted in a significant increase in total metabolites levels in comparison to 
day one baseline levels, before and after the final treatment administration. This may 
suggest that resveratrol concentrations can increase from regular exposure; yet, whether 
this can then result in an increase in biological activity of resveratrol is still a matter of 
debate.   
The current thesis takes note of the above pharmacokinetics properties and proposes that 
a 500 mg dose of resveratrol seems to evince a promising profile. Sergides, et al. (2016) 
assessed the absorption and bioavailability of a single, oral dose of 500 mg of resveratrol 
in 15 fasted participants. Peak plasma concentrations were achieved at around 1.3hrs post 
administration and, in line with other investigations within the literature, the predominant 
conjugates identified were glucuronated (62.53%) and sulphated resveratrol (22.73%), 
with small amounts of free resveratrol (0.28% of the total resveratrol) detected. The 
authors concluded the plasma concentrations of resveratrol seen here were above the 
proposed range to promote the pharmacological and biological activities of resveratrol in 
vitro. The following sections will demonstrate that 500 mg resveratrol is capable of 
eliciting significant psychophysiological effects, supported by controlled human trials. 
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1.2.3 Polyphenols, brain localisation and the blood brain barrier (BBB) 
With much evidence now demonstrating that polyphenols and their metabolites can enter 
systemic circulation, investigations have also directed interest at the ability of 
polyphenols to reach the central nervous system (CNS). Indeed, a number of 
epidemiological investigations have found polyphenol rich diets can have a beneficial 
impact on human cognition and brain function (Letenneur et al., 2007; Kesse-Guyot et 
al., 2011; Devore et al., 2012). Although, this may be the result of both direct and indirect 
interactions with the CNS, the capacity by which some polyphenols can exert such 
benefits on brain tissue appears dependent upon their individual ability to traverse the 
brain blood barrier (BBB). Evidence of polyphenols penetrating the BBB in animal 
models is well documented (El Mohsen et al., 2002; Andres-Lacueva et al., 2005; Ferruzzi 
et al., 2009; Janle et al., 2010; Janle et al., 2014). It is notable however, that the quantities 
of polyphenols and their metabolites found within brain tissue is significantly lower than 
the quantities found in other tissues. As an example, supplementation of the flavanol 
quercetin showed its metabolites to be at their lowest concentrations within the brain 
(∼0.12 nmol/g tissue), in comparison to other tissues such as the kidney (11.6 nmol/g 
tissue) and the lung (15.3 nmol/g tissue) within rodents (de Boer, 2005).  
This appears to be a common finding as, on review of the literature, polyphenols have 
been found to localise within brain tissue at levels below 1 nmol/g (Schaffer & Halliwell, 
2012). The degree to which polyphenols can cross the BBB appears dependent upon the 
lipophilicity of individual polyphenols and their capacity to interact with efflux 
transporters (Youdim et al., 2004; Spencer, 2010; Vauzour, 2012). With regards to the 
former, despite glucuronides being found to traverse the BBB (Aasmundstad et al., 1995), 
the Youdim et al. (2003) in vitro model demonstrated that less polar O-methylated 
metabolites have a higher permeability through the BBB, in comparison to their more 
polar glucuronidated conjugates. Interestingly, despite evidence suggesting prolonged 
polyphenol administration may lead to an increase in circulating levels of metabolites 
(Wightman et al., 2015), a handful of chronic studies have suggested that polyphenol 
metabolites may not necessarily accumulate in higher concentrations within the brain 
from regular exposure. For example, chronic supplementation of quercetin failed to 
accumulate in higher concentrations within the brain when compared with a single dose 
in pigs (Bieger et al., 2008) whilst, despite readily crossing the BBB, the activity of 
resveratrol within the brain has been found to last up to only 4 hours in gerbils (Wang et 
al., 2002). This may indicate that concentrations of polyphenols and their metabolites 
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reflect the last meal and may be unable to accumulate in the brain over time (Rendeiro et 
al., 2015). 
Despite some authors finding accumulation in the brain in a non-specific regional manner 
(Janle et al., 2010), polyphenols and their metabolites have been found to accumulate at 
different concentrations in different brain regions (Janle et al., 2014). This includes 
several key areas of the brain such as the hippocampus (Tsai et al., 2011) and cerebral 
cortex (Peng et al., 1998). Indeed, anthocyanins have been found to localise in various 
brain regions important for learning and memory, which may allow them to exert their 
benefits centrally (Andres-Lacueva et al., 2005). Moreover, levels of flavonoids and their 
metabolites have been reported to be sufficient to exert pharmacologic effects, even when 
present at low concentrations (10–300 nM) (Spencer, 2010). Collectively, sufficient 
evidence exists regarding the ability of polyphenols to transverse the BBB and localise 
within brain tissue in quantities sufficient to exert neurological actions.  
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1.3 Polyphenols as cell signalling molecules: the potential for improved health and 
brain functioning. 
The consumption of polyphenols is almost unavoidable given their abundant nature in 
plant tissue (Kennedy, 2014). Although not considered ‘essential’, polyphenols make up 
an inevitable part of the human diet and can be considered phytonutrients. Habitual 
polyphenol consumption has attracted great interest, namely due to increasing evidence 
from epidemiological correlations suggesting that polyphenol rich foods can exert 
beneficial effects on human health (D’Archivio et al., 2010) and aspects of cognitive 
functioning (Nurk et al., 2009; Lamport et al., 2014). 
 
1.3.1 Polyphenol consumption and health: epidemiological correlations 
Recent meta-analyses have revealed total flavonoid intake can significantly reduce all-
cause mortality (Ivey et al., 2015; Liu et al., 2017). Moreover, as cardiovascular disease 
(CVD) and hypertension are the largest causes of mortality in the UK (Bhatnagar et al., 
2015), it is noteworthy that recent epidemiological investigations have also revealed an 
inverse relationship between total polyphenol consumption and the incidence of CVD 
(Wang et al., 2014; Tresserra-Rimba et al., 2014; Medina-Remón et al., 2015). 
Conversely, individuals who consume low quantities of flavonoids have been found to 
display a higher number of non-fatal cardiovascular events in comparison to those who 
consume high amounts of flavonoids (Ponzo et al., 2015). This may imply that the regular 
consumption of polyphenol-rich foods and beverages can lead to cardiovascular benefits. 
As an example, The Mediterranean diet is one that is characterised by copious 
consumption of plant foods (fruit, vegetables, beans, nuts & seeds), whilst consuming 
moderate amounts of dairy products, fish and poultry and low quantities of red meat 
(Willett et al., 1995); this diet therefore, is naturally high in polyphenols. Consequently, 
a series of systematic reviews and meta-analyses have revealed that adherence to the 
Mediterranean diet may reduce mortality and protect against vascular disease (Sofi et al., 
2008; Sofi et al., 2010; Grosso et al., 2015).  
Similarly, habitual consumption of individual flavonoid rich foods such as chocolate 
(Buitrago-Lopez et al., 2011), tea (Arab et al., 2013), fruits and vegetables (Wang, et al., 
2014; Aune et al., 2017) have all been linked with reductions in CVD and its associated 
biomarkers. Red wine has also been credited with cardiovascular benefits and is 
associated with the ‘French paradox’. This is the observation that certain populations 
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(such as the eponymous French) have a low incidence of coronary heart disease (CHD) 
despite a diet rich in saturated fat (Kopp, 1998; de Leiris & Boucher, 2008); this is 
assumed to be due to protective dietary factors, such as moderate consumption of red 
wine. Indeed, consumption of moderate quantities of red wine has been found to lead to 
improvements to blood pressure, endothelial functioning and platelet aggregation 
(Saleem & Basha, 2010). Equally, habitual consumption of grape juice and grape derived 
foods have also shown to significantly reduce the risk of CVD (Dohadwala & Vita, 2009). 
This demonstrates that the cardiovascular benefits of red wine are not the sole result of 
its alcohol content and is likely to be the result of overall grape phenolic content and/or 
the efficacy of individual polyphenols such as resveratrol (Catalgol et al., 2012).  
Alongside the increased risk of CVD, ageing also brings with it an increased risk of 
neurodegenerative diseases and cognitive impairment (Fratiglioni & Qiu, 2009; Bishop 
et al., 2010). Consequently, interest is growing in therapeutic nutritional interventions 
which may offer protection and/or a reduction in risk factors and biomarkers of these 
neurological disorders. Indeed, evidence has also suggested that flavonoid intake may 
contribute to a significant reduction in the risk of dementia (Commenges et al., 2000), 
Parkinson’s (Checkoway et al., 2002) and Alzheimer’s disease (AD) (Dai et al., 2006). 
Moreover, older adults who regularly consume moderate quantities of polyphenol-rich 
red wine have shown a reduced incidence of developing AD, vascular dementia and 
ischemic stroke (Orgogozo et al., 1997; Djoussé et al., 2002).  
Epidemiological correlations have also revealed that dietary polyphenol intake may delay 
the effects of cognitive ageing and maintain brain function. In a longitudinal investigation, 
Letenneur et al. (2007) reported that elderly populations (aged 65≥) in the upper quartile 
for flavonoid consumption scored significantly better on cognitive tasks in comparison to 
those in the lower quartile. On a 10 year follow up, the same authors found that those in 
the lower quartile showed a greater reduction in performance on the tasks in comparison 
to those in the upper quartile. Similarly, a further cross-sectional study of participants 
aged between 70-74 years, revealed that those who habitually consumed a combination 
of chocolate, tea and wine demonstrated significantly superior mean cognitive test scores 
(Nurk et al., 2009). Interestingly, these effects were found to be dose dependent for both 
chocolate (~10 g/day) and wine (75-100 ml/day); with this effect being more pronounced 
for the latter. Habitual tea consumption alone has also been significantly associated with 
a lower prevalence of cognitive impairment (Ng et al., 2008) and associated with lower 
risk of neurocognitive disorders in a dose and duration dependent manner in elderly 
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women (Feng et al., 2016). Additionally, in a recent longitudinal prospective 
investigation, regular consumption of chocolate was shown to reduce global cognitive 
decline in a cohort of 531 participants aged ≥65 on a 2 year follow up (Moreira et al., 
2016). This effect was only observed in individuals who consumed <75 mg of caffeine 
daily. Crichton et al. (2016) also found that more frequent chocolate consumption in older 
adults was significantly associated with better performance on a wide range of cognitive 
domains and assessments. Here, participants who reported to consume chocolate more 
than once a week were found to score significantly better on the Global composite score, 
visual-spatial memory and scanning and tracking. Interestingly, the increases observed in 
cognitive performance in this study were still present even when independent of 
cardiovascular, lifestyle and dietary factors. However, despite white, milk and dark 
chocolate all containing varying amounts of polyphenols (Marsh et al., 2017), the authors 
did not measure the type of chocolate consumed by the participant; making it is difficult 
to identify the exact relationship of polyphenols consumed and the cognitive benefits 
observed.  
The above briefly outlines the potential cardiovascular and cognitive benefits from 
habitual consumption of flavonoid-rich food. However, such results should be interpreted 
with caution as epidemiological evidence is naturally limited due to its susceptibility to 
confounding variables (e.g. social economic status, lifestyle & unknown dietary factors); 
therefore, one can only infer the relationships between average polyphenol consumption 
and their contribution towards health claims and reported mortality. Furthermore, as a 
polyphenol-rich diet also provides high levels of vitamins, minerals and fibre, it becomes 
difficult to determine the efficacy of phenolics alone as these compounds all contribute 
to energy metabolism (Huskisson et al., 2007), brain function (Haller, 2005; Kennedy, 
2016) and are essential for normal cellular functions (Said, 2011). Nevertheless, the above 
has prompted an extensive literature of controlled intervention trials which will be 
outlined further in the subsequent subsections. 
 
1.3.2 Polyphenols as cellular signalling molecules 
The initial attention of polyphenols from the scientific community was based on their 
innate activity as antioxidants based on their ability to scavenge free radical species (e.g. 
reactive oxygen species (ROS)) or their potential ability to influence intracellular redox 
status (Rice-Evans et al., 1995; Rice-Evans, 2001). Given that ROS related mechanisms 
have been indicated as the precursors of several human pathologies (Aruoma, 1998; 
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Moskovitz et al., 2002), this was initially thought to be the underlying basis of all health 
claims of polyphenols. However, despite promising in vitro support for polyphenols to 
function as hydrogen donating antioxidants, there has been little compelling evidence to 
support this in vivo (Halliwell, 2013). This is further reinforced by the observation that 
flavonoid concentrations within plasma and tissues may be too low to effectively reduce 
ROS in humans (Brunetti et al., 2013). This is particularly evident within the brain, where 
concentrations of phenolics and their metabolites fail to localise in large quantities 
(Spencer, 2008; 2010).   
More compelling evidence has suggested that polyphenols and their metabolites are more 
likely to exert their biological activity through their capacity to directly interact with 
cellular transduction and signalling cascades that mediate cellular responses to stressors 
(Kennedy, 2014; pp 162). These survival pathways are a vital mechanism for life, 
particularly for inflammatory, cardiac, and neurological functions (Mansuri et al., 2014). 
Equally, their dysfunction is associated with the pathogenesis of cerebrovascular and 
neurodegenerative diseases (Williams & Spencer, 2012; Kennedy, 2014). The most 
notable of these signalling cascades includes the mitogen-activated protein kinase 
(MAPK) pathway, phosphatidylinositide 3-kinase (PI3K) Akt/protein kinase B (Akt/PKB) 
and protein kinase C (PKC). MAPK in particular, plays a key role in transducing various 
extracellular signals (inclusive of the mitogenic extracellular signal-regulated protein 
kinase (ERK) pathway and the stress activated c-Jun N-terminal kinase (JNK) and p38 
cascades) into intracellular responses to downstream transcription factors, such as nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-kB) and cAMP response 
element-binding protein (CREB).  
In the first instance, polyphenols can initiate cellular signalling at the cell membrane. 
Here, polyphenols can interact with extracellular signalling molecules (namely growth 
factors and hormones) or bind directly to extracellular receptors imbedded within the cell 
membrane (e.g. Tyrosine kinase and G protein receptors), causing a change in the 
conformation of the receptor. This enables the relevant protein receptor to transduce its 
activation into the cell and consequently trigger a signalling cascade encompassing the 
numerous protein kinases (Aiyer et al., 2012; Kennedy, 2014); ultimately leading to the 
activation of downstream transcription factors which drive gene expression (Vauzour et 
al., 2010). Polyphenols and their metabolites can also be taken up into intracellular 
compartments including the cytosol and mitochondria, where they can mediate additional 
biological actions. For example, polyphenols such as EGCG have shown to interact 
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within the cytosol via increases to other intracellular second messengers such as calcium 
(Ca2+) or through binding to nuclear receptors (Kim et al., 2014). 
In addition, polyphenols and their metabolites can also alter the phosphorylation state of 
the components of these cellular signalling cascades (Hou & Kumamoto, 2010; Mansuri 
et al., 2014). This can ultimately result in the removal of proteins attached to transcription 
factors in the cytosol allowing them to translocate to the nucleus, or alternatively, 
interactions with transcription factors within the nucleus (Kennedy, 2014). This may 
suggest that polyphenols can interact selectively within signalling cascades (Spencer, 
2008) as polyphenolic compounds have been found to suppress the phosphorylation of 
various protein kinases with differing affinity and selectivity (Hou et al., 2012). Finally, 
the nature of nuclear receptor ligand-binding may also facilitate flavonoid mediated 
transcriptional regulations (Avior et al., 2013). For example, the flavanone naringenin has 
been found to bind to and activate estrogen receptor α and induce anti-estrogenic effects 
(Ruh et al., 1995).  
 
1.3.3 Molecular targets of resveratrol 
Resveratrol has also been found to interact within cellular transduction and signalling 
cascades. Evidence shows resveratrol can increase or inhibit phosphorylation of 
components of signal transduction pathways (Kumar et al., 2016; Jin et al., 2016), or 
alternatively, mediate effects via modulation of cellular Ca2+ homeostasis (Chang et al., 
2013). Indeed, resveratrol has been found to interact with a number of sirtuins, kinases, 
transcription factors, and multiple other protein targets (Kuršvietienė et al., 2016). Most 
notably, resveratrol has been found to activate sirtuin 1 (SIRT1), a protein that plays a 
key role in the regulation of mitochondrial respiration, metabolic homeostasis and the 
aging process (Cantó & Auwerx, 2009; 2012). Interestingly, activation of SIRT1 has also 
been found to mimic the benefits of calorie restriction (Cantó, 2016); an acknowledged 
means of preventing chronic disease and ultimately extending the lifespan in animal 
models (Bordone & Guarente, 2005). Consequently, administration of resveratrol has 
shown promising results in improving the lifespan and health of metabolically 
compromised mammals (Bhullar et al., 2015). As an example, chronic resveratrol 
administration has shown to extend the lives of mice fed a high fat diet (Baur et al., 2006). 
Such effects may also have ramifications for brain functioning, as supplementation of 
resveratrol in addition to a calorie restricted diet has shown to significantly improve 
cognitive performance in primates (Dal-Pan et al., 2011).  
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SIRT1 is also a precursor for the activation of peroxisome proliferator-activated receptor 
gamma coactivator-1α (PGC-1α); a gene which modulates mitochondrial biogenesis. As 
a result, resveratrol consumption has been suggested to mimic the effects of aerobic 
exercise (Narkar et al., 2008). In support, resveratrol activates SIRT1, heightening PGC-
1α activity and in turn, increases mitochondrial function, improves aerobic capacity and 
subsequently increases energy expenditure (EE) in rodent models (Lagouge et al., 2006). 
It is noteworthy that some authors have questioned the capacity of resveratrol to module 
SIRT1 directly (Baur, 2010). However, it has been proposed that resveratrol can active 
SIRT1 indirectly by binding to phosphodiesterase and triggering cAMP signalling which 
consequently stimulates 5’ adenosine monophosphate activated protein kinase (AMPK) 
(Price et al., 2012). AMPK itself is a key regulator of energy sensing procedures 
(especially under physiological conditions of energy stress, such as exercise and hypoxia), 
and subsequently whole-body metabolism (Kulkarni & Cantó, 2015). Once activated, 
AMPK has been shown to regulate mitochondrial biogenesis (Reznick et al., 2007), 
glycaemic response and energy homeostasis (Hardie et al., 2012). The capacity for 
resveratrol to interact with these energy signalling cascades and proteins may allow for 
whole body and perhaps even cerebral metabolic effects. In support, resveratrol (150 mg 
/day) has been found to improve mitochondrial function in the skeletal muscle and reduce 
basal EE after 30 days administration in obese, but otherwise healthy men (Timmers et 
al., 2014). While, Most et al. (2016) found a 3 day supplementation of a combination of 
both resveratrol (150 mg) and EGCG (300 mg) was capable of increasing both fasting 
and postprandial EE at rest. As EGCG was unable to increase EE alone, the researchers 
concluded either resveratrol alone or a synergistic effect had taken place. This highlights 
that resveratrol has the ability to influence metabolic changes in EE during a fasted state, 
even after short term supplementation. 
 
1.3.4 Polyphenols and brain function 
The capacity of polyphenols to exert their multiplicity of effects on the CNS appears to 
be dependent upon their interactions with numerous protein and lipid kinase signalling 
cascades (Williams et al., 2004; Vauzour, 2017). Here, polyphenols can improve brain 
functioning by the inhibition/attenuation of neuroinflammation, protecting neurons from 
injury and thereby preserving cognitive functioning. Alternately, polyphenols may 
promote memory, learning and cognitive functioning through direct neuronal activation, 
synaptic strengthening and the modulation of cerebral blood flow (CBF) (Spencer, 2010). 
32 
 
 
1.3.4.1 Polyphenols and neuroinflammation 
Inflammation is the principal, localized bodily response to injury or infection. Chronic 
systemic inflammation, however, involves the overproduction of pro-inflammatory 
mediators (such as cytokines). The transcription factor NF-kB has been shown to lead to 
the expression of cytokines and additional inflammatory molecules such as 
cyclooxegenase-2 (COX-2), tumour necrosis factor α (TNFα) and inducible nitric oxide 
synthase (iNOS) (Karunaweera et al., 2015; Lawrence, 2009; Bhat et al., 2002), making 
NF-kB central to both pro and anti-inflammatory responses (Lawrence, 2009; 
Karunaweera et al., 2015). A growing wealth of literature shows that polyphenols can 
inhibit this signalling cascade and reduce pro-inflammatory cytokines in animal models 
(Goya et al., 2016). For example, the flavonoid quercetin has been shown to suppress NF-
κB translocation leading to the inhibition of iNOS and COX-2, within RAW 264.7 cells 
in vitro (Endale et al., 2013). Moreover, resveratrol has also been found to block NF-kB 
activation and subsequent COX-2 expression in mouse skin in vivo (Kundu et al., 2006). 
Despite exploration being somewhat more difficult in humans, a series of reviews have 
shown that polyphenols can reduce inflammatory biomarkers and anti-inflammatory 
effects in humans (Joseph et al., 2016; Goya et al., 2016). The efficacy of polyphenols to 
inhibit inflammatory mediators, may present a cogent therapeutic technique to reduce 
systemic inflammation and its associated risk factors (Gomez-Pinilla & Nguyen, 2012).  
Even ‘normal’ brain aging is associated with elevated levels of neuroinflammation 
(Simen et al., 2011). However, over expression of these pro-inflammatory mediators 
leads to an increase in the risk factor in age-related pathologies (Cevenini et al., 2013) 
including neurodegenerative diseases (Santangelo et al., 2007). Moreover, evidence has 
also suggested that neuroinflammation can obstruct the physiological processes of 
memory and learning and, in turn, may play an important role in the pathogenic 
mechanism underlying many cognitive and behavioural disorders (Scapagnini et al., 
2011). Building on promising epidemiological data, and the ability of polyphenols to 
interact with these inflammatory signalling cascades, it is proposed that polyphenols can 
attenuate inflammation and thus provide support for protection of brain function. Indeed, 
blueberry polyphenols have been found to attenuate learning impairments following the 
insult of neurotoxicity in rodent models via the inhibition of pro-inflammatory mediators 
in rodent models (Shukitt-Hale et al., 2008). Moreover, resveratrol administration can 
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prevent elevations of inflammatory cytokines (TNFα & IL1β) leading to a reversal in age-
related impaired cognitive functions in male Wistar albino rats (Gocmez et al., 2016).  
 
1.3.4.2 Polyphenols and neuroplasticity  
As polyphenols have the capacity to cross the BBB, they also possess the ability to 
directly modulate brain plasticity via modulation of receptor activity (Spencer, 2010; 
Rendeiro et al., 2015). Moreover, evidence has also suggested that flavonoids can exert 
such effects on brain plasticity via modulation of individual cascades such as CREB 
signalling; a transcription factor that can promote gene expression associated with 
synaptic plasticity and memory (Spencer, 2012; Spencer et al., 2012). Conversely, 
disruption to CREB obstructs the formation of memory, particularly long-term memory 
(Bourtchuladze et al., 1994). Xu et al. (2010) found that 7 weeks administration of 
procyanidins (50-100 mg/kg body weight) from lotus seedpod resulted in declines in 
phosphorylation to CREB in the hippocampus of cognitively impaired aged rats. 
Moreover, Williams et al. (2008) demonstrated that supplementation with a (flavonoid-
rich) blueberry diet for 12 weeks, was capable of improving memory performance after 
only 3 weeks, which remained until the end of the testing period in rats. Interestingly, this 
increase in cognitive performance was found alongside the activation of CREB. Although 
no causal relationship can be made, this would certainly imply that there is potential for 
flavonoids to induce direct modulation of cognitive performance.  
The capacity of polyphenols to interact with CREB can also lead to direct protein 
synthesis. Indeed, consumption of polyphenols has been found to elevate levels of brain 
derived neurotrophic factor (BDNF) (De Nicoló et al., 2013). BDNF is a protein that is 
associated with both short term and long-term memory formation (Lu et al., 2014), while 
also being a critical component in synaptic plasticity and long-term potentiation (Baudry 
et al., 2015). Consequently, increased circulating levels of BDNF following chronic 
administration of polyphenols may explain subsequent improvements to memory and 
global cognitive functioning in healthy individuals (Neshatdoust et al., 2016). 
Intriguingly, circulating BDNF levels have also been found to increase after one hour 
following administration of a flavonoid-rich blueberry drink in humans (Dodd, 2012). 
Bell et al. (2015) note that if BDNF levels can increase in a short period of time following 
flavonoid administration, it is unlikely that this facilitation would result in direct global 
cognitive effects after only 1–2 hours. However, the authors do argue that this could result 
in cognitive improvements at later time points. 
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1.3.5 Polyphenols and nitric oxide (NO) signalling 
An alternative cognitive-enhancing mechanism attributed to polyphenols pertains to their 
ability to induce endothelial vasodilation. Several flavonoids have been found to interact 
with the PI3K/ Akt pathway and modulate intracellular Ca2+, leading to an increase in 
endothelial nitric oxide synthase (eNOS) expression (Vauzour et al., 2010). eNOS is 
required for the release of nitric oxide (NO); a cell signalling molecule that modulates the 
vasodilatory response, and therefore regulation of vascular tone and blood flow (Tsai et 
al., 2007; Xia et al., 2014). Cocoa-flavanols in particular have been found to bolster NO 
production and endothelial functioning (Fraga et al., 2010). In support, Schroeter et al. 
(2006) found that oral ingestion of a flavanol-rich cocoa drink (containing 917 mg of 
flavanols) lead to an increase in the concentration of NO-derived species in the plasma 
and urine of healthy subjects. The subsequent vasodilatory actions of acute flavanol-rich 
cocoa are also significantly blunted with the introduction of NG-nitro-L-arginine methyl 
ester (a NO inhibitor) (Fisher et al., 2003).  
Resveratrol has also been credited with the capacity to increase eNOS expression and NO 
production (Xia et al., 2010). In a similar manner to cocoa-flavanols, the ability of 
resveratrol to initiate eNOS-dependent vasodilation results from its capacity to cause an 
initial increase in intracellular Ca2+. This Ca2+ then binds to the calmodulin protein-
binding site that initiates the NOS enzyme (Figure 1.1). Elíes et al. (2011) demonstrated 
that resveratrol induced a concentration-dependent increase in cytoplasmic Ca2+ levels 
within human endothelial cells, in vitro. Interestingly, the authors found that this effect 
was diminished with the introduction of Ca2+ channel blockers, inhibition of intracellular 
Ca2+ release and inhibition of eNOS. The authors argue that resveratrol does not modify 
eNOS activity directly, suggesting instead that the observed inducement of NO generation 
ensues via resveratrol mediated mobilisation of Ca2+. 
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Figure 1.1. The resveratrol interaction with nitric oxide (NO)-dependent 
endothelium vasodilation. The initiation of eNOS is calcium (Ca2+) dependent.  
Resveratrol can incite this initial influx of Ca2+, which binds to the calmodulin protein 
binding site which initiates the NOS enzyme. This then catalyses oxygen and the amino 
acid L arginine, which instigates NO production. This then diffuses into the smooth 
muscle cell from the endothelium, activating soluble guanylyl cyclase (SGC) which, in 
turn, actives cyclic guanosine monophosphate (cGMP). This then stimulates downstream 
protein synthesis, ultimately resulting in smooth muscle relaxation and vasodilatation. 
Figure based on Klabunde (2016).  
eNOS is also the isoform found in the endothelium of cerebral blood vessels (Peterson et 
al., 2011) and mediates the movement of blood through the cerebral arteries and veins 
supplying the brain; playing a key role in maintaining CBF and preventing neuronal injury 
(Greco, 2017). This suggests that the ability of polyphenols to modulate the expression 
of eNOS could result in vasodilation within the brain and, consequently, augmented CBF. 
Considering the above evidence of polyphenol accumulation within specific brain regions, 
this mechanism may lead to the induction of angiogenesis and new cell growth in keys 
areas of the brain associated with learning and memory; such as the hippocampus 
(Spencer, 2010). The capacity of polyphenols to induce modulation of NO-dependent 
vasodilation has also sparked wide interest as an acute method of cognitive enhancement. 
In part, this is due to the hypothesized improved delivery and availability of blood borne 
neural fuels, namely oxygen (O2) and blood glucose, to the brain, via increases in CBF. 
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1.4 The use of polyphenols for cerebrovascular and neurocognitive enhancement. 
The above has briefly outlined the ability of polyphenols to interact with signalling 
pathways within the CNS and how this may potentially offer direct improvements to brain 
functioning via neuronal activation, synaptic strengthening and the inhibition/attenuation 
of neuroinflammation (Spencer, 2010; Rendeiro et al., 2015). Equally, evidence is 
growing to suggest that the capacity of polyphenols to interact with eNOS expression 
which can lead to the modulation of peripheral (in the body) and cerebrovascular blood 
flow. Effective functioning of the endothelium is critical in mediating vascular tone, 
regulating blood pressure, general vascular homeostasis and the avoidance of both 
cardiovascular and cerebrovascular disease (Xia et al., 2014; Bleakley et al., 2015; 
Chistiakov et al., 2015). Moreover, an uncompromised delivery of blood to the cerebral 
vasculature is critical for brain health and functioning (Chen et al., 2014). Therefore, 
given the link between vascular health and cognitive functioning (Dinges, 2006), the 
ability of polyphenols to promote increased blood flow capacity through the modulation 
of endothelial functioning may offer an indirect mechanism by which dietary polyphenols 
may exert their effects on brain function and cognition (Rendeiro et al., 2015). 
 
 1.4.1 Polyphenols and cardiovascular health 
Building on the above epidemiological evidence, which indicated an inverse association 
between polyphenols and CVD (see section 1.3.1), a series of controlled intervention 
studies have demonstrated that administration of individual and a mixture of polyphenols 
can also improve several aspects of cardiovascular functioning. Meta-analyses and 
systematic reviews of randomised, controlled, human trials have revealed both acute and 
chronic consumption of cocoa-flavanols can reduce systolic blood pressure in healthy and 
hypertensive cohorts (Reid et al., 2017). Similarly, chronic supplementation of resveratrol 
in doses of >150 mg/day have been reported to induce a reduction in blood pressure in 
healthy populations with higher doses evincing the greatest consistency across the 
literature (Liu et al., 2015). 
In addition to elevated blood pressure, CVD is also associated with several risk factors 
including increased lipid levels, impaired glucose metabolism and endothelium 
dysfunction (Mozaffarian et al., 2016; Ginsberg, 2000; Brown & Hu, 2001). Interestingly, 
administration of individual polyphenol subclasses including flavanols, flavanones, 
stilbenes and anthocyanins have resulted in significant improvements to these 
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cardiovascular risk factors (Cassidy et al., 2016). For example, on review of randomised 
trials, resveratrol has been found to significantly lower systolic blood pressure, total 
cholesterol and fasting glucose when consumed regularly at doses of ≥300 mg/day 
(Huang et al., 2016). A review of 42 acute and sub-chronic (<18 weeks) studies also found 
that chocolate or cocoa can significantly improve insulin resistance and reduce diastolic 
blood- and mean arterial pressure (Hooper et al., 2012). However, only marginally 
significant effects were found for a reduction in low-density lipoprotein (LDL) and 
increases in high-density lipoprotein (HDL) cholesterol. In a more recent review of the 
literature, Vlachojannis et al. (2016) reported that cocoa-flavanol consumption can result 
in moderate improvements to blood glucose and lipid metabolism in healthy individuals, 
with even stronger associations seen in increased flow-mediated vasodilatation (FMD); a 
quantitated index of endothelial function. 
 
1.4.2 Vasodilatory and blood flow effects of polyphenols 
The above sub-sections demonstrate the ability of polyphenols to interact with eNOS 
expression and, in turn, to enhance the vasodilatory response and endothelial functioning.  
Controlled intervention trials with cocoa-flavanols support such mechanisms in humans. 
For example, Fisher et al. (2003) found that supplementation with 821 mg of flavanol-
rich cocoa, across four consecutive days (in daily 230 ml drinks), significantly increased 
peripheral FMD. Moreover, an acute dose administered on the fifth day had an even more 
pronounced effect within the young, healthy cohort. Meta-analyses and systematic 
reviews since have shown that FMD can be improved after both chronic and acute 
supplementation with cocoa-flavanols, with optimal effects resulting from 500 mg, 2 
hours after consumption (Hooper et al., 2012). Additionally, citrus fruit flavanones such 
as hesperidin have also demonstrated a capacity to bolster NO production and endothelial 
vasodilatation (Rizza et al., 2011) and has been causally linked to the microvascular 
endothelial reactivity effects of orange juice (Morand et al., 2011). Likewise, tea 
polyphenols have shown to increase FMD from acute and chronic dosing in controlled 
human trials (Grassi et al., 2008; Duffy et al., 2001; Hodgson, et al., 2002).  
Endothelial function is a key indicator of cardiovascular health and its dysfunction can 
lead to an impaired vasodilatory response and a reduction in blood flow capacity. Several 
lifestyle factors have been shown to compromise the endothelium in the vasculature, 
including smoking and obesity (Verze et al., 2015; Park & Park, 2015). This is attributed, 
in part, to both smoking and obesity reducing NO bioavailability and consequently 
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hindering the vasodilatory responsiveness of the endothelium (Messner & Bernhard, 
2014). Interestingly, it has been proposed that the ability of polyphenols to increase blood 
flow via NO-dependent signalling may provide an increased utility in such cohorts with 
endothelial dysfunction. In support of this, Heiss et al. (2006) demonstrated that acute 
administration with a flavanol-rich cocoa beverage (176-185 mg) was capable of 
improving NO bioavailability and consequently endothelium-dependent dilation in 11 
smokers. Further improvements to blood pressure and endothelial functioning have been 
observed from acute supplementation of cocoa-flavanols in obese cohorts (Shiina et al., 
2009) and chronically with other populations with CVD risk factors such as hypertension 
(Grassi et al., 2005). 
As the aging process is usually accompanied by some degree of endothelial dysfunction 
and arterial stiffness (Lee, 2010; Sun, 2015), it is intuitive that the peripheral vasodilatory 
response of polyphenols may be able to attenuate such declines in function and, as such, 
may offer more prominent effects in healthy ageing adults. Indeed, a 6 month 
supplementation of a flavanone-rich grapefruit juice has been shown to reduce carotid-
femoral pulse wave velocity (a measure of arterial stiffness) in healthy, postmenopausal 
women in comparison to placebo (Habauzit et al., 2015). In addition, Fisher and 
Hollenberg (2006) found that several measures of endothelial function were more 
pronounced following cocoa-flavanol administration in healthy older participants (>50 
years of age) than their younger (<50 years of age) counterparts. Despite enhancing 
parameters in both groups, cocoa-flavanol administration significantly increased systolic 
blood pressure and FMD in the older group of participants only. It is important to interpret 
such results with caution however, as there was no direct comparison made between the 
two age groups.  
Heiss et al. (2015) administered 450 mg of cocoa-flavanols, or a nutrient-matched, cocoa 
flavanol-free control, to 22 healthy, young (<35 years) and 20 elderly (50–80 years) 
participants for 2 weeks. FMD was found to improve in both young and older participants 
with a similar effect size. However, the authors do note that the systolic blood pressure 
of the elderly participants was elevated at baseline, and that supplementation with cocoa-
flavanols led to a decreased aortic augmentation index and consequently systolic blood 
pressure. This may suggest different mechanisms between the young and old samples 
with net effects seen in the former but a relieving of age-related stiffness in the latter. 
Indeed, in a recent meta-analysis, Reid et al. (2017) reports that baseline blood pressure 
may play a role in the subsequent effects of cocoa-flavanols. Here subgroup analysis of 
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trials with pre-hypertensive and hypertensive participants revealed a greater blood 
pressure-reducing effect of cocoa compared to normotensive participants. 
1.4.2.1 Vasodilatory and blood flow effects of resveratrol 
Given the mutual capacity of resveratrol to interact with endothelial NO (see section 
1.3.4), the above evidence would also suggest that resveratrol may also possess the ability 
to modulate NO-dependent vasodilation. In a meta-analysis, grape polyphenols have been 
found to significantly increase FMD within two hours after oral ingestion; with peak FMD 
occurring ~30 min after consumption (Li et al., 2013). Although this does not identify the 
vasodilatory effects of resveratrol specifically, the fact resveratrol has been shown to 
increase NO production in endothelium cells in vitro (Elíes et al., 2011), may imply a role 
in these findings. Indeed, in a controlled trial, daily administration of relatively low doses 
of resveratrol (10 mg) in patients after a myocardial infarction for 3 months, was found 
to significantly increase FMD and left ventricular diastolic function in comparison to 
controls (Magyar et al., 2012). Like the aforementioned cocoa-flavanols, evidence of 
increased blood flow from the vasodilatory effects of resveratrol and other grape 
polyphenols are claimed to be more pronounced in cohorts with high cardiovascular risk 
factors (Li et al., 2013).  
For example, in a randomised, double-blind, placebo-controlled, crossover human 
intervention study, Wong et al. (2011) assessed the acute vasodilatory effects of 3 doses 
of resveratrol (30, 90 & 270 mg) in 15 obese males and 5 postmenopausal women, with 
untreated borderline hypertension. Here, participants arrived fasted (for at least 4 hours) 
to consume the treatment for the day before resting for 45 minutes. Participants then had 
their endothelial function assessed via FMD and provided blood samples for the 
assessment of plasma resveratrol concentrations. The researchers found that all 3 doses 
of resveratrol produced a significant increase in FMD following one hour of 
administration. Moreover, this effect was also reported to be in a significant dose 
dependent pattern, which coincided with plasma concentrations in a positive linear 
relationship.  
In a follow up chronic investigation, Wong et al. (2012) explored the capacity of 
resveratrol to improve FMD in a cohort of older (mean age = 61) obese adults, in a 
randomised, crossover design. Participants were randomised to consume either 75 mg of 
resveratrol or a placebo (matched for colour) daily for six weeks. Following this six-week 
treatment period, participants arrived fully fasted for 18 hours before having their BMI, 
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blood pressure, arterial compliance and FMD assessed. Participants then crossed over to 
the alternate supplementation arm for another six weeks; returning in week 12 to complete 
a second assessment session (identical to the first). The results showed 6 weeks 
supplementation of 75 mg resveratrol resulted in a 23% increase in FMD response in 
comparison to placebo. The authors argue that as the chronic assessment was measured 
at least 18 hours since the last administration of the resveratrol supplement, this 
demonstrates that the effects of resveratrol are not restricted to acute but also chronic 
vasodilatory effects. Interestingly, it has since been suggested that such vasodilatory 
mechanisms of resveratrol are not confined to cardiovascular-protection, but may also 
offer cerebrovascular enhancement and, consequently, cognitive functioning in both 
young and older adults (Wong et al., 2013). 
 
1.4.3 Polyphenols and cerebral perfusion 
As noted previously, eNOS is the isoform found in the endothelium of cerebral blood 
vessels and mediates movement of blood through the cerebral arteries and veins. Thus, it 
is of no surprise that polyphenols can consequently increase CBF via interaction with this 
mechanistic pathway. In support, Francis et al. (2006) supplemented 16 young, healthy 
adults with flavanol-rich cocoa (150 mg) for 5 days before assessing their cerebral 
haemodynamic response (via functional magnetic resonance imaging (fMRI)) during 
cognitive tasks. Although no behavioural effects were observed here, the researchers 
found that the 150 mg flavanol drink significantly increased CBF during task performance 
when compared to a low flavanol control. Similarly, in an acute pilot study within the 
same publication, a single acute dose (450 mg flavanols) of flavanol-rich cocoa could 
also significantly increase CBF. It was proposed that this increase was mediated by an 
effect on the cerebral vasculature, rather than a direct effect on neuronal function.  
Effects have also been seen here in older adults. For example, using fMRI, Lamport et al. 
(2015) found significantly increased region-specific perfusion in the anterior cingulate 
cortex and regions of the parietal lobe (post 2-hour consumption), following a 494 mg 
cocoa-flavanol drink in comparison to a nutrient matched control (23 mg cocoa flavanols) 
in subjects aged 50-65 years. Sorond et al. (2008) found that two weeks of daily 
administration with 900 mg of cocoa flavanols, significantly increased cerebral blood 
velocity in the middle cerebral artery in comparison to a low flavanol control, within a 
cohort of (N=34) 59–83 year old adults. In a follow up investigation, increases in cerebral 
blood flow velocity resulting from administration of cocoa-flavanols (451 mg) were 
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highly correlated with changes in CBF (measured by fMRI), in a cohort of older adults 
(62-80 years) (Sorond et al., 2010).  
 
1.4.4 Polyphenols and cognitive performance 
In a recent review, Bell et al. (2015) examined 21 acute controlled studies of flavonoid 
subclasses and concluded that flavonoids may provide cognitive enhancement to several 
cognitive domains, most notably: attention, working memory, and psychomotor 
processing speed. Most of these beneficial cognitive outcomes were observed with an 
acute time frame of 0–6 hours, in a dose dependent manner. One of the first studies to 
observe the cognitive enhancing qualities of polyphenols was Scholey et al. (2010), who 
found significant improvements to accuracy on the Rapid visual information processing 
(RVIP) task from high doses of cocoa-flavanols (994 mg), and on the Serial 3 subtraction 
task with a lower dose (520 mg) in 30 young, healthy humans. Moreover, Field et al. 
(2011) demonstrated significant improvements to spatial memory and aspects of the 
choice reaction time task following 2hrs post consumption of a commercially available 
dark chocolate bar (containing 773 mg of cocoa-flavanols) in comparison to a white 
chocolate control (trace cocoa polyphenols).  
In a randomized, placebo-controlled, double-blind investigation, Massee et al. (2015) 
found that acute administration with 250 mg of cocoa-flavanols significantly improved 
cognitive performance on the Serial 7 subtraction task in the first repetition of the task 
battery, in 24 young, healthy adults. Single doses of fruit flavanones have also been found 
to significantly improve cognitive performance. Lamport et al. (2016) supplemented 
young, healthy adults with a flavanone-rich orange juice (70.5 mg total flavanones) or a 
nutrient matched control. Following 2 hours administration, a single significant 
improvement to cognitive performance was observed on a digit symbol substitution task 
(processing speed) in comparison to controls. Although no cerebral haemodynamics were 
measured in the aforementioned studies, the research teams of these investigations 
postulated that these cognitive improvements could be the result of the polyphenol 
interventions bolstering NO-dependent cerebral perfusion.  
 
1.4.5 The cerebrovascular and cognitive effects of polyphenols  
It is notable that trials administrating acute single doses of polyphenols have revealed 
mixed results in young, healthy samples. Other trials have observed no cognitive benefits 
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from acute cocoa-flavanol administration (Pase et al., 2013), even when in the presence 
of significant increases to CBF (Francis et al., 2006; Decroix et al., 2016). As other 
vasoactive polyphenols, derived from apples, have also shown no behavioural benefits 
from acute administration in young, healthy cohorts (Bondonno et al., 2014) this may 
highlight that vasoactive polyphenols may not possess the efficacy to sufficiently enhance 
cognitive performance in young, healthy individuals and may potentially question the 
mechanism of augmented CBF as a method of cognitive enhancement in this age group.  
In a recent review of the literature, Socci et al. (2017) reported that despite consistent 
cerebral and peripheral blood flow effects following cocoa-flavanols, such observations 
are seldom found in conjunction with cognitive findings. However, it was noted that 
discrepancies in findings may be a result of high variance between protocols, as acute 
administration appears to provide enhancement to performance in younger cohorts during 
high cognitive demanding conditions, such as fatigue and sleep loss. Moreover, the 
authors noted that the current evidence does points towards regular flavanol intake 
providing beneficial cerebrovascular and cognitive effects. This was proposed to be 
particularly evident in individuals at risk of cerebrovascular and metabolic dysfunction, 
thereby protecting human cognition or counteracting different types of cognitive decline. 
Consequently, as ageing is associated with endothelial dysfunction and therefore a 
reduction in blood flow capacity, it appears the vasodilatory effects of polyphenols may 
provide an increased utility in (otherwise healthy) older adults. This is supported by the 
observation that both arterial stiffness and elevated blood pressure are associated with 
cognitive decline (Pase et al., 2012; Pase et al., 2013) and the proposition that 
interventions that can prevent or reduce said arterial stiffness may benefit cognitive 
functioning in the elderly (Zeki Al Hazzouri & Yaffe, 2014). 
In a controlled, parallel-arm study, Desideri et al. (2012) assessed the efficacy of cocoa-
flavanols in a range of doses (993 mg, 520 mg, or 48 mg), in 90 older adults with mild 
cognitive impairment (MCI), for 8 weeks. Both the high and intermediate flavanols 
groups showed a significant reduction in the time required to complete the Trail Making 
Test (A–B), in comparison to those assigned to the low flavanol group. Moreover, the 
high and intermediate flavanol groups also showed a significantly improved verbal 
fluency test score relative to the low flavanol group. These cognitive improvements were 
observed alongside decreased insulin resistance, blood pressure, and lipid peroxidation 
among subjects in both the high-flavanol and intermediate-flavanol groups. Interestingly, 
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the researchers reported that insulin resistance explained ~40% of the cognitive 
improvements observed.  
In a follow up investigation by the same research team, Mastroiacovo et al. (2015) found 
that the 993 mg and 520 mg doses showed significant improvements to overall cognitive 
performance following 8 weeks consumption of cocoa-flavanols in 90 healthy older 
adults. On comparison between treatments, acute supplementation of both higher doses 
was found to lead to significantly better performance on the verbal fluency and Trail 
Making Test (A–B) relative to the lower dose. In addition, significant reductions in 
systolic blood pressure were found for the higher doses of flavanols in comparison to the 
low dose; detailing the cardiovascular mechanisms of the polyphenols. The authors again 
found ~17% of changes in cognitive performance of the overall composite Z scores could 
be attributed to changes in insulin resistance. Both studies highlight the vasodilatory 
mechanism of cognitive enhancement of cocoa-flavanols, as a reduced blood flow 
capacity, commonly associated with ageing, can lead to a compromised supply of insulin 
and glucose to the brain and, consequently, a reduction in cognitive performance (Messier, 
2005; Anstey et al., 2015).  
In a double blind, crossover investigation, Brickman et al. (2014) administered 3 months 
of flavanols (900 mg cocoa-flavanols with 138 mg (−)-epicatechin) or a low flavanol 
control (10 mg cocoa-flavanols with 2 mg (−)-epicatechin) with or without aerobic 
exercise, to a healthy cohort, of 50-69 years old adults. The high-flavanol intervention 
group was found to have enhanced dentate gyrus activation (a region in the hippocampus 
that is a mediator age-related cognitive decline), when measured by fMRI, while 
demonstrating improved cognitive performance. Although not measured simultaneously, 
the authors report that this improvement in regional activation does correlate with 
improved performance on a delayed retention task, associated with dentate gyrus 
functioning.  
Interestingly, the cognitive effects of polyphenols may even begin to be evident from 
middle age. In a double blind, randomised, placebo controlled investigation Alharbi et al. 
(2015) found that a single dose of flavanone-rich (272 mg) orange juice improved 
executive function and psychomotor speed alongside increased self-reported levels of 
alertness, relative to a nutrient matched placebo control in a sample of 24 middle aged 
men (mean age 51 years). A subsequent chronic investigation saw 8 weeks daily 
supplementation of a high-flavanone (305 mg) orange juice improve global cognitive 
44 
 
performance in 37 healthy older adults (mean age 67 years). However, these benefits were 
not found in conjunction with any improvements to cardiovascular parameters (Kean et 
al., 2015).  
It is important to note that the majority of published research identifying cognitive 
benefits of vasoactive polyphenols have done so without the simultaneous measurement 
of CBF. Therefore, there is a pressing need for future investigations to monitor cerebral 
haemodynamics in conjunction with cognitive performance to elucidate the efficacy of 
this proposed mechanism of cognitive enhancement (Bell et al., 2015). Although, the 
small number of investigations which have simultaneously measured both cognitive and 
CBF parameters of polyphenols, have shown no clear cognitive benefits despite 
consistent CBF effects (Francis et al., 2006; Decroix et al., 2016; Kennedy et al., 2010; 
Wightman et al., 2014; 2015) 
1.4.6 Polyphenols and mood 
The above demonstrates how polyphenols can interact directly and indirectly with various 
mechanisms to improve cognition. Although, their interactions with other CNS 
mechanisms might also suggest effects on mood. Indeed, acute administration of 
polyphenol rich beverages, such as concord grape juice (136.6 ml/l anthocyanins), have 
resulted in increases self-reported ratings of ‘calm’ (Haskell-Ramsey et al., 2017), while, 
a wild blueberry drink (253 mg anthocyanins) has been found to significantly increase 
self-reported levels of ‘Positive Affect’ on the PANAS-NOW mood scale, in both young 
adults and children (Khalid et al., 2017). Moreover, Watson et al. (2015) found that 
administration of a blackcurrant extract (525 ± 5 mg polyphenols per 60 kg of bodyweight) 
resulted in increased self-reported alertness and reduced fatigue but this was only found 
to be significant at 140 minutes following treatment. With regards to individual 
administration of polyphenols, a single dose of 300 mg EGCG has been shown to lead to 
significant improvements to self-reported calmness and stress (Scholey et al., 2012). 
Interestingly, this improvement in mood was also found in conjunction with increased 
activation in the frontal gyrus and medial frontal gyrus. The authors therefore proposed 
that participants who consumed EGCG may have been in a more relaxed and attentive 
state in comparison to those within the placebo condition.  
Cocoa-flavanols have also been found to induce mood enhancing capabilities. In addition 
to observed cognitive improvements from the single administration of a 520 mg cocoa 
flavanol drink, Scholey et al. (2010) also found this dose was capable of significantly 
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reducing self-reported levels of mental fatigue following each of the 6 repetitions of a 10 
minute cognition battery (with the exception of repetition 3) in comparison to a nutrient 
matched control. Improvements to mood have also been observed from chronic cocoa-
flavanol consumption. Pace et al. (2013) found that a 500 mg dose of cocoa polyphenols 
significantly improved self-rated calmness and contentedness following 30 days of 
supplementation. The authors postulated that cocoa polyphenols may provide a boon in 
situations where a calm or content temperament is advantageous, i.e. under conditions of 
high stress or anxiety.  
In a randomized, double-blind, placebo-controlled trial, Cox et al. (2015) supplemented 
healthy older adults aged 60-85 (N=60) with a solid lipid curcumin (a curcuminoid 
polyphenol) formulation, containing 80 mg curcumin for 4 weeks. In addition to acute 
and chronic improvements to cognitive performance, the curcumin treatment was found 
to significantly reduce physical fatigue and provide a greater resistance to mental fatigue 
(induced by cognitive performance) following 4 weeks administration. Moreover, 
curcumin administration was found to significantly improve self-reported calmness and 
contentedness following high cognitive demand. Interestingly, similar findings have been 
replicated with the polyphenol curcumin in a cohort with depression. Participants (N=56) 
diagnosed with major depressive disorder were supplemented with either 500 mg of 
curcumin or placebo for 8 weeks. The results showed that during the second half of the 
investigation (between weeks 4 to 8), curcumin was significantly more effective in 
improving several depression-related symptoms in comparison to placebo (Lopresti et al., 
2014).  
In sum, the capacity of polyphenols to influence human mood states appears to be centred 
around anxiolytic, anti-depression and fatigue reducing like qualities. This may 
tentatively present a future for polyphenols as a therapeutic intervention for situations of 
high stress and or fatigue. The mechanisms of action in which polyphenols exert these 
mood effects are still unknown, yet, a number of flavonoids have been identified as 
inhibitors of monoamine oxidase (MOA)-A and MAO-B in animal (Jäger & Saaby, 2011) 
and human trials (Watson et al., 2015). As MAO is involved in the oxidation of 
neurotransmitters, including the regulation of serotonin, inhibiting MAO has been 
suggested as a viable method to reduce anxiety, depression and fatigue (Nemeroff et al., 
2002). Thus, the ability of polyphenols to inhibit MAO offers a potential avenue in which 
polyphenols may promote positive mood states following both acute and chronic 
supplementation (Pathak et al., 2013). 
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1.4.7 The cerebral blood flow, cognitive and mood effects of resveratrol  
Given that resveratrol has also been established to stimulate NO production pathways 
within the endothelial cells in vitro (Elíes et al., 2011), this is the likely mechanism 
underlying peripheral blood flow effects in humans (Wong et al., 2011; Wong et al., 2012) 
and suggests that resveratrol too could be capable of cerebral perfusion and the ensuing 
cognitive benefits. However, to date, only a limited number of human intervention studies 
have investigated the cognitive effects of resveratrol following acute and chronic 
consumption, with the small quantity of research that does exist providing mixed results 
regrading improvements in cognitive performance.  
Kennedy et al. (2010) investigated the CBF and cognitive effects of 250 mg and 500 mg 
oral resveratrol consumption, in a placebo controlled, repeated measures, double blind, 
crossover study. The researchers employed functional near infrared spectroscopy (NIRS) 
to measure localised cerebral haemodynamic response in the prefrontal cortex, whilst 
assessing cognition via performance on a range of tasks (previously shown to activate the 
prefrontal cortex). Following a 45-minute absorption period, resveratrol administration 
instigated a dose-dependent modulation of CBF during post dose task performance. This 
was indexed by significantly higher concentrations of both total haemoglobin (total-Hb) 
and deoxygenated haemoglobin (deoxy-Hb) in comparison to placebo. The authors 
propose that the increase in deoxy-Hb concentrations observed across the post-dose task 
period demonstrates an increased O2 extraction and utilization. However, despite the 
promising resveratrol-mediated cerebral haemodynamic changes observed these were not 
complimented with any behavioural improvements. The authors hypothesized that the 
low bioavailability of resveratrol may be a contributing factor for a lack of cognitive 
benefits.  
In a follow up investigation by the same research team, Wightman et al. (2014) utilised 
20 mg piperine as a bioavailability enhancer of resveratrol, in order to establish if 
increasing the bioavailability could amplify the cognitive benefits of resveratrol. Similar 
to the methodology of Kennedy et al. CBF was also measured throughout the full testing 
session via NIRS, whilst the bioavailability of the treatments was evaluated in a separate 
cohort. The results revealed that administration with 250 mg of resveratrol alone had no 
significant effects on overall total-Hb during the performance of cognitively demanding 
tasks. However, the same dose of resveratrol, when supplemented with 20 mg piperine, 
induced a significant increase in CBF across the post-dose task period in comparison to 
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placebo. The authors therefore suggested that either piperine is capable of CBF 
modulation itself or amplifies the capacity of resveratrol to do so. The latter explanation 
is more likely given that the previous CBF findings with resveratrol (Kennedy et al., 2010) 
and the absence of such evidence with piperine (Wightman et al., 2014). Despite this, 
pharmacokinetic analysis showed no significant differences in the plasma concentrations 
of resveratrol and its metabolites between either of the resveratrol treatments; suggesting 
that the CBF effects of the combined treatment was not due to an increase in 
bioavailability. Moreover, neither treatment displayed any significant differences in 
cognitive performance or in self-reported ratings of mood.  
As single acute doses had failed to show any benefits to cognitive performance in young, 
healthy populations, Wightman et al. (2015) proposed that increasing exposure of 
resveratrol through frequent dosages could improve bioactivity. Here cognitive 
performance was measured on day 1 and day 28 of supplementation, whilst assessment 
of CBF and cerebral blood velocity were measured via NIRS and transcranial Doppler 
respectively. Sleep quality and mood were also measured via questionnaires at weekly 
intervals. The acute blood flow findings showed that resveratrol administration (with 10 
mg of piperine) significantly increased higher total and oxygenated haemoglobin (oxy-
Hb) concentrations, across both the absorption and post dose task performance periods, 
in contrast to placebo. Whilst plasma levels of resveratrol were increased after 28 days of 
exposure, CBF, subjective sleep quality and health were not modulated. Additionally, no 
difference in blood flow velocity was observed acutely or chronically. However, self-
reported fatigue was reduced following 500 mg resveratrol consumption after 7, 21 and 
28 days, with a trending reduction nearing significance after 14 days.   
Interestingly, cognitive effects were noticed as a result of both acute and chronic 
resveratrol supplementation, demonstrating a significant reduction in overall errors made 
during Serial subtraction tasks in comparison to placebo. However, supplementation with 
resveratrol was also found to significantly decrease the number of correct responses in 
comparison to placebo in the Serial 7 subtraction task, which may imply a trade off in 
performance rather than any treatment-mediated effects. In addition to the modulation of 
Serial subtraction performance, the authors also found resveratrol increased the number 
of correct responses on the 3-Back task compared to placebo after 28-days of 
supplementation. Yet, in the absence of any significant modulation to CBF, this result is 
somewhat hard to interpret and was viewed as more likely representing a type I error by 
the authors.  
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The above studies suggest that acute administration of resveratrol is capable of CBF 
enhancement and increased O2 delivery and extraction (indexed by increases in total-Hb, 
deoxy-Hb and oxy-Hb respectively). However, none of the above studies were able to 
demonstrate that this increase could translate into cognitive benefit in humans. It is 
noteworthy that the aforementioned studies all employed young, healthy samples 
(average age ~20), who may already be in the peak of their cognitive capacities (Rönnlund 
et al., 2005). Thus, the scope for resveratrol-mediated cognitive improvements in these 
populations, may be minimal due to their ceiling effects. This argument is supported by 
evidence from cocoa-flavanol trials which have also shown greater and more consistent 
improvements within populations who are not at their cognitive peak (i.e older individuals 
or those with MCI). 
To this author’s knowledge, there remains only one study that has examined acute doses 
of resveratrol in ageing populations. Scholey et al. (2014) demonstrated that acute 
administration with resveratrol-enhanced wine was capable of improving cognitive 
performance, in comparison to wine alone, in a cohort of older adults (aged 65–78 years). 
After completing a cognitively demanding battery, wine enhanced with 200 mg of 
resveratrol was found to improve performance on the Serial 7 subtraction task across all 
6 post dose repetitions (but only significantly at repetition 2 & 4). No significant effects 
on mood were reported. Such findings should be taken lightly however, as there was no 
dealcoholized control to compare to, nor was there any monitoring of CBF parameters to 
elucidate the proposed mechanism of CBF. Nevertheless, CBF effects have been 
observed in cohorts with compromised blood flow capacity. Wong et al. (2016) examined 
a range of acute doses of resveratrol (75, 150, and 300 mg) in individuals with type 2 
diabetes mellitus (aged 49-78 years). All three doses significantly increased blood flow 
velocity in the middle cerebral arteries, yet, only the lower 75 mg dose was found to 
additionally increase blood flow velocity in the posterior cerebral arteries. 
As a reduction in estrogen within women has been linked with reduced cerebrovascular 
sensitivity (Penotti, 1996), further support for the vasodilatory mechanism of resveratrol 
in ageing populations can also be found from investigations into postmenopausal women. 
Evans et al. (2017) investigated whether 75 mg of resveratrol (administered twice daily 
over 14 weeks) could improve cognitive performance and mood by enhancing 
cerebrovascular responsiveness in postmenopausal women. Subjects abstained from the 
treatment for 12 hours on the day of testing before undergoing cognitive assessments. 
Resveratrol was found to modulate cerebrovascular responsiveness (assessed via blood 
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flow velocity in the middle cerebral arteries using transcranial Doppler), during cognitive 
performance. Despite a consistent lack of significant improvements on individual tasks, 
overall cognition was significantly improved in participants taking resveratrol in 
comparison to the control group. In addition, the authors reported treatment related 
increases in cerebrovascular responsiveness during the cognitive test battery and these 
were significantly correlated to the improvements seen in overall cognitive performance.  
Summarising remarks 
The above literature review details how polyphenols can interact with the human CNS 
via cellular signalling pathways and, subsequently, may offer a means of cognitive 
enhancement. The stilbene polyphenol resveratrol has shown to induce NO-dependant 
vasodilation and consequently the capacity to exert positive increases in CBF. This CBF 
enhancement is hypothesized to provide an increased access to neural metabolic 
substrates (namely O2 & glucose) and, in turn, cognitive benefits. Despite this, 
administration of acute high doses of resveratrol to young, healthy samples have been 
found to induce the anticipated cerebrovascular benefits, but these have not been found 
in conjunction with improved cognitive performance. This has called into question the 
ability of increased CBF alone to provide a viable mechanism of cognitive enhancement. 
Nevertheless, it is possible that increased CBF may provide more utility in those suffering 
mild (natural) cognitive decline or a reduction in blood flow capacity, yet further research 
is needed to elucidate this claim.  
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1.5 Cerebral metabolism, cognition and ageing. 
Despite its relatively small size, the human brain accounts for approximately 11% of total 
cardiac output, equating to ~20% of overall body metabolism at a resting state (Raichle, 
2010). To satisfy this large metabolic demand, the brain requires an abundant supply of 
O2. This large utilisation of O2 is necessary to support the high rate of adenosine tri-
phosphate (ATP) production to, amongst other actions, maintain the continual 
transmission of neuronal signals (Lutz et al., 2003). However, despite its sizable energy 
consumption, the brain itself cannot store its own energy source. Consequently, a 
continuous supply of blood-borne metabolic neural fuel substrates is essential for not only 
cognition, but maintenance and regulation of physiological function (Parrott et al., 2004). 
 
1.5.1 Cerebral metabolism 
The key mechanism whereby humans generate metabolic energy is through the process 
of oxidative phosphorylation of ATP within the mitochondria (Erecińska & Silver, 1989); 
making ATP the sole cellular energy currency of the brain. The main metabolic fuel of 
the brain is blood borne glucose. When fully oxidised in the presence of O2, this produces 
an increased yield of energy in the form of ATP in the mitochondria (30–36 ATPs) 
(Magistretti & Allaman, 2015), whereas anaerobic (without O2) glycolysis produces only 
2 ATP. Therefore, the oxidation of glucose is the dominant form of ATP production in 
the brain. A large proportion of this ATP budget is utilised to maintain and restore the 
transmembrane Na2+ and K+ ion channels, which deteriorate with continuous neuronal 
firing (Attwell & Laughlin, 2001). A comprehensive overview of the oxidation of glucose 
can be found in more detail elsewhere (Erecińska & Silver, 1989; McLaughlin et al., 
2007).  
 
1.5.1.1 Neurovascular coupling 
As neural demand increases, the requirement for metabolic resources subsequently 
increases, leading to an elevation in CBF to ensure an ample supply of neural fuel 
substrates, namely O2 and glucose (Parrott et al., 2004; pp. 204). Thus, CBF is adjusted 
to accommodate the relative increase in cerebral metabolic rate (Tameem & Krovvidi, 
2013); this process is referred to as neurovascular coupling. CBF is tightly coupled to the 
metabolic requirements for neural fuels, notably the cerebral metabolic rate of O2 
(CMRO2) and glucose utilisation (Hyder et al., 1998; Hoge et al. 1999). However, 
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contrary to common belief, the increased level of CBF during sustained neuronal activity 
is greater than the rise in both CMRO2 and ATP consumption (Leithner & Royl, 2014; 
Raichle 2010; Lin et al., 2010). It is proposed that this large volume of blood is necessary 
to transport the vast quantity of fuel substrates and so even small relative reductions to 
CBF can comparatively reduce mental performance (Leithner & Royl, 2014).  
1.5.1.2 Neural fuel substrates 
Despite the brain possessing other high-energy reservoirs (in the form of the phosphate 
creatinine system), glucose and O2 almost exclusively meet most of human neural 
demand (Owen & Sunram-Lea, 2011). Therefore, variations in the availability of both 
blood-borne fuel substrates can impact brain metabolism and consequently cognitive 
function. Indeed, it is well established that administration of glucose can enhance aspects 
of cognitive performance in healthy humans (Gonder-Frederick et al., 1987; Craft et al., 
1994; Sünram-Lea et al., 2011). Conversely, in hypoglycaemic populations, reduced 
circulating glucose leads to cognitive deterioration (Gonder-Frederick et al., 2009), while 
a blood glucose level of between 2.6–3.0 mmol/l within healthy cohorts has been claimed 
to impair cognitive function (Warren & Frier, 2005). Fairclough and Houston (2004) 
report that blood glucose levels are sensitive to ‘time-on-task’, demonstrating that blood 
glucose declines in a dose dependent manner the longer participants spend engaging with 
cognitive activity. Additionally, glucose administration can significantly improve 
cognitive performance on tasks with higher cognitive load (Kennedy & Scholey, 2000; 
Sünram-Lea et al., 2001; Scholey et al., 2001). This is hypothesized to be the result of 
increased mobilised fuel reserves as part of an inherent response to more physiologically 
demanding tasks (Kennedy & Scholey, 2000).  
Like glucose, availability of O2 within the cerebral vasculature can impact cognitive 
functioning. Additional supplementation of O2 improves memory formation and 
consolidation (Scholey et al., 1998), attention and vigilance (Moss et al., 1998). Blood O2 
saturation has also been found to positively correlate with cognitive performance (Chung 
et al., 2006). Most cells cannot exist anaerobically for sustained periods and so reductions 
in O2 saturation may be more significant during cognitive performance. Indeed, several 
investigations have demonstrated exposure to hypoxic conditions can lead to cognitive 
decline (Virués-Ortega et al., 2004; Petrassi et al., 2012).  In sum, the relative increase in 
either or both of these neural fuel substrates allow for enhanced cognitive performance. 
Conversely, relative decreases in the availability of either of these fuels leads to a 
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comparative decrease in cerebral metabolism and, consequently, deteriorated cognitive 
functioning. It is proposed that any substrate or method that may enhance the energy 
supply of the brain, is capable of cognitive enhancement (Owen & Sunram-Lea, 2011); 
this may be particularly evident when individuals are depleted or suffer a reduction in 
these fuels. 
 
1.5.2 Ageing of the cerebral vasculature  
With an increasing ageing population, research into both natural and pathological ageing 
has become of increasing importance. During the ageing progress, the brain undergoes 
comprehensive changes in its function and physiology (Lu et al., 2010) including regional 
atrophy (Scahill et al., 2003; Chen et al., 2011), reduction in size (& weight) (Peters, 2006) 
and deterioration of the neural myelin sheath (Fields, 2008). Cognitive decline as part of 
the natural process of ageing has been well documented in scientific literature (Harada et 
al., 2013). However, the causes and mediating factors of cognitive decline are still to be 
fully elucidated. Advancements in neuroscience have identified the age-related 
deterioration in the function of the cerebral vasculature as a significant contributor to 
cognitive decline. Indeed, the reduced efficacy of cerebrovascular functioning is thought 
to be a significant contributor to several neurodegenerative diseases (ladecola, 2010; 
Kalaria, 2009) and the associated decline in cognitive functioning (Gorelick et al., 2011). 
This is perhaps unsurprising given that the brain’s requirement for continuous 
replenishment of neural fuels is totally dependent upon the circulation of blood. 
Understanding changes in CBF of healthy, older adults, may provide important insight 
into why cognitive performance naturally declines with age.  
CBF is an important biomarker of brain health and function (Durduran & Yodh, 2014) 
with declining regional CBF (rCBF) being well acknowledged to positively correlate with 
age (Zemcov et al., 1984; Melamed et al., 1980; Martin et al., 1991; Kalaria, 2009; De 
Vis et al., 2015) and indeed, negatively correlate with cognitive function (de Eulate et al., 
2017). It is important to note that changes in CBF are not uniform across the brain, with 
subcortical regions remaining relatively unaffected by reduced blood flow (Chen, et al., 
2011). Lu et al. (2010) assessed the age-related differences to brain metabolism and 
cerebral vasculature in a cohort of healthy subjects ranging from 20-89 years. The 
researchers reported that decline in CBF was widespread across the brain, but increasing 
age was found to most notably reduce CBF in the prefrontal cortex, insular cortex, and 
caudate. This is particularly interesting given that older adults have been found to perform 
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poorer on measures that require frontal lobe function, in comparison to younger adults 
(West, 1996, 2000; Kievit et al., 2014), whilst both older and younger adults perform very 
similarly on tasks of non-frontal function (Ardila & Rosselli, 1989). As a reduction in 
CBF would indicate a decline in cerebral function, age related decreases will lead to a 
compromised delivery of neural fuels and, consequently, hindered cerebral metabolism.  
Given the importance of blood flow to supply these neural fuels, it would be logical to 
assume that a reduction in CBF would axiomatically lead to a reduction in CMRO2. De 
Vis et al. (2015) found that CBF was significantly lower, while O2 extraction fraction 
(OEF) was significantly higher, in the frontal, temporal and the deep grey matter of the 
older subjects in comparison to younger participants. The research team also found 
significantly lower CMRO2 in these regions of the older subjects. This could demonstrate 
that the reductions in rCBF experienced with age, can lead to an increase in the extraction 
of O2 in an attempt to offset the reduction in supply of O2. However, Aanerud et al. (2012) 
reported that values of CBF were found to decline to a greater extent than values of 
CMRO2 during the ageing process. The researchers postulate that the higher O2 extraction 
lowers the average tension of O2 within the cerebral capillaries, disrupting the partial 
pressure gradient. In turn, this compromises the delivery of O2 to brain tissue and, 
subsequently, energy yield. Although the exact mechanism of disruption is perhaps 
unclear, consistent evidence points towards ageing inflicting an associated reduction in 
regional blood supply, causing disruption to the energy homeostasis of the brain and, 
consequently, a gradual decline in energy metabolism.  
 
1.5.3 Cognitive decline in the ageing brain 
As several variables play a role in the progression or delay of the ageing process, the age 
at which cognitive decline significantly progresses is unclear. Salthouse (2009) postulated 
that cognitive ageing can even begin as young as 20–30 years of age for specific cognitive 
domains, yet general decline has been estimated to take hold at approximately middle age 
(Aartsen, et al., 2002; Rönnlund et al., 2005). This would also coincide with the onset of 
reductions in rCBF (Lu et al., 2010; Aanerud et al., 2012). Cognitive ageing is thought to 
accelerate from approximately 70 years old (Filley & Cullum, 1994) and, consequently, 
from this age onward there is a greater risk of pathological and neurodegenerative decline 
(Howieson, 2015).  
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With regards to specific cognitive domain decline, the most consistently reported age-
related declines to cognition appear generally in speed of processing, executive 
functioning and memory. Indeed, many subsequent reductions in cognitive performance 
are thought to be the result of increased speed of processing (Salthouse, 1996). Attention 
is highly associated with the speed of information processing as tasks associated with 
cognitive domain typically require periods of sustained attentiveness and responsiveness. 
As a result, sustaining attention during vigilance tasks (Filley & Cullum, 1994; Berardi 
et al., 2001) and the more taxing attentional paradigms, such as divided attention (Zanto 
& Gazzaley, 2014), show a large variance between age groups. These declines in attention 
can also have consequences for everyday function; for example, increasing age shows a 
greater risk of car accidents in older adults (Braver & Trempel, 2004). 
Older adults commonly report difficulty in remembering or changes in the quality of their 
memory function. However, with the exception of reductions in episodic memory 
(Isingrini & Taconnat, 2008; Lundervold et al., 2014), long term memory appears to 
remain relatively intact with age as procedural, implicit and semantic memory typically 
show little to no decline (Balota et al., 2000; Craik, 1994). Moreover, most well learned 
facts and knowledge seems to be highly resistant to age-related deficits (Craik, 1994). 
Yet, in contrast, processing and recalling new information appears to be more affected 
(John & Cole, 1986). Regarding the stages of memory function, both acquisition and 
retrieval of recently acquired information appears to be impacted with age (Duchek, 1984; 
Craik & McDowd, 1987; Balota, et al., 2000); evidenced by poorer recall (Howieson, 
2015). However, retention of information appears to be surprisingly preserved (Kliegel 
et al., 2000). Finally, short term memory declines more readily with age; with clear 
observable reductions in working memory (Li et al., 2001). 
Not all cognitive domains deteriorate equally however (Glisky, 2007), with speech and 
language processing remaining largely intact in older adults and extensive vocabulary has 
been found to improve with age (Salthouse, 2009). This could be result of the ageing 
process causing regional specific decline to the brain (Burke & Barnes, 2006), leading 
such areas to be more at risk to the effects of ageing or even pathological deficits. 
Additionally, accuracy remains relatively intact with age yet, in the presence of increased 
reaction times, this would clearly imply an age-related difference in speed-accuracy trade-
offs (Staub et al., 2013). (The reader is directed to the following texts for a more extensive 
overview of natural ageing reductions in cognition: Peters, 2006 Glisky, 2007; Salthouse, 
2000, 2010; Harada et al., 2013; Hartshorne & Germine, 2015.) 
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1.5.4 Multifactorial ageing brain: A need to model cognitive ageing 
It is clear that the ageing brain is subject to progressive physiological decline with 
reductions in rCBF and O2 metabolism contributing to cognitive domain specific age-
related reductions. Regarding the current PhD thesis, resveratrol has been identified to 
increase cerebral perfusion and, consequently, may operate to attenuate reductions in 
CBF and offer cognitive enhancement as a result. This is hypothesised to be the result of 
increased access to neural fuel substrates attenuating age-related reductions in rCBF and, 
in turn, CMRO2. However, despite age-related cognitive decline being well documented 
within the literature, individual variability of biological (including health), psychological, 
environmental, and lifestyle factors contribute to the rate and the extent of cognitive 
decline (Harada et al., 2013).  
Research into this area generally assumes the trajectory of ageing is similar for all persons 
yet, as ageing is a multifactorial biological process, several confounding factors arise 
when measuring cognitive functioning in ‘normal’ or ‘healthy’ older adults. Indeed, the 
brain undergoes a series of other physiological changes in conjunction with observed 
reductions to rCBF. Varying levels of regional atrophy, increased neuroinflammation and 
glucose tolerance are all shown to contribute to declining cognitive functioning with age 
(Peters, 2006; Cevenini et al., 2013; Lamport et al., 2009). This highlights that there is 
not one common cause of cognitive decline but a multiplicity of factors. Lifestyle factors 
such as midlife hypertension, diabetes, smoking, stress and obesity can all increase the 
progression of cerebrovascular ageing (Debette et al., 2011) while factors such as aerobic 
exercise contribute to decelerating the cognitive ageing process (Steffener et al., 2016). 
In support, cognitively demanding tasks have been reported to be sensitive to aerobic 
capacity, with higher complex cognitive speed performance linked to higher aerobic 
fitness (van Boxtel et al., 1997).  
Cognitive ability is highly diverse in individuals yet variance is thought to increase further 
in older adults (Jiang et al., 2017). Research has even shown cognitively intact humans 
aged 100 years (Perls, 2004) demonstrating the diversity which can take place within 
‘normal’ ageing. Individual differences in cognition can also be dependent upon the 
capacity of an individual to engage in effortful cognitive endeavours (Cacioppo et al., 
1996). Indeed, maintaining cognitive activity; including engaging with intellectual 
activities (e.g. puzzles), has been found to attenuate progressive cognitive decline 
(Verghese et al., 2003). Furthermore, cognitive ageing seems also dependent upon 
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cognitive ability in youth (Karama et al., 2014), with higher levels of intelligence and 
education linked to better cognitive function in older age (Rönnlund et al., 2005; Marioni 
et al., 2014).  
From the above, it would appear necessary to first model the age-related reduction to 
neural fuels to assess if the mechanism of augmented CBF can improve cognitive 
performance through the mitigation of such reductions. This would identify that (1) there 
is merit to the proposed CBF mechanism of resveratrol and (2) the attenuation of rCBF 
and CMRO2 reductions observed in ageing populations can result in improved cognitive 
performance; without the interference of other confounding variables, as briefly outlined 
above, and individual variability. Given the importance of O2 in cerebral metabolism and 
consequently cognitive functioning, manipulating the availability of this neural fuel 
substrate may provide a means of modelling age-related decline in CMRO2. Indeed, the 
use of hypoxia has been credited as a representative, experimental model for the ageing 
process (Cataldi & Di Giulio, 2009). Therefore, as reductions in CBF are tightly coupled 
with the supply and availability of neural fuel substrates, reducing the O2 supply in 
healthy, young individuals may provide a means of testing this hypothesis. 
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1.6 Hypoxia as a model for cognitive ageing 
The previous section proposed that disrupting O2 delivery via an induced state of hypoxia, 
may offer a representative, experimental model for the ageing process. This would 
provide a viable method to assess the efficacy of the CBF mechanism of resveratrol (given 
that CBF enhancement should be expected to increase the depleted O2), whilst also 
providing a model of the ageing brain (where O2 utilization is less efficient). For clarity, 
the state of hypoxia in this PhD thesis will be simply defined as a reduction in the fraction 
of inspired O2 (FiO2). 
 
1.6.1 The atmosphere at sea level and altitude 
The atmosphere is mainly made up of nitrogen (~78%) and O2 (~20.93%), with the rest 
consisting of small amounts of argon (>1%), carbon dioxide (~0.04%) and other gases / 
water vapour. At sea level, barometric pressure (the weight / force applied to the 
atmospheric gasses) is approximately 760 mmHg; this allows for 100% of the available 
atmospheric O2 to be extracted by the human alveolus. With increasing altitude, 
barometric pressure reduces, and consequently the partial pressure (the specific pressure 
applied by a specific gas) also falls; this results in less available O2 from the atmosphere 
for extraction and absorption by the body (West et al., 1983; Beall, 2001). As a 
consequence of the resulting reduction in available O2, ascent to altitude can cause a 
variety of impairments to mood, vision and higher mental faculties (Shukitt & Banderet, 
1988; Shukitt-Hale et al., 1998; Hornbein, 2001; Yan, 2014; West, 2016), and in more 
extreme cases, headache, nausea, loss of consciousness and even death (Netzer et al., 
2013; Zafren, 2014; Severinghaus, 2015). 
 
1.6.2 Acute physiological response to hypoxia and altitude 
The ability of the brain and tissues to respond to lowering levels of O2 is an essential 
requirement for survival, therefore exposure to hypoxia instigates a series of 
physiological responses to maintain O2 homeostasis. Non-acclimatised individuals who 
encounter altitude induced hypoxia experience several immediate and gradual adaptations 
to pulmonary-vascular and metabolic parameters in response to the insufficient supply of 
O2. These adaptations are assumed to be beneficial, aiding in protection against disease, 
cellular dysfunction, and increased O2 delivery. Indeed, in sporting and athletic contexts, 
exposure to prolonged bouts of hypoxia have been employed to improve aerobic 
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performance (McLean et al., 2014); due to hypoxia provoking an increase in 
erythropoiesis (Garvican et al., 2012; Garvican-Lewis et al., 2015) and, in turn, improving 
O2 supply. However, not all adaptations are advantageous. The large stress imposed upon 
the pulmonary-vascular system from chronic exposure to hypoxia results in structural 
alterations, leading to a significantly increased risk of pathological diseases, such as 
pulmonary hypertension (Penaloza & Arias-Stella, 2007) and polycythemia (excessive 
red blood cells) (Naeye, 1967). The fundamental integrated reflexes induced by acute 
exposure to hypoxia include changes to ventilation, carriage of O2 and cardiac output. 
Understanding these physiological responses and their interactions with one another is 
critical for the understanding of global and rCBF regulation in hypoxia (Ainslie & 
Subudhi, 2014). Naturally, the impact of these physiological responses is dependent upon 
the rate, duration and intensity of exposure to hypoxia, which will be detailed, where 
appropriate, in this review. 
 
  1.6.2.1 Hypoxic ventilatory response 
Individuals living at sea level (normoxia) naturally have a low resting ventilation, but this 
is rapidly increased upon immediate exposure to hypoxic conditions along with a fall in 
O2 saturation in the blood (Beall, 2001); referred to as the hypoxic ventilatory response 
(HVR). The purpose of a HVR is to allow more O2 to be taken in and be passed through 
the lungs, offsetting the hypoxic effect. It should be noted however, that this response is 
not universal; there is considerable variation in the HVR between individuals 
(Kronenberg & Drage, 1973) with both age and smoking being identified as factors that 
increase the ventilatory response to hypoxia further (Nesthus et al., 1997; Richalet & 
Lhuissier, 2015). HVR is particularly noteworthy, as its role is to increase the partial 
pressure of arterial oxygen (PaO2) and reduce that of CO2 (PaCO2), which consequently 
affects O2 carriage and CBF.  
 
 1.6.2.2 Oxygen carriage  
As the circulatory system is the sole supplier of O2, adjustments to the affinity for O2 
during bouts of hypoxia may contribute significantly to hypoxic adaptation (Samaja et al., 
2003). Once inspired, PaO2 is approximately 100 mm/Hg in the human alveolus, while 
PaO2 at the capillary is ~40 mm/Hg. Through the process of diffusion (moving from a 
high concentration to a low concentration), O2 transfers across the alveolar membrane to 
bind to the four heme groups present in the haemoglobin (Hb) of the red blood cell. This 
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allows the transport of O2 around the body to muscle and other tissues (McLaughlin et al., 
2007).  
In healthy humans, at sea level, arterial oxygenation within the haemoglobin will be on 
average 98-100%. This is a result of the high PaO2 ensuring almost complete Hb 
saturation. This amount of O2 is sufficient to meet most of the metabolic requirements of 
the body, however, in the event of reduced blood flow, uptake in O2 becomes 
proportionate to the rate of delivery (McLaughlin et al., 2007). The oxyhaemoglobin 
curve (Figure 1.2) depicts the dissociation of Hb saturation at the normal range. As partial 
pressure begins to fall with ascent to altitude, O2 extraction becomes compromised at a 
progressive rate. During moderate hypoxia, this curve can be seen to shift slightly to the 
right, indicating O2 is less bound to the heme groups and, thus, is more available to be 
diffused into the surrounding tissues. However, at higher altitudes this shifts further to 
the left, indicating a higher retention of O2, as the body struggles to maintain the demand 
for O2.  
 
 
 
 
 
 
 
 
 
Figure 1.2. The oxyhaemoglobin dissociation curve, with demonstration of the Bohr 
effect. Adapted from Beasley et al. (2007). 
Delivery of O2 requires a stable microenvironment. Therefore, the binding affinity of O2 
is also dependent upon blood pH and body temperature. The Bohr Effect demonstrates 
that when the pH of blood is lowered (increased acidity), due to the build-up of excessive 
carbon dioxide (CO2) and waste products, dissociation of O2 occurs at a higher arterial 
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partial pressure of O2 (McLaughlin et al., 2007). Core temperature also plays a role in this 
process, as relative increases in temperature will cause the same effect. This enables a 
higher dissociation of O2, leading to increased delivery to the working tissue. In contrast, 
decreases to core temperature and increases in pH result in the opposite reaction, causing 
O2 to be less available to diffuse into the tissues. The Bohr effect emphasises the role 
which temperature and blood pH can play in the body’s reaction to hypoxic conditions. 
Although the impact of these two variables will be discussed further below, this highlights 
that the physiological response to hypoxia can be varied and should be considered when 
adapting the proposed hypoxia model of ageing. 
1.6.2.3 Cerebral haemodynamic response  
During initial exposure to atmospheric hypoxia, cerebral tissue O2 saturation decreases 
which induces an increase in CBF to offset lower cerebral O2 delivery and subsequently 
meet O2 demand (Harris et al., 2013; Brown et al., 1985). This acute compensatory 
increase in CBF is hypothesized to be a result of NO signalling and NO mediated 
endothelial vasodilation (Blitzer et al., 1996). In support, evidence from native inhabitants 
of high altitude where native Tibetan highlanders live at ~4200 m above sea level (85% 
O2 saturation) shows significantly (up to 7 times) higher NO transfer from the lung (Hoit 
et al., 2005). This was reported to give a higher potential for increased vasodilation of the 
pulmonary blood vessels, compensating for the hypoxic environment. In addition, 
evidence has suggested that NO inhibitors can blunt CBF and vasodilation in young 
healthy low landers when exposed to acute hypoxia (Van Mil et al., 2002). Despite an 
immediate increase in CBF (within the first 12 hours of exposure to high altitude) this 
ceases after 3–5 days, returning to near sea level values (Ainslie & Subudhi, 2014). This 
would appear to be due to significant cerebrovascular adaptations taking place, enhancing 
the carrying capacity of O2 in the blood after only a few days at altitude (Willie et al., 
2014).   
As detailed earlier, the physiological responses to acute hypoxia influence one another; 
hence fluctuations of one consequently dictates the subsequent response. Hypoxia incites 
stimulation of the peripheral chemoreceptors, leading to hyperventilation, and eventually 
to hypocapnia and respiratory alkalosis (Petrassi et al., 2012). Both hypocapnia and 
respiratory alkalosis incite cerebral-vasoconstriction (Raichle & Plum, 1972). 
Interestingly, extreme hyperventilation has also been found to induce intracellular 
acidosis, resulting from hypercapnia, which conversely provokes vasodilation (Vavilala 
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et al., 2002). It is assumed that both hypercapnia and hypocapnia cause fluctuations in 
PaCO2, inducing changes in pH and consequently elicits vasodilation or constriction, 
respectively (see the above detailed ‘Bohr effect’). This emphasises that the response to 
hypoxia is not straightforward, and individual reactions in hyperventilation may 
coordinate the CBF response. Although acute exposure to hypoxic conditions increases 
HVR, this is estimated to reduce within 20 minutes in healthy individuals (Beall, 2001). 
This may remain elevated for up to 60 minutes in comparison to baseline measures 
(Huang et al., 1984), but would imply any impact of hypocapnia would subside within a 
short period of time.  
 
 1.6.3 Neurovascular coupling in hypoxia 
Davranche et al. (2016) assessed whether specific cognitive processes and cerebral 
hemodynamics (measured via functional NIRS) correlated during acute and prolonged 
high-altitude exposure. Eleven healthy males were exposure to 4350 m altitude for 4 days, 
with measurements for cognitive and CBF taken at initial ascent (3-5 hours exposure) and 
2 and 4 days following ascent. After 3-5 hours of exposure, participants displayed a 
reduction in information processing evidenced by poorer reaction times and an increased 
number of errors. However, these reductions were attenuated following 2 days exposure 
suggesting acclimatisation. More importantly however, cerebral haemodynamics were 
found to correlate with acute cognitive performance on the Simon task1. The authors 
calculated a total oxygenated tissue index, which was found to negatively correlate with 
speed of reaction time performance, while a significant positive correlation between 
levels of deoxygenated Hb and reaction time was also found. The results of this study 
demonstrate that the despite hypoxia leading to decreases in cognitive performance (i.e. 
slower reaction times), a more effective CBF response can function to attenuate this 
reduction.   
It is noteworthy that the brain is hypothesised to be able to withstand a certain threshold 
of hypoxia. Mild hypoxic conditions may initiate sufficient compensatory adaptive 
responses in healthy cohorts which function to attenuate any observable reductions in 
cognitive performance. Indeed, the stable levels of CMRO2 found consistently during 
mild / moderate acute hypoxic conditions may suggest that the vasodilatory response is 
                                                          
1 The Simon task for the present study required participants to respond to either a square or a circle 
presented either to the left or to the right of a prior presented fixation point. Response pads consisted of left 
and right response keys corresponding to one of the shapes (e.g. left response for a circle & right for a 
square) which were counterbalanced across participants, creating congruent and incongruent trials.  
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sufficient to compensate for the reductions in O2 (Xu & LaManna, 2006). However, rapid 
exposure to hypoxia may result in only minimal adaptations to the body, supporting 
claims that maximal cognitive deficits are more apparent within the early stages of 
exposure. Therefore, further investigations into mild and moderate altitude are still 
warranted, if it is employed in short bouts, to enable maximal deficits and minimal 
adaptation to take place (Petrassi et al., 2012).  
 
1.6.4 Cognitive performance in acute altitude induced hypoxia  
As the partial pressure of O2 (PO2) decreases with the ascent to altitude, O2 availability 
also decreases. This causes an offset in O2 saturation and exposes vital organs and tissues 
to hypoxic conditions leading to reduced performance and function. Given that brain 
function is especially vulnerable to the effects of hypoxia (Larson, et al., 2014); exposure 
to increasing hypoxic conditions leads to an increasing level of detrimental effects on 
cognitive performance, yet this is dependent upon the rate and duration of exposure. The 
impact of altitude-induced hypoxia has been shown to be domain specific, with 
performance on complex tasks appearing to be more adversely affected at altitude in 
comparison to more simple ones (Cahoon, 1972; Babbar & Agarwal, 2012). Whilst well 
learned tasks seem to be more resistant to the effects of hypoxia in comparison to novel 
tasks, impairments to learning, reaction time, decision-making and (certain aspects of) 
memory are commonly reported at altitude (Petrassi et al., 2012). Increased error rates 
are also commonly reported (Wu 1998; Du et al., 1999), despite researchers noting that 
subjects may slow their responses further as a strategy designed to minimise mistakes 
(Abraini et al., 1998).  
Executive function, memory, and attention have also been found to be impacted by acute 
exposure to high altitude (Asmaro et al., 2013). Most of these studies suggest that the 
cognitive impairments are directly related to the severity of hypoxia induced. 
Nevertheless, there remains a level of ambiguity regarding whether low levels of altitude 
can impact cognitive domains sufficiently, as most investigations only document 
consistent domain specific cognitive deficits beginning at around 3000 m above sea level 
(Bahrke & Shukitt-Hale, 1993). Indeed, it has been proposed that the ‘crucial zone’ for 
cognitive deficits to take hold is between 4000-5000 m above sea level (equivalent to 
12.7-11.2% FiO2) (Nelson, 1982). However, reductions in mental performance have been 
reported at levels as low as 1524 m altitude during exercise (equivalent to 84% of the O2 
available at sea level), in which complex reaction time was found to decrease when 
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exposed to a novel task (Denison et al., 1966). Moreover, learning (Farmer et al., 1992), 
attention, working memory (Wu et al., 2002) and reaction time (Ando et al., 2010) have 
all been found to be negatively impacted at low levels of stimulated altitude (2440 m, 
2800 m and 2134 m, respectively). Therefore, it does appear that mild or even low levels 
of hypoxia, can induce behavioural deficits.  
 
1.6.5 Mood in acute hypoxia 
It is perhaps unsurprising that hypoxia can also negatively influence mood parameters in 
addition to cognitive performance. Altitude induced hypoxia has been found to induce a 
wide range of adverse psychological changes including increased feelings of anxiety, 
depression, aggression, and fatigue, complemented by reduced feelings of vigour and 
happiness (Bahrke & Shukitt-Hale, 1993; Shukitt-Hale et al., 1998; Bardwell et al., 2005). 
Li et al. (2000) explored the effects of acute mild and moderate hypoxia on mood in 18 
healthy males, via simulated altitude at 300 m (baseline/ control), 2800 m, 3600 m and 
4400 m for 1 hour in a hypobaric chamber. This study demonstrated that acute exposure 
for as little as 1 hour, to mild hypoxia (2800 m), had a negative impact on mood state in 
healthy individuals, which seems to further progress with further ascent to altitude. 
Similarly, Shukitt, and Banderet (1987) found only self-reported ‘sleepiness’ was found 
to increase at low levels of hypoxia (1600 m). At 4300 m significant reductions were 
found to friendliness and clear thinking, whilst significant increases were found to 
dizziness, sleepiness, and unhappiness in comparison to baseline controls (200 m). Again, 
the greatest differences in mood were found after only short term (3 hours) exposure to 
hypoxic conditions. 
Legg et al. (2016) investigated complex cognition and mood at 8000 ft (2438 m) and 
12,000 ft (3658 m). Despite complex cognition being unaffected by either altitude, self-
reported fatigue was increased and vigour was found to be reduced at 12,000 ft. 
Interestingly, these were found to be restored when subjects were supplemented with 100% 
O2. This would support the hypothesis that reduced access to O2 plays a role in reductions 
in mood at altitude yet, as few studies have examined the role of mood at hypoxia, it is 
unclear whether improvements in CBF may also significantly improve mood parameters. 
However, evidence from studies supplementing additional O2 at both hypoxia and 
normoxia would certainly support this proposed mechanism.  
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1.6.6 General considerations for the use of hypoxia as an experimental model of 
cognitive ageing.  
The rationale behind utilizing the environmental chamber in the current thesis was to 
remove the extraneous variables that result from the multifactorial nature of cognitive 
ageing (see section 1.5.4). As the capacity of the aging brain to extract and utilise O2 and 
other nutrients declines significantly at the neuron (Campos et al., 2014), this 
compromises the delivery of O2 to brain tissue and subsequent energy yield. Similarly, a 
reduction in FiO2 results in a subsequent decrease in maximal uptake and delivery of O2 
to neural tissue allowing for a suitable comparison. Additionally, as section 1.6.4 details, 
induced hypoxia from 2000-4500 m may reduce cognitive performance on a series of 
differing cognitive domains including memory, reaction time, and rate of errors. This is 
of particular interest given that ageing populations tend to display similar reductions to 
these cognitive domains as detailed previously in this literature review (section 1.5.3). 
The above would suggest that there is merit in the modelling of cognitive ageing with 
hypoxia-induced performance deficits, as this not only mirrors the disruption of O2 that 
occurs with age, but also the measurable behavioural reductions that might ensue are 
directly comparable to naturally ageing populations. 
It should also be noted that physical activity, ambient temperature, acclimatisation, and 
individual response variability, all play a role in the relative reduction in behavioural 
performance within hypoxia. Moderate and extreme reductions / increases in ambient 
temperature have been reported to negatively affect performance further at hypoxia 
(Taylor et al., 2016). This would emphasise the need for a controlled environment within 
hypoxia and utilising temperatures that reflect those at sea level for a fair comparison. 
Moreover, as physical exercise naturally increases O2 demand on the body, it is possible 
that studies which perform behavioural testing alongside, or conjunction with, exercise 
are biased in demonstrating exaggerated reductions in performance. Indeed, cognitive 
performance can be impacted at lower altitudes more readily in investigations when 
combined with strenuous physical exertion (Petrassi et al., 2011). Therefore, it is 
important to establish cognitive responses at rest and isolate any extraneous or additional 
demands on O2 consumption. Additionally, physiological variability from one individual 
to another can impact adaptation and response to hypoxia. It is of course important to 
allow such individual differences to represent the natural variance that exist within the 
population. Nevertheless, variance in responsiveness brought on by lifestyle factors (such 
as obesity & physical fitness) and pre-acclimatisation must be screened out.  
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Moreover, it is noteworthy that the individual response of hyperventilation in reaction to 
immediate exposure to hypoxic conditions can play a large role in the acute cerebral 
haemodynamic response to hypoxia. HVR may induce cerebral vasodilation as a natural 
reflex to offset O2 deficiencies yet, in contrast, rapid hyperventilation may also prompt 
hypercapnia; stimulating vasoconstriction. However, previous investigations have 
demonstrated that hypercapnia itself is associated with age related impairment to 
cognitive performance (Zheng et al., 2008; Mitschelen et al., 2009). Moreover, as 
resveratrol has been noted to increase CBF via increasing NO bioavailability and NO 
levels, this will aid in overcoming vasoconstriction or exaggerate a beneficial response of 
vasodilation respectively, and therefore should present a measurable increase in CBF in 
either case. In support, evidence from studies administrating nitrate (with evidenced 
vasodilatory effects (Clements et al., 2014)), have shown beneficial adaptations to 
physiological function and exercise during moderate / high altitudes via increased 
modulation of blood flow parameters (Presley et al., 2011; Shannon et al., 2017).  
Finally, rapid ascent to altitude results in minimal adaptations to the body, thus, the 
greatest reductions to cognitive performance arise within the early stages of exposure 
(Petrassi et al., 2012; Davranche et al., 2016). This would suggest that an effective 
hypoxic model should only implement short bouts of hypoxia within subjects, to ensure 
that any measurable effects are not masked by the efficacy of the body’s natural 
adaptations. It is clear from this review that responses to hypoxia are not straightforward, 
and isolation and control over a number of factors is required to host a reliable hypoxic 
model of ageing.  
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1.7 Concluding remarks and the aims of this thesis.  
Polyphenols and their metabolites have been found to interact with cellular transduction 
and signalling cascades, which are proposed to be the underpinning of their numerous 
health benefits in humans. The non-flavonoid polyphenol resveratrol has shown to 
modulate NO within endothelial cells, and, in turn, capable of augmenting NO-dependent 
vasodilation. Interestingly, the capacity of resveratrol to induce vasodilation has not only 
been found to promote cardiovascular benefits but has also been suggested to offer 
cerebrovascular enhancement. Indeed, habitual resveratrol consumption has been 
associated with a reduction the risk of cardiovascular and cerebrovascular disease, while 
both acute and chronic resveratrol administration have been found to increase peripheral 
and cerebral blood flow. Intriguingly, the ability of resveratrol to increase CBF has been 
suggested as an indirect mechanism to provide cognitive enhancement in humans. This is 
based upon the premise that enhancing the provision of blood-borne metabolic substrates 
(O2 & glucose) will subsequently increase the energy yield of the brain and, in turn, 
cognitive performance in young, healthy humans.  
To date, only a limited number of human intervention studies have investigated the CBF 
and cognitive effects of resveratrol following acute and chronic administration; with the 
small quantity of research that does exist providing conflicting results. Indeed, despite 
research demonstrating increases in CBF and O2 extraction and utilisation (as indexed by 
increased concentrations of deoxy-Hb), such effects have not been found in conjunction 
with the hypothesised enhancement to cognitive performance in young, healthy samples. 
Furthermore, other vaso-active polyphenols such as cocoa-flavanols and fruit flavanones 
have demonstrated similar inconsistent cognitive benefits in healthy, young cohorts, 
despite a growing body of literature supporting their CBF effects.  
This may suggest the high neurocognitive efficacy of the young, healthy populations 
employed in previous investigations maybe unable to benefit from the resveratrol-
mediated increases in CBF, as such populations are acknowledged to be in the peak of 
their cognitive abilities and are already possess a sufficient supply of blood to meet 
demand. It therefore remains to be elucidated whether the vasodilatory effect of 
resveratrol is an appropriate mechanism to enhance cognitive performance. However, 
research has demonstrated that resveratrol is capable of enhancing O2 extraction and 
utilisation during cognitive performance, while also being found to modulate 
mitochondrial aerobic respiration and cellular energy production. Examining the 
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metabolic consequences of resveratrol during high cognitive demand may provide 
support for the CBF mechanism of cognitive enhancement, as doing so may demonstrate 
the capacity of resveratrol to modulate the utilisation of the hypothesized heightened 
supply of neural substrates and / or a subsequent increase in cerebral metabolic output, 
which comes concomitant with relative increases in CBF. 
Given the above, it is also noteworthy that the natural ageing process is associated with 
reductions to rCBF and subsequent cognitive deficits. It is proposed therefore, that the 
CBF effects of resveratrol may provide an increased utility in ageing populations, 
amplifying the delivery of neural fuel substrates and improving cognitive performance. 
Although, ageing is, of course, multifactorial. The observed reduction in rCBF is only 
one of many factors that lead to enviable cognitive decline in ageing humans. It is 
therefore purposed that a model of cognitive ageing will provide a clearer picture of how 
resveratrol-mediated increases in CBF can improve cognitive performance, before testing 
these effects directly in a healthy, ageing sample. Given the importance of O2 to sustain 
cellular processes, the use of hypoxia has been suggested as a representative, 
experimental model for the ageing process. This may also be extended to a model of 
cognitive ageing, due to the relative decreases in delivery and utilisation of cerebral O2 
that occur from reduced rCBF during natural ageing. In further support, these reductions 
in O2 have shown to induce deficits to aspects of cognitive performance which resemble 
those commonly found in naturally ageing cohorts. Thus, utilising a hypoxic model would 
demonstrate the link between reduced O2 and poorer cognitive performance, whilst also 
confirming the CBF effects of resveratrol to attenuate these reductions to cognition 
directly.  
The current aims of this thesis aimed to: 
1) Examine the capacity in which resveratrol can impact metabolism and fuel 
utilisation during high cognitive demand (Chapter 3). 
2) Establish the use of mild and moderate hypoxia as a representative model of the 
cognitive ageing process (Chapter 4 & 5 respectively), to mimic the role of 
decreased rCBF and subsequent CMRO2 of a naturally ageing sample.  
3) Assess the ability of resveratrol to augment CBF within hypoxia, to attenuate 
consequential reductions in cognitive performance due to a diminished O2 supply 
(Chapter 4 & 5).  
4) Assess if a single, acute dose of resveratrol can increase CBF and cognitive 
performance in a healthy, naturally ageing sample (Chapter 6). 
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Chapter 2: General methods, apparatus and procedures. 
The current chapter will explain the general methods and apparatus employed in the 
following experimental studies. Any subsequent study specific materials or procedures 
will be expanded upon in the relevant chapter.  
2.1 Near-Infrared Spectroscopy (NIRS) 
Building on the blood oxygenation level dependent signal, NIRS is a non-invasive brain 
imaging technique, which exploits the differing diamagnetic and paramagnetic properties 
of haemoglobin, allowing for the measurement of cerebral hemodynamics within brain 
tissue. Human tissues are relatively transparent, but natural visible light (~450-700 nm) 
can only transverse to the depth of around 1 cm. In contrast, infrared light (~700-1000 
nm) can travel up to 8 cm (Pellicer & Bravo, 2010), where the light is absorbed by 
chromphores (pigment compounds), namely blood haemoglobin. Working via a simple 
transmitter-receiver output, NIRS transmits an ‘arced’ ray of photons (see Figure 2.0). 
The subsequent calculation of the absorption and scattering of infrared light on return to 
the receiver, allows for the measurement of oxygenated (oxy-Hb), deoxygenated 
haemoglobin (deoxy-Hb) and total haemoglobin (total-Hb). The latter comprises the 
addition of the two former outputs, providing a proxy for total blood flow.  
As NIRS data has been found to correlate strongly with that of fMRI (Strangman et al., 
2002), it has been suggested that NIRS can be used as a suitable substitute for fMRI when 
investigating cortical brain activity associated with cognitive tasks (Cui et al., 2011). The 
relative changes in oxy-Hb and deoxy-Hb observed in the prefrontal cortex can show the 
relative changes in cerebral metabolic rate (Tamura et al., 1997; Jackson & Kennedy, 
2013). As increased neural activity subsequently increases the requirement for O2 to be 
metabolised, CBF consequently increases. The subsequent increase in CBF to match 
demand results in localised neural activation elevating concentrations of total-Hb and 
oxy-Hb (Obrig & Villringer, 1997) and, in turn, lowering deoxy-Hb concentrations due 
to increased cerebral oxygenation (Obrig & Villringer, 2003). This is a consequence of 
the CBF response to neural activation being greater than that of CMRO2 (Leithner & Royl, 
2014) and therefore, deoxy-Hb concentrations occupy a smaller fraction of overall blood 
flow.  
With regards to cerebral haemodynamics and cognitive performance, increases in 
concentrations of oxy-Hb in the prefrontal cortex have been found to positively correlated 
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with superior (lower) reaction times during the Stroop task; this may suggest that an 
increased availability of O2 could be related to improved cognitive performance (León-
Carrion et al., 2008). Moreover, acute consumption of certain nutritional supplements has 
been observed to significantly increase concentrations of deoxy-Hb during cognitive 
performance whilst using NIRS. For example, Kennedy et al. (2010) found a single dose 
of 500 mg resveratrol significantly increased deoxy-Hb concentrations in comparison to 
placebo, during cognitive performance. Although no cognitive benefits were found 
alongside such findings, the researchers claimed this increase in deoxy-Hb indexed an 
enhanced O2 extraction and utilisation. Interestingly, caffeine has been observed to 
significantly increase concentrations of deoxy-Hb in conjunction to improved 
performance on attention tasks (Dodd et al., 2015). Despite no direct correlation being 
made between the relative increases in deoxy-Hb and cognitive performance, the 
researchers did highlight that increased deoxy-Hb concentrations were only observed 
across the post dose task period and not the absorption period; supporting that this 
haemodynamic response may be indicative of increased neural activation. 
 
 
 
 
 
 
 
Figure 2.0 Demonstration of the infrared arc ray produced by NIRS. Working via a 
transmitter (source ‘S’) to receiver (detector ‘D’) output, NIRS transmits an ‘arced’ ray 
of infrared photons allowing for the absorption and scattering to be calculated on return 
to the receiver. This permits the continuous monitoring of oxygenated (oxy-Hb) and 
deoxygenated haemoglobin (deoxy-Hb) concentrations. The continuous wave (CW) 
NIRS employed for the current thesis, consisted of two pairs of transmitter – receiver 
outputs. These were separated from one another by 4 cm, placed across the forehead, 
measuring the hemodynamic response of both the left and right hemispheres of the 
prefrontal cortex (figure adapted from Phillips (2009)). 
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2.1.1 Continuous wave (CW) NIRS  
All continuous wave (CW) NIRS devices operate by emitting light at a constant frequency 
and amplitude. The differences in light intensity on return to the receiver can detail the 
relative changes in concentrations of haemoglobin, through the modified principle of 
Beer-Lambert law2 (Obrig & Villringer, 2003). The CW-NIRS device assumes that the 
degree of scatter and the differential path length (estimated distance travelled by the light) 
are both homogenous and fixed (Davies et al., 2016). CW-NIRS has been deemed 
sensitive enough to assess changes in cerebral haemodynamics within the prefrontal 
cortex in response to neural activity following supplementation with nutritional 
interventions (Jackson & Kennedy, 2013). To illustrate, caffeine, a well-established 
vasoconstrictor (Addicott et al., 2009) has been found to cause significant reductions in 
CBF when monitored by NIRS (Kennedy & Haskell, 2011). In contrast, previous 
intervention studies have demonstrated increased blood flow from vasodilators such as 
multivitamins (Kennedy et al., 2016). Of interest to the current thesis, previous research 
has also shown that resveratrol administration can increase both total-Hb and deoxy-Hb 
concentrations in the prefrontal cortex when using this method (Kennedy et al., 2010; 
Wightman et al., 2014). All of the above research supports the utility of CW-NIRS to 
monitor hemodynamic changes during cognitive tasks following treatment interventions 
in the current PhD thesis.  
The Oxymon system (Artinis Medical Systems B.V.) was employed for the current PhD 
thesis. This NIRS system emits two nominal wavelengths of light (~765 & ~855 nm), 
modulated at 50 Hz, via a simple transmitter–receiver opitode headband. The headband 
consisted of two transmitter- receiver pairs (i.e. two channels), which were separated from 
each other by 4 cm and covered the full forehead; thus, measuring the hemodynamic 
response of both the left and right hemispheres (see Figure 2.0). This 4 cm distance 
between transmitter and receiver provides sufficient spatial resolution for a photo light 
path to penetrate to a depth of 0.5-2 cm (Fukui et al., 2003); which is sufficient to reach 
the blood vessels and capillaries of the prefrontal cortex (Haque et al., 1998). Although 
CW devices have been criticised for being influenced by superficial tissue, this may be 
due to lower separation differences and, therefore, shallower readings. The 4 cm 
                                                          
2 The Beer-Lambert law assumes that light attenuation is proportional to the change in the concentrations 
of tissue chromophores (Kocsis et al., 2006). 
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separation employed here has been credited to sufficiently reach the cerebral ventricles 
and provide an accurate measure of cerebral oxygenation (Murkin & Arango, 2009). 
As a reference point, each transmitter-receiver pair recorded data from an area of the 
prefrontal cortex that is inclusive of those corresponding to the international 10-20 system 
Fp1 and Fp2 electroencephalogram (EEG) positions. All results and outputs from the 
current device will be detailed as concentration change in micromoles per litre (μmol/L) 
for oxy-Hb, deoxy-HB, and total-Hb calculated using the modified Beer-Lambert law.  
 
2.1.2 Frequency Domain Near-infrared spectroscopy (FD-NIRS) 
Frequency domain (FD) NIRS measures both the specific light intensity attenuation and 
phase shift. The measurement of the latter allows for the quantification of the specific 
degree of light scatter in the tissue (Davies et al., 2016). Hence, the values are no longer 
fixed or assumed and so the FD-NIRS allows for ‘absolute’ concentrations of oxy-Hb and 
deoxy-Hb to be calculated (Fantini et al., 1999). It is noteworthy that both CW and FD-
NIRS measurements have been found to be in good agreement with one another when 
monitoring brain oxygenation (Fantini et al., 1999). For example, Davies et al. (2016) 
compared the abilities of both CW and FD-NIRS in the detection of changes in cerebral 
tissue saturation in an experimentally induced incremental hypoxia (PaO2 at 60 & 40 
mmHg respectively). The authors reported no significant differences were observed 
between saturation changes of either device in both hypoxic conditions. 
The OxiplexTS Frequency Domain Near-Infrared Tissue Oximeter (model 99200), with 
OxiTS software version 3.1 was employed for the current PhD thesis. This NIRS 
instrument consists of two fiber-optic optodes, comprising light sources/ laser diodes 
(eight per channel) and a light detector for each. For each of the 8 channels of the laser 
diodes (modulated at a frequency of 110 MHz), four emit wavelengths of light at 690 nm 
and the remaining four 830 nm. Working by the multi-distance principle, each of the eight 
fibres were coupled (two per each wavelength) with each pair located at 2.0-, 2.5-, 3.0-, 
and 3.5 cm respectively from the detector. A light source is turned on and light passes 
from one emitter fibre, through the tissue and into the receiver. Once the first light source 
has been measured, this is turned off and the next light source is activated; this process 
repeats with each emitter. The FD-NIRS device was calibrated to the manufacturer’s 
specified parameters before the start of each testing session.  
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The standard formula utilised by the current CW-NIRS is based upon the recommended 
formula by Duncan et al. (1995), and are valid only for measurements on brain tissue for 
17-50 year old humans. Therefore, as the final experimental study employed 50-70 year 
old humans, the FD-NIRS was utilized over the CW device. Moreover, it is imperative 
that the CW device remains attached throughout the course of the full testing session, to 
ensure the detection of any potential treatment-related change in cerebral haemodynamic 
response is not masked upon the reattachment of the device. This is due to the device only 
measuring concentration change, which only reflects how haemoglobin concentrations 
have changed during a recording period. To illustrate, the removal and then the 
subsequent reattachment of the device post administration of treatment would fail to 
acknowledge the role of an already heightened treatment-related blood flow response, 
therefore nullifying any treatment related effects when changed from the baseline 
measure. Further, given the age of the older participants in the experimental chapter in 
question, and the extended testing sessions (~2 ¼ hours), it may have been uncomfortable 
to commit to an extended testing session without access to a comfort break. The 
measurement of absolute values naturally attenuates the above mentioned methodological 
constraint and allows for the removal and reattachment of the device without the loss of 
data and is therefore a more suitable choice in this case. 
2.2 Indirect Calorimetry (ICa) 
The consumption of nutrients to be metabolised by the body is essential in order to 
produce energy. The most common form of extracting the chemical energy potential of a 
substrate is to oxidise it into CO2 and water (Ferrannini, 1988). Although the pure energy 
currency of a cell stems from ATP alone, the re-synthesis of ATP is most commonly 
ascertained by the oxidation of carbohydrates, fat, and protein. Measuring the rate and 
quantity of these substrates can provide insight into bodily metabolism and fuel oxidation 
(indicating at what capacity the body is working aerobically). Indirect calorimetry (ICa) 
is a non-invasive method which provides an accurate estimate of whole body energy 
expenditure (EE) and fuel substrate utilisation, through the measurement of inhaled O2 
and exhaled CO2. Although changes in localised CBF may reflect the overall patterns of 
cerebral metabolic activity, they cannot quantify the extent of cerebral metabolic change, 
nor the relative change in EE as a whole (Al Naher et al., 2016). Thus, the overall rationale 
for the utility of ICa in the current thesis is to build upon the monitoring of CBF in the 
prefrontal cortex and provide insight into cerebral metabolism.  
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The use of ICa as a proxy for the measurement of cerebral metabolism is small but 
growing. Studies have found increased overall EE during performance of cognitive tasks 
(Seematter et al., 2000; Al Naher et al., 2016) and a shift in fuel utilisation during a 
cognitively demanding game of chess (Troubat et al., 2009). Al-Naher et al. (2016) 
concluded that ICa was sufficiently sensitive to detect even subtle differences on overall 
EE during cognitive demand and simple cognitive motor tasks, in healthy participants. 
The use of ICa during the measurement of cognitive performance following 
administration with nutritional interventions remains relatively novel however. Here one 
study found that ICa was capable of observing significant increases in both fat oxidation 
and total EE during cognitive performance, as a result of administration with a 
multivitamin supplement in comparison to placebo (Kennedy et al., 2016). 
The utilisation of ICa in this thesis will add to the growing number of investigations which 
utilise it as a proxy for cerebral metabolism. Given that increased O2 utilisation, EE and 
local blood-supply are closely related to neural activity and that resveratrol augments 
localised CBF in the prefrontal cortex, ICa provides an appropriate tool to further explore 
this concept. For the current PhD thesis, the on-line gas analysis Metalyzer 3B (Cortex, 
Leipzig, Germany) system was adopted to measure relative changes in pulmonary gases, 
in conjunction with MetaSoft Studio software. This high-resolution spiroergometric 
system, provides functional analysis of metabolism at rest and during exercise, breath-by-
breath. Measurements of O2 inhalation and CO2 excretion were obtained through a face 
mask connected to the participant covering both the nose and mouth. The standard 
formula was employed to calculate total EE, carbohydrate and fat oxidation (Frayn, 
1983). 
 
2.3 Environmental chamber 
In all chapters which employ the use of hypoxia, testing was completed within the 
normobaric environmental chamber at Northumbria University (Manufacturer: TISS, 
Model: Environment Simulation for Human Performance). This testing facility is a 20 m2 
laboratory (see Figure 2.1) capable of creating temperatures from −25 to 55oC (± 0.1oC), 
humidity of 10-98% (+ 0.1%) and of a maximum simulated altitude of 5800 m (fraction 
of inspired oxygen (FiO2) = 9.75%). The chamber was equipped with hypoxia silencers, 
an external compressor and an entrance lobby (from which entry and exit does not 
interfere with the environment setting of the chamber). The relevant conditions utilised 
by each study will be detailed in the relevant chapters.  
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It was hypothesized that the hypoxic environment induced by the chamber would act as 
a representative, reversible, experimental model of cognitive ageing. The rationale behind 
the employment of the environmental chamber was to induce the relevant hypoxic 
environment without the interference of extraneous factors outlined in section 1.6.7, such 
as environmental conditions (namely humidity and temperature).  As air pressure lowers 
upon the ascent to altitude, temperature also decreases by an average rate of 1oC every 
150 m above sea level, in a process known as lapse rate (West et al., 2007; pp 32). As 
extreme temperatures have been shown to negatively affect cognitive performance 
(Taylor et al., 2016) the use of an artificial environment allows for control over this factor 
to neutralise any impact that would occur.  
The use of an environmental chamber over other methods of artificially inducing hypoxia 
may provide a more effective method of blinding the participant to the differing 
environmental conditions. Indeed, a series of recent experiments have utilised a hypobaric 
chamber to achieve cognitive deficits; with some authors reporting that participants are 
unaware of their decline in performance whilst within a hypobaric chamber (Asmaro et 
al., 2013). Finally, although use of hypoxic gases (via a face mask) provides an alternative 
and effective method of inducing cognitive deficits (Turner et al., 2015), the additional 
constrains of wearing several items of restrictive equipment (i.e. neuroimaging) may 
potentially introduce physical and/or psychological noise into the data set.  
 
 
 
 
 
 
 
 
Figure 2.1 An image of the environmental chamber at Northumbria University.  
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2.4 Computerised Cognitive tasks 
The Computerised Mental Performance Assessment System (COMPASS) was developed 
by the Brain, Performance and Nutrition Research Centre at Northumbria University. 
This software was used to administer all cognitive and mood assessments across all four 
experimental studies. Responses to cognitive tasks were registered via Cedrus RB-530 
response pads, with the exception of word recall and subtractions tasks, which were 
measured through pen and paper responses and keyboard entries respectively. The below 
tasks are reported to be sensitive to nutritional interventions (Kennedy & Scholey, 2000; 
Kennedy & Scholey, 2004; Reay et al., 2006) and (with the exception of the memory 
tasks) have been found to activate the prefrontal cortex (Drummond et al. 1999; Lawrence 
et al., 2002; Coull et al., 1996; Kazui et al., 2000; Jansma et al., 2000; León-Carrion et 
al., 2008). The inclusion of the memory tasks despite their inability to stimulate the 
prefrontal cortex is based upon the fact that both ageing and hypoxic conditions have been 
found to decrease aspects of memory performance (see sections 1.5.3 and 1.6.4). The 
relevant chapter will outline the tasks and the order in which they are presented in the 
cognitive demand battery, although all task descriptions will be detailed below for cross 
reference: 
Immediate Word Recall – All the words utilized in this task were all proper nouns and 
between 4-9 letters long (e.g. ‘judge’, ‘beach’, ‘bowl’). Each ‘target’ word list generated 
for each participant was randomised along with a ‘decoy’ list of words (for the word 
recognition task) from a depository of words. All individual words were selected on the 
basis that there was no similarity of spelling between the other words chosen. For example, 
the word ‘LECTURER’ was removed from either list if the word ‘LECTURE’ was 
included. For this task, the twelve words of the target word list were individually 
presented on the screen with a display and interstimulus time of 1000 ms. Once all the 
words had been shown, the participants were given 60 seconds (an onscreen timer was 
provided) to recall as many of the words as possible on a separate sheet of paper. Upon 
completion, participants were instructed to turn over the sheet of paper. The task was 
scored for the number of correct and incorrect words submitted. 
Delayed Word Recall – Participants were required to recall as many words as possible 
from those originally presented in the first immediate recall task. The participants were 
given 60 seconds (an onscreen timer was provided) to recall as many of the words as 
possible on a separate sheet of paper. Upon completion, participants were instructed to 
76 
 
turn over the sheet of paper. The task was scored for the number of correct and incorrect 
words submitted. 
Delayed Word Recognition – This task required participants to respond to individually 
presented words. Each word was either part of the original presentation of words in the 
immediate recall task or a decoy. Participants responded to either ‘no’ (left) or ‘yes’ (right) 
to each word to indicate whether that word had been previously presented in the initial 
word presentation or not. The task was scored for the percentage of correct responses and 
reaction time (ms) for these correct responses. 
Serial subtractions (3s, 7s & 17s) – Participants were presented with the standardised 
instruction screen, which informed the participant to continuously subtract the Serial 
number (either 3, 7 or 17) from a given starting number (between 800-999), as quickly 
and accurately as possible; using the numeric keyboard in front of them to enter each 
response. Upon giving their first answer, the starting number was then removed from the 
screen and their response was to be mentally retained. Sequential responses were then 
entered but were covered by an asterix. Pressing the enter key signalled the end of each 
response and cleared the three asterisks from the screen. With regards to incorrect 
responses, any subsequent responses were recorded as correct if they were accurate in 
relation to the new number. The duration of the Serial subtraction tasks is detailed in the 
individual chapters. The task was scored for the number of correct entries and the number 
of errors.  
Rapid Visual Information Processing (RVIP) – This task required the participant to 
monitor a continuous sequence of single digit numbers (1-9) appearing individually on 
the screen in rapid succession (a rate of 100/min in pseudo-random order). Participants 
were required to respond to sequences of 3 consecutive even (e.g. 4-8-2) or 3 consecutive 
odd (e.g. 5-7-1) numbers by pressing the central key on their response pad. The task ran 
continuous for 2 minutes, with 8 correct target strings being presented in each minute. 
The task is scored for the percentage of correctly identified sequences, average reaction 
time for these responses (ms) and the number of false alarms (responding when a correct 
sequence was not present).  
Choice Reaction Time (CRT) – An arrow pointing either LEFT (←) or an arrow pointing 
RIGHT (→) would appear on the screen individually, at irregular intervals (varying 
interstimulus interval of between 1 and 3.5 seconds). Participants were required to 
respond to each appearance of the directional facing arrow, using the corresponding 
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‘LEFT’ or ‘RIGHT’ buttons on the keypad in front of them, as quickly and as accurately 
as possible. Forty stimuli were presented in total per repetition of the task (lasting ~2 
minutes). The task scored for the percentage of correct responses and the reaction time to 
the correct responses (in ms). Responses made in less than 150 ms of the presentation of 
the stimuli were not registered.  
Stroop Task – Building on the original Stroop task (Stroop, 1935), four colour names 
(RED, YELLOW, GREEN, BLUE) would display individually on the screen written in a 
coloured font. Participants were required to make a response based on the colour font, 
rather than the written word depicted on the colour-coded response pad. Participants were 
shown a mixture of both congruent (name of colour and colour of ink the same) or 
incongruent (name of colour and colour of ink different) stimuli. Forty stimuli were 
presented in total per repetition of the task (lasting ~1½ minutes). Participants were asked 
to respond as quickly and as accurately as possible; responses made in less than 150 ms 
of the presentation of the stimuli were not registered. This task was scored for the 
percentage of correct responses (irrespective of congruence of the stimuli) and mean 
reaction time (in ms) for the correct responses. 
3Back – A continuous sequence of letters (upper and lower case) appeared individually 
on the screen (45 in total), with a display time 500 ms and an inter-stimulus interval of 
2.5 seconds. Participants were required to respond if the letter on screen was the same as 
that of the letter of 3 previous by pressing either ‘no’ (left) or ‘yes’ (right) on the response 
pad in front of them, as quickly and as accurately as possible. This task was scored for 
percentage accuracy and reaction time (in ms). 
Visual analogue scale (VAS) – Each scale was employed to measure an individual mood 
parameter. Here, participants were initially presented with the adjective (e.g. ‘mental 
fatigue’) of the corresponding mood, before being presented with a 100 mm line anchored 
at either side, describing the two extremes of the specific mood being measured (e.g. ‘Not 
at all’ – ‘Extremely’). Participants were required to click (using a computer mouse) at a 
point on the scale which represented how they felt at that particular point in time. The 
individual mood domains measured by individual chapters will be detailed in the relevant 
method section. 
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2.5 Ethics 
All studies in this thesis received ethical approval from the Northumbria University 
Psychology Department (within the faculty of Health and Life Sciences) Ethics 
Committee and were all conducted according to the Declaration of Helsinki (1964).  
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Chapter 3 
The effect of resveratrol consumption on whole body metabolism during 
continuous high cognitive demand: A double blind, randomised, placebo-
controlled investigation. 
3.1 Introduction 
Dietary polyphenols are found in abundance within plants. Their consumption has been 
associated with an array of health benefits in humans including reducing the risk of 
neurodegenerative disorders and CVD (Vauzour, 2017). The bioactivity of polyphenols 
is primarily attributed to their capacity to interact with various cellular signalling cascades, 
which regulate survival transcription factors, subsequent gene expression and/or protein 
synthesis (Spencer, 2010; Kennedy, 2014). Resveratrol (3,4',5-trihydroxy-trans-stilbene) 
a stilbene phytoalexin, has been found to bolster NO synthesis within human endothelial 
cells in vitro, via its ability to induce an increase in cytoplasmic Ca2+ levels (Elíes et al., 
2011). Consequently, chronic resveratrol consumption has been found to lower blood 
pressure (Liu et al., 2015), improve endothelial function (Carrizzo et al., 2013; Wong et 
al., 2013) and lead to a reduced risked of CVD and its associated risk factors (Bonnefont-
Rousselot, 2016). In addition, acute resveratrol administration has been found to promote 
vascular tone and induce endothelial vasodilation (Wong et al., 2011; Wong et al., 2013).  
As eNOS is also the isoform found in the endothelium of cerebral blood vessels (Peterson 
et al., 2011) it is also responsible for the movement of blood through the cerebral arteries 
and veins supplying the brain, and, therefore, the modulation of CBF. The capacity of 
resveratrol to induce NO-dependent vasodilation has consequently sparked interest in its 
ability to facilitate cognitive enhancement. This, in part, is based on the premise that 
enhanced neurovascular coupling provides increased access to neural fuel substrates 
(namely O2 & glucose), increasing cerebral metabolism through increased aerobic 
glycolysis. This is supported by a number of human trials which have shown that the 
administration of O2 (Moss et al., 1998; Scholey et al., 1998; Chung et al., 2006) and 
glucose (Kennedy & Scholey, 2000; Scholey et al., 2001) alone, can enhance aspects of 
cognitive performance.  
Kennedy et al. (2010) found acute oral resveratrol consumption (250 & 500 mg) induced 
dose dependent increases to CBF and superior O2 extraction (indexed by higher levels of 
deoxy-Hb) during the absorption period and post-dose (+45-90 mins) cognitive battery. 
However, despite positive modulation of CBF and fuel utilisation, no cognitive effects 
were observed from oral resveratrol administration. Two follow-up studies also failed to 
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demonstrate any robust cognitive effects from acute (Wightman et al., 2014) or chronic 
(Wightman et al., 2015) resveratrol consumption. It is noteworthy that the above 
investigations all employed young, healthy participants, who may already be at the peak 
of their cognitive capacities (Rönnlund et al., 2005). Further, such young, healthy samples 
experience an elevated CBF response to a concentration higher than demand during 
heightened neural activity (Raichle, 2010); thus, any additional exaggeration of this CBF 
response by resveratrol may be surplus to requirement. This is supported further by 
findings of other vasoactive polyphenols, such as cocoa-flavanols, which have also shown 
mixed results in the improvement of cognitive performance in young, healthy samples 
(Socci et al., 2017) even when present in conjunction with increases in CBF (Francis et 
al., 2006; Decroix et al., 2016). It is unclear therefore, whether augmented CBF is a 
suitable mechanism to induce acute cognitive enhancement in a young, healthy cohort.   
Despite its relative small size, the human brain accounts for approximately 11% of whole 
cardiac output, equating to ~20% of overall body metabolism at a resting state (Raichle, 
2010). This continuous provision of CBF is to supply the large amount of O2 and glucose 
required to meet demand. Therefore, increased neural activity is closely related to 
localised blood supply. However, the body tightly regulates the proportion of the fuel 
utilised by the brain. As neural fuel substrates are absorbed by the brain via facilitated 
diffusion (Takata et al., 1997) directly increasing the quantity of fuel (i.e supplementation 
with O2 and or glucose) can naturally enhance fuel capacity. However, CBF during 
sustained neural activity is always greater than the rise in both CMRO2 and ATP 
consumption (Raichle & Gusnard, 2002; Leithner & Royl, 2014). This may explain why 
the CBF mechanism of resveratrol thus far has been unsuccessful in improving cognitive 
performance.  
However, the increased levels of O2 extraction observed during task performance in 
previous investigations (Kennedy et al., 2010; Wightman et al., 2014) would suggest that 
resveratrol may also exert direct effects on mitochondrial aerobic respiration and cellular 
energy production. Indeed, resveratrol has been found to be an activator of the SIRT1-
AMPK-PGC-1α pathway (Dolinsky & Dyck, 2014), which is a key regular of 
mitochondrial biogenesis and EE (Cantó & Auwerx, 2009). Consequently, resveratrol 
administration has been found to improve mitochondrial functioning, aerobic capacity 
and EE within rodent models (Baur et al., 2006; Lagouge et al., 2006). Although, 
measuring changes in the cerebral haemodynamic response only reflects the pattern of 
cerebral metabolic activity and does not quantify the extent of cerebral metabolic change 
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or cerebral EE (Al Naher et al., 2016). Consequently, resveratrol mediated increases in 
CBF and O2 extraction observed during task performance (Kennedy et al., 2010; 
Wightman et al., 2014) does not necessarily detail whether this is facilitating cerebral 
metabolism and fuel utilisation directly.   
ICa is a non-invasive technique which measures the inhalation and excretion of 
pulmonary gases, providing an accurate estimate of body EE. It is postulated that this 
method can provide a proxy of cerebral metabolism and examine the changes in EE and 
fuel utilisation during cognitive demand. Al Naher et al. (2016) found that ICa sufficiently 
detected subtle differences in cognitive demand between tasks with identical response 
requirements. In addition, Kennedy et al. (2016) utilised ICa to assess the metabolic 
consequences of acute and chronic supplementation of multivitamins and minerals in 
healthy women. The researchers found that acute supplementation with higher doses of 
multi-vitamins and minerals were capable of increasing fat oxidation and overall EE; 
which was further consolidated after 8 weeks supplementation. The lower dose of the 
vitamin and mineral supplement was found to modulate CBF after an acute dose. Here, 
significant increases in both total and oxy-Hb were also found throughout the post-dose 
task battery, 60 minutes post administration. Although no significant influences on 
cognition or mood parameters were found, the above supports the use of ICa to explore 
the potential benefits of resveratrol further.  
Indeed, as the measurement of pulmonary gases that inform ICa are based upon the 
efficacy of O2 transport and mitochondrial content/function, ICa should also be sensitive 
to nutritional supplements that increase blood flow, as both also provide important 
indication of an efficient cardiovascular system (Dolinsky & Dyck, 2014). Moreover, by 
examining the metabolic consequences of resveratrol during increased neural demand, 
this could provide further support for the capacity of resveratrol to modulate the 
hypothesized additional neural substrates that come concomitant with relative increases 
in CBF. The current chapter therefore aimed to examine of the ability of resveratrol to 
influence whole body metabolism (as a proxy for cerebral metabolism) and fuel utilisation 
during high neural demand. 
To the best of this researcher’s knowledge, no investigation to date has employed the 
novelty of ICa to examine the whole body metabolic profile of resveratrol administration 
during neural demand. It is hypothesized that an acute dose of resveratrol will amplify 
fuel utilization and whole-body EE during increasing neural demand. Given the novelty 
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of the current paradigm, the hypothesis for fuel utilisation will be left fairly open. It is 
noteworthy however, that metabolic rate and fuel utilisation during cognitive 
performance are dependent upon the immediate fuel available to the body. While, Troubat 
et al. (2009) found that the body switches from an initial higher carbohydrate (CHO) 
oxidation after an acute response to a cognitive demanding game of chess, to a more 
oxidative fuel supply (i.e. increased fat oxidation) when in a fasted state. 
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3.2 Method 
3.2.1 Participants 
Twenty-seven (15 male, 12 female) healthy participants were recruited for the current 
investigation (see Table 3.0 for demographics of the current sample). All participants self-
reported themselves to be in good health and to have good or corrected vision. Participants 
were unable to take part if they had any food intolerances or sensitivities, or had any 
gastrointestinal, hepatic or renal diagnoses; this was to ensure no extraneous factors 
interfered with the absorption of the treatments. Participants reported themselves to have 
not suffered any neurological trauma (such as a head injury) or possess any 
neuropathologies. No participant reported themselves to be taking any herbal or 
pharmaceutical treatments (with the exception of the contraceptive pill & topical acne 
medication), whilst only consuming low to moderate amounts of caffeine (<6 cups of 
coffee / tea or its caffeine equivalent daily). Due to the requirements of the tasks, 
participants were excluded if they had dyscalculia (or any relevant learning difficulty). 
Participants were required to fast for 12 hours (except for water) and avoid strenuous 
exercise prior to each testing session. Each participant confirmed to still be in line with 
the study inclusion / exclusion criteria at the start of every testing session. They received 
£60 for their participation upon completion of the study. 
 
Table 3.0 The mean and standard deviation (SD) of demographics for participants. 
 
3.2.2 Cognitive Task Battery 
Based on previous literature suggesting that more substantial cognitive demand is 
required in young, healthy samples in order to hinder ceiling ability, the current study 
adopted a demanding battery of tasks. In terms of CBF, neural fuel utilisation is also 
sensitive to increases in both time and difficulty of the task during cognitive performance 
Parameters Mean (SD) 
Age (years) 22.15 3.64 
Stature (m) 1.74 0.10 
Mass (kg) 69.30 14.03 
BMI (kg/m2) 22.71 2.39 
Average Weekly Physical Activity (hours per week) 3.33 1.14 
Average Daily Fruit and Vegetable intake 
(UK portions) 
5.37 3.90 
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(Kennedy & Scholey, 2000; Fairclough & Houston, 2004). The cognitive battery for this 
chapter employed the Serial 3, 7 and a less utilized Serial 17 subtraction task. The use of 
Serial subtraction tasks has been reported previously to be cognitively demanding by 
participants and demonstrated to increase both glucose utilisation and heart rate beyond 
that of peripheral mechanisms (Scholey et al., 2001; Kennedy & Scholey, 2004; Kennedy 
et al., 2016). To avoid any task-time bias, the order of the tasks was counterbalanced in a 
Latin square. Each task lasted 5 minutes, thus each repetition lasted for 15 minutes in 
total. All tasks in each repetition of the battery were completed in a continuous fashion, 
in order to induce maximal cognitive demand and fatigue to the participants. Two visual 
analogue scales (VAS) were employed pre and post completion of all the Serial 
subtraction batteries, measuring self-reported ‘Mental Tiredness’ and ‘Concentration’.   
3.2.3 Treatments 
Active treatments of resveratrol were acquired from megaresveratrol.net (Danbury, CT, 
USA). The integrity of the extract used was 99.73%, as verified by the manufactures 
statement. Treatments were administered on separate days, with each testing session 
being conducted no more than 48 hours before, and no more than 14 days after the 
previous session. During the three study visits, participants received three single-dose 
treatments in an order dictated by random allocation to a (Latin Square) counterbalanced 
order. Two capsules were consumed on each testing day either: 
 
1) ×2 placebo capsules (CABOT MP5 fumed silica). 
2) ×1 250 mg dose of resveratrol with ×1 placebo. 
3) ×2 250 mg resveratrol capsules (equating to a 500 mg dose).  
 
All treatments were administered within the same vegetarian soft-gel capsules. All 
treatments were counterbalanced and were prepared by the lead investigator, then coded 
by a third party who had no further involvement in any aspect of the study. No member 
of the investigational team was aware of the contents of the capsules until completion of 
the statistical analysis. This was the procedure for all subsequent studies of this thesis. 
 
3.2.4 Indirect Calorimetry (ICa)  
For the current investigation, inhaled and expired pulmonary air was measured using an 
on-line analysis system (Metalyzer 3B, Cortex, Leipzig, Germany). The standard formula 
was employed to calculate EE, CHO and fat oxidation (Frayn, 1983). The gas analysis 
system was attached to the participants via a facemask, which covered both the nose and 
mouth, connected by falconia tubing.  
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3.2.5 Procedure 
Participants were required to attend the Brain, Performance and Nutrition Research 
Centre at Northumbria University on four separate occasions. The first of these visits to 
the laboratory was to screen the participant against the inclusion / exclusion criteria and 
familiarise them with the cognitive demand battery. Here, the participants completed 2 
full repetitions of the task battery to achieve an appropriate level of competency for the 
tasks. The following three testing visits were identical to each other: participants arrived 
at 8 am, fully fasted (consuming nothing but water) for 12 hours prior to the session; this 
was to restrict any influence from prandial factors. Participants were also required to 
refrain from engaging in any strenuous exercise that morning. Upon arrival, each 
participant was asked to confirm they were still compliant with the inclusion criteria 
before testing began. Following confirmation, participants were connected to the gas 
analysis equipment via a facemask and mouthpiece. The mask was adjusted to ensure 
there were no gaps, and was fitted to the participant’s comfort. Participants then remained 
at rest for 10 minutes, watching a nature documentary (BBC’s Planet earth). After, 
participants completed a pre-dose baseline measurement of the Serial subtraction 
cognitive demand battery and mood scales. Upon completion, participants were then 
disconnected from the gas analysis equipment and then administrated with their treatment 
for the day, before continuing to rest for a further 35 minutes.  
Participants were then reconnected to the gas analysis device and completed a post-dose 
rest period for 10 minutes whilst continuing to watch the documentary. This measure was 
included in response to the blood flow effects of resveratrol being observed at thirty-five 
to forty-five minutes, post administration at rest (Kennedy et al., 2010; Wightman et al., 
2014), while also coinciding with pharmacokinetic data which has detected resveratrol in 
plasma metabolites from approximately 30 minutes (Walle, et al., 2004). After 
establishing a post-dose rest measure, the participant then completed the first of the post-
dose mood scales and cognitive demand battery. The participants were then required to 
complete the battery and VAS scales at further 2-hour and 3-hour post administration 
time points. This was due to the half-life of resveratrol being noted up to 3 hours (Almeida 
et al., 2009). ICa measures were taken throughout all task performances (Figure 3.0). 
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Figure 3.0 Timeline for study 1 testing day 
3.3 Statistical approach 
All ICa analysis was completed within Minitab 17 Statistical Software (State College, PA: 
Minitab, Inc.), while all behavioural data was analysed in SPSS version 22 for windows 
(IBM SPSS Statistics Armonk, NY). 
 
3.3.1 Main ICa analysis 
Raw data was extracted and averaged across 1-minute epochs for each task within the 3 
individual post dose repetitions. Each of the five, 1-minute epochs were first cleaned 
before being condensed and averaged to represent a 5-minute average time point. Here 
data was first graphed to highlight potential extreme values or large inconsistent shifts in 
overall patterns. This cleaning process led to the removal of two full data sets and a further 
set was not included due to data catchment errors (missing baseline performance). The 
final sample for ICa analysis was N=243 (post-dose rest analysis data N=23). 
All remaining ICa data during cognitive demand was converted to change from baseline, 
utilising the relative baseline task performance from each task. Analysis consisted of 3 × 
3 × 3 within-subjects’ ANOVAs assessing Treatment (250 mg resveratrol, 500 mg 
resveratrol & placebo) × Task (Serial 3, Serial 7 & Serial 17 subtractions) × Repetition 
(×3). Subsequently, planned comparisons were conducted upon the emergence of 
significant interaction effects, utilising the mean square (MS) error values from the initial 
ANOVA. Only comparisons to placebo and not between active treatments were 
                                                          
3 The novelty of the study meant there was no directly comparable data for calculation of an appropriate 
sample size. Therefore, a sample size was based upon the power analysis of the 3-prior resveratrol / NIRS 
studies and was also used throughout the following studies of this thesis.  
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conducted. With regards to the analysis of the post dose rest measure, an overall average 
was created for the 10-minute period, before a series of one-way ANOVAs were 
conducted to assess difference between the two resveratrol treatments against placebo.  
3.3.2 Behavioural analysis 
Raw cognitive data was cleaned before being converted into a change from baseline 
measure (N=26). Raw baseline scores for each task were then analysed to assess if there 
was any difference between treatment baseline scores. Following this, nine within-
subjects’ ANOVAs investigating Treatment (500 mg resveratrol, 250 mg resveratrol & 
placebo) × Repetition (×3) × Task (3s, 7s & 17s) were conducted, followed, where 
appropriate, by Bonferroni corrected post-hoc pairwise comparisons. Only significant 
treatment related results will be reported from the cognitive analysis.  
Concerning mood analysis, scores for ‘concentration’ and ‘mental fatigue’ were converted 
to change from baseline (the score submitted following completion of the baseline battery 
of cognitive tasks was used as a baseline). Two within-subjects’ ANOVAs investigating 
Treatment (500 mg resveratrol, 250 mg resveratrol & placebo) × Repetition (×3) × Time 
(pre-completion & post-completion of the cognitive battery) were conducted. Again, this 
was followed up with Bonferroni corrected post-hoc pairwise comparisons on the 
presentation of a significant F test. Only significant treatment related results will be 
reported, with the exception of any main effects of time; this was reported to provide 
support for the claim that the cognitive battery was ‘cognitively demanding’. 
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3.4 Results 
3.4.1 ICa data for task performance  
 
Total energy expenditure (EE) 
The repeated measures ANOVA revealed no significant of treatment or treatment related 
interaction on EE during cognitive performance.  
 
Carbohydrate (CHO) oxidation 
The within-subjects’ measures ANOVA revealed no significant of treatment or treatment 
related interaction on CHO oxidation during cognitive performance. 
 
Fat oxidation 
The ANOVA revealed no significant of treatment or treatment related interaction on fat 
oxidation during cognitive performance. 
 
Respiratory exchange ratio (RER) 
 
The within-subjects’ ANOVA demonstrated a significant treatment × task × repetition 
interaction [F (8, 184) = 1.13, p = .039] indicating a significant treatment related change 
in fuel utilisation during task performance. Follow up planned comparisons demonstrated 
that administration of 250 mg resveratrol evinced a significant increase in RER during 
Serial 3 (p =.002) and an increase nearing significance4 during Serial 7 (p =.085) and 
Serial 17 (p =.068) subtraction performance during repetition 1. Moreover, administration 
with 250 mg resveratrol significantly increased RER during Serial 3 (p =.001) and 7 (p 
=.001) task performance during repetition 3 in comparison to placebo. However, the same 
dose was found to induce a significant reduction in RER during Serial 17 task 
performance (p <.001) at the final repetition in comparison to placebo.  In addition, 
administration with 500 mg resveratrol evinced an increase in RER across all tasks and 
repetitions in comparison to placebo. These were found to be significant during Serial 3 
and 7 subtraction performance at repetition 1 (S3: p =.029; S7: p =.018) and 3 (S3: p 
=.003; S7: p =.001), whilst trending an increase in RER during Serial 3 (p =.061) and 17 
(p =.066) subtraction performance during repetition 2 relative to placebo (Figure 3.1).  
 
                                                          
4 Trending or nearing significance is highlighted when the p value is between >.05 and ≤.09. This was the 
case for the rest of the thesis.  
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Figure 3.1 The acute effects of 250 mg and 500 mg resveratrol on respiratory 
exchange ratio (RER). Graph depicts mean changes in change from baseline RER (with 
SEM error bars), during the three repetitions of the post-dose tasks in 24 healthy adults 
following 500 mg resveratrol, 250 mg resveratrol or placebo. *p <.05, **p <.01 and t – 
trend (nearing significance). 
 
The proportion (%) of carbohydrate oxidation to overall energy expenditure. 
The omnibus ANOVA revealed a significant treatment × task × rep [F (8, 184) = 2.14, p 
= .034] interaction in percentage change in CHO oxidation during post-dose performance. 
With regards to follow up planned comparisons, administration of 250 mg resveratrol 
demonstrated a significantly higher percentage CHO of total EE during Serial 3 
subtractions at repetition 1 (p =.006) in comparison to placebo. Similarly, the same dose 
showed significant increases in CHO of total EE during Serial 3 (p =.004) and 7 (p =.004) 
subtractions but evinced a significant decreased during Serial 17 (p =.001) subtraction 
performance during the final repetition in comparison to placebo. The 500 mg dose of 
resveratrol consistently increased the percentage CHO of total EE across all tasks at all 3 
repetitions, relative to placebo. These increases were found to be significant during Serial 
3s and 7s at repetitions 1 (S3: p =.044; S7: p =.020) and 3 (S3: p =.007; S7: p =.001) and 
trending during repetition 2 for Serial 3 (p =.077) and 17 (p =.082) subtractions (Figure 
3.2). 
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Figure 3.2 The acute effects of 250 mg and 500 mg resveratrol on the proportion of 
carbohydrate oxidation (g) making up overall energy expenditure (% EE). Graph 
depicts mean changes in the percentage of carbohydrate oxidation (with SEM error bars), 
during the three repetitions (rep) of the post-dose tasks in 24 healthy adults following 500 
mg resveratrol, 250 mg resveratrol or placebo. *p <.05, **p <.01 and t – trend (nearing 
significance). 
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3.4.2 ICa Post dose rest 
The series of one-way ANOVAs revealed no significant treatment related differences 
during the 10-minute rest period post administration for any of the metabolic outputs (EE, 
CHO oxidation, Fat oxidation or RER). 
 
3.4.3 Behavioural Data 
Baseline analysis – Prior to any analysis, a series of one-way ANOVAs were conducted 
on baseline scores for each cognitive task outcome and the two mood sub-measures. No 
significant differences were found between any of the baseline scores for any of the mood 
or cognitive outcomes (p >.10). 
 
3.4.3.1 Mood Analysis  
No significant treatment related or treatment interaction effects were found on either self-
reported concentration or mental tiredness. However, a significant main effect of time 
was found for mental tiredness [F (1, 25) = 10.711, p = .003], where by post completion 
of the cognitive battery (M = -1.31) lead to significantly higher self-reported mental 
tiredness in comparison to scores reported prior to completion (M = -7.84). Mood data is 
reported in full in Appendix 1.0. 
 
3.4.3.2 Cognitive Performance 
No significant cognitive results of treatment or treatment related interactions were found 
in the current study. Cognitive performance data is reported in full in Appendix 1.1. 
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3.5 Discussion 
The aim of the current investigation was to build upon the small, but growing literature 
surrounding the efficacy of resveratrol as a cognitive enhancer in healthy, young humans 
(Kennedy et al., 2010; Wightman et al., 2014; Wightman et al., 2015).  Previous 
investigations have demonstrated resveratrol-mediated increases in CBF and O2 
extraction during cognitive performance. However, such modulation has failed to result 
in any subsequent improvements to performance. It remains unclear whether augmented 
CBF and O2 extraction is capable of cognitive improvements in young, healthy humans. 
The current study employed ICa to provide a proxy for cerebral metabolism and neural 
fuel utilisation in order to elucidate the metabolic profile of resveratrol under high 
cognitive demand5.   
The current study observed a significant (treatment × task × repetition) interaction effect 
for change in RER across post dose task performance. RER provides insight into 
predominant fuel oxidation, with higher RER values suggesting a greater utilisation ratio 
of CHO to fat (Simonson & DeFronzo, 1990). Follow up analysis revealed that 
administration of both doses of resveratrol induced significant increases in RER; although 
only the 500 mg resveratrol demonstrated consistently higher RER across all tasks and 
repetitions in comparison to placebo. In addition to increases in RER, a single dose of 
500 mg resveratrol was found to subsequently increase the proportion of CHO oxidation 
generating overall EE during Serial 3 and 7 subtraction performance, 45 minutes and 3 
hours post administration. Together these results highlight that resveratrol can induce a 
subtle, yet significant, increase in the oxidation of glucose during cognitive performance. 
However, no cognitive benefits of resveratrol were observed in the current study.  
In the absence of a somatic control, it is difficult to distinguish whether the 
aforementioned metabolic effects of resveratrol were influenced further by the varying 
levels of difficulty of the individual Serial subtraction tasks. As the artefact of typing rates 
varies for the Serial subtraction tasks (i.e. higher number of attempts during Serial 3s to 
Serial 7 etc.), this muddies the water of current paradigm, making it uncertain if the 
resveratrol-mediated changes in metabolism was task dependant. It should be noted 
however, that there was no significant increase in the total number of responses attempted 
between any of the three treatment conditions for any of the individual Serial subtraction 
                                                          
5 The concept of the cognitive task battery being ‘cognitive demanding’ is supported by the significant 
increase in self-reported mental tiredness registered by the participants following the completion the 
battery compared to before undertaking it.  
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tasks (see Appendix 1.1). This suggests that the shift in fuel oxidation of the 500 mg 
resveratrol was not mediated by additional somatic movements. In sum, a single dose of 
resveratrol can increase oxidation of CHO during high neural demand. Such findings 
clarify that acute oral resveratrol administration can increase the uptake / utilisation of 
available fuel substrates in the young, healthy populations; although, as anticipated, this 
increase in metabolic activity has not been found in conjunction with cognitive 
enhancement in a cohort with a hypothesized high neurocognitive ability.  
In the absence of significant modulation to cognitive performance by any treatment, it is 
unclear whether the resveratrol-mediated modulation of metabolism observed here has 
been beneficial. Currently, only two investigations have observed significant modulation 
of RER in conjunction with improved cognitive performance. However, these studies 
have revealed opposing results; reporting a significant increase (Delistraty et al. 1991) 
and a significant decrease (Troubat et al., 2009) in RER during task performance 
respectively. However, as CHO oxidation produces a (15%) greater ATP yield in 
comparison to fat, higher CHO oxidation has been suggested to represent an O2-saving 
strategy, to economize O2 when performing energy-demanding tasks in 
environments/events of lower O2 (Schippers et al., 2012). This may suggest the effects of 
resveratrol are more beneficial in populations that suffer a reduction in O2 metabolism.  
The lack of cognitive improvements observed in the current study coincide with those in 
previous investigations (Kennedy et al., 2010; Wightman et al., 2014; Wightman et al., 
2015) and suggests that the young, healthy sample employed here are likely unable to 
benefit resveratrol administration. As the CBF response to sustained neural activity is 
always greater than that of the rise in both CMRO2 and ATP consumption (Raichle & 
Gusnard, 2002; Leithner & Royl, 2014), any further modulation of this process may be 
redundant. In addition, this population may be in the peak of their cognitive capacities 
(Rönnlund et al., 2005) leaving little scope for cognitive improvement by resveratrol. In 
contrast, the natural ageing process is associated with significant reductions in cognitive 
performance (Peters, 2006; Glisky, 2007; Salthouse, 2010; Harada et al., 2013). This, in 
part, is due to the diminishing efficacy of the human vasculature, which results in the 
supply and CMRO2 becoming increasingly compromised with age. It is possible 
therefore, that the vaso-metabolic effects of resveratrol will be of increased utility to 
naturally ageing populations who suffer a reduction in maximal O2 uptake and O2 
metabolism. 
94 
 
Chapter 4 
The cerebral hemodynamic response and cognitive effects of acute resveratrol 
administration in young, healthy adults in hypoxic and normoxic conditions: a 
model for the ageing brain 
 
4.1 Introduction  
The results of Chapter 3 demonstrated that a single 500 mg dose of resveratrol was 
capable of significantly shifting fuel utilisation towards higher glucose oxidation during 
cognitive demand. However, as this increase in metabolism was not found in conjunction 
with any improvements in cognitive functioning, it was proposed that resveratrol may be 
unable to provide consistent cognitive enhancement to young, healthy samples due to 
their already heightened neurocognitive ability. It was suggested therefore, that the CBF 
and metabolic effects of resveratrol may be of increased utility in cohorts that suffer a 
reduction in cognitive performance and /or cerebral metabolism, such as natural ageing 
populations.    
As the brain cannot store its own energy source, it requires a continuous provision of CBF 
to provide the large quantity of neural fuel substrates to meet demand. Consequently, a 
tightly regulated relationship between CBF and cognitive functioning exists, whereby 
even a small comparative decline to blood flow can negatively impact cognitive 
performance (Duschek & Schandry, 2007; Poels et al., 2008). Given that the natural 
ageing process leads to an observable reduction in rCBF (Martin et al., 1991; Kalaria, 
2009; De Vis et al., 2015) and a subsequent decrease in CMRO2 (Aanerud et al., 2012; 
Chen et al., 2011), it is perhaps of no surprise that the age-related deterioration of the 
cerebral vasculature has been shown to be a significant contributor to cognitive decline 
(Celsis et al., 1997). It is noteworthy however, that the rate of reduction in CBF is not 
uniform across the brain, with subcortical regions remaining relatively unchanged (Chen 
et al., 2011) while areas such as the prefrontal cortex appear to be more notably affected 
(Lu et al., 2010).   
The ability of resveratrol to promote an increase in both CBF and O2 extraction within 
the prefrontal cortex (Kennedy et al., 2010; Wightman et al., 2014; Wightman et al., 2015) 
may present a viable method with which to attenuate age-related reductions in rCBF and, 
in turn, cognitive performance. Other vasoactive polyphenols such as cocoa-flavanols, 
have already been found to induce increases in cerebral perfusion in older cohorts (Sorond 
et al., 2008; Sorond et al., 2008; Sorond et al., 2010; Brickman et al., 2014; Lamport et 
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al., 2014). Further, a small but growing number of controlled intervention studies have 
demonstrated improvements to aspects of cognitive functioning and cardiovascular 
measures following chronic cocoa-flavanol administration in older adults (Mastroiacovo 
et al., 2015; Desideri et al., 2012; Brickman et al., 2014). Although evidence regarding 
the efficacy of acute doses and the simultaneous measurement of both CBF and cognition 
is lacking, the growing cocoa-flavanol research in elderly samples may lend support to 
the argument that resveratrol has the capacity to increase cognitive performance in 
naturally ageing cohorts, via augmented CBF.   
However, age-related cognitive decline is, of course, multifactorial. Individual variability 
in biological, psychological, and lifestyle factors, are all likely to contribute to differing 
levels of cognitive performance in ageing populations (Harada et al., 2013). Indeed, the 
brain undergoes a series of other physiological changes in conjunction with observed 
reductions to rCBF. For example, varying levels of regional atrophy, increased 
neuroinflammation and declining gluco-regulation have all been shown to contribute to 
declining cognitive functioning with age (Peters, 2006; Cevenini et al., 2013; Lamport et 
al., 2009). Research has also found ‘cognitively intact’ humans up to 100 years of age 
(Perls, 2004); demonstrating the diversity of individual variability that can take place 
within ‘normal’ ageing. The challenge here, therefore, consists of identifying any 
potential cognitive benefits that may be the direct result from resveratrol-mediated 
attenuation of reductions in rCBF and CMRO2.  
A diminishing efficacy of the human vasculature during ageing alters the diffusion of O2 
at the capillary level. Thus, ageing is commonly characterized by a decrease in O2 supply 
(Valli et al., 2015). Consequently, the use of hypoxia has been suggested as an 
experimental model sufficient for studying ageing processes (Cataldi & Di Giulio, 2009). 
As the brain has a particular susceptibility to a reduction in O2 supply (Larson et al., 2014), 
the current study therefore proposes that the disruption of O2 availability in young, 
healthy samples, may serve to induce cognitive impairments which will resemble those 
experienced as part of the ageing process. In support, a series of reviews have revealed 
that exposure to acute (altitude induced) hypoxia can induce observable, yet reversible, 
reductions in cognitive performance in humans (Petrassi et al., 2012; McMorris et al., 
2017). Indeed, poorer attention, reaction time and error rates have all been found during 
exposure to altitude induced hypoxia (Davranche et al., 2016; Petrassi et al., 2012). This 
is particularly interesting given that these specific cognitive domain reductions are also 
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observed in natural ageing populations (Glisky, 2007; Harada et al., 2013), offering a 
direct comparison between populations.  
There is some ambiguity regarding the level at which cognitive deficits begin to occur 
during hypoxia. Despite no consistent cognitive deficits having been reported below 3000 
m altitude (Bahrke & Shukitt-Hale, 1993) many investigations have adopted varying 
durations of exposure to the hypoxic conditions. Instant exposure to hypoxia ensures 
minimal adaptations to the body, suggesting that cognitive deficits may be more apparent 
within the initial stages of exposure. Therefore, the use of mild hypoxia (< 3000 m 
stimulated altitude) is still warranted if it is employed in a short and immediate bout, to 
enable maximal deficits and minimal adaptation to take place (Petrassi et al., 2012). Given 
the novelty of the current paradigm, it is proposed that this concept should be explored 
initially at a mild hypoxic level (equivalent to 16% FiO2) to assess if even small reductions 
in cerebral oxygenation can disrupt cognitive performance.  
The current study aimed to ascertain whether the use of acute hypoxia could be employed 
to model the cognitive impairments experienced during the natural ageing process. In 
addition, the current chapter aimed to assess whether oral resveratrol administration was 
capable of attenuating the subsequent reductions in cognitive performance, evinced by 
exposure to the proposed hypoxic model (in a young, healthy cohort). It is anticipated 
that the previously observed increases to oxy-Hb and deoxy-Hb in the prefrontal cortex 
(Kennedy et al., 2010; Wightman et al., 2014; Wightman et al., 2015) induced by 
resveratrol, will be replicated here irrespective of the environmental condition. Although 
hypoxia can induce either hypocapnia mediated vasoconstriction (Raichle & Plum, 1972) 
or hypercapnia mediated vasodilation (Vavilala et al., 2002), this is not anticipated to 
influence the outcome of the current study. Given that resveratrol can bolster NO 
production and improve NO bioavailability (Xia et al., 2010), this should allow for a 
greater exaggeration of CBF during exposure to acute hypoxia irrespective of hypoxia 
induced vasodilation or vasoconstriction. Consequently, as a result of the increases to 
CBF, it is predicted that such effects will subsequently lead to increased cognitive 
performance within the hypoxic condition. 
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4.2 Method 
4.2.1 Participants  
Twenty-four adults (8 males, 16 females; mean age = 22, range = 18-34) with good or 
corrected vision were recruited for the current study. All participants reported themselves 
to be in good health and did not suffer from any food intolerances / allergies or digestive 
problems, which may interfere with the supplementation and absorption of the treatment. 
No participants reported themselves to be using any social drugs (including tobacco), 
medication (excluding the contraceptive pill), or supplementing with any herbal / food 
extracts; they also confirmed to consume <6 cups of caffeinated tea / coffee a day (or the 
450 mg caffeine equivalent). Participants were also screened for any neurological or 
neuro-developmental disorders and were unable to take part if they had suffered a head 
injury. Given the nature of the current study, participants also confirmed that they had not 
lived at an altitude of 2000 m or above in the last 3 months; this was to avoid any 
advantageous adaptations (such as exaggerated erythropoiesis). Moreover, as the 
cognitive tasks utilised here have not been validated on non-native English speakers, all 
participants reported to have English as their 1st language.  
Participants arrived at the laboratory on testing days fully fasted from liquids (except for 
water), food and having had no alcohol for least 24 hours, whilst confirming that they 
were still in compliance with the exclusion criteria. A fasted state was considered a more 
appropriate protocol, given the unknown effects of individual foodstuffs on resveratrol 
consumption.  
 
4.2.2 Treatments 
During the four testing study visits, participants received a single-dose treatment in 
compliance with a randomised allocation to a (Latin Square) counterbalanced order. 
Treatments were administered on separate days, with each testing session being 
conducted no more than 48 hours before, and no more than 14 days after, the previous 
session. Two capsules were consumed by participants on each testing day being either: 
 
1) ×2 placebo capsules (CABOT MP5 fumed silica). 
2) ×2 250 mg resveratrol capsules (equating to a 500 mg dose).  
Again, all treatments were prepared by the lead investigator, before being coded by a third 
party who had no further involvement in any aspect of the study. No member of the 
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investigation team was aware of the contents of the capsules until the completion of the 
statistical analysis.   
 
4.2.3 Near-Infrared spectroscopy (NIRS) 
The functional NIRS employed for this study was Oxymon system (Artinis Medical 
Systems B.V.). The NIRS headband was worn for the full duration of all four of the testing 
sessions. Markers were inserted throughout the recording of the NIRS data to time stamp 
specific epochs corresponding to individual cognitive tasks. Data collected during the 
memory tasks was excluded from the analysis due to artefacts caused by the physical 
movement associated with the paper and pencil responses. 
 
 
4.2.4 Environmental chamber  
All testing for the current study was completed within the environmental chamber at 
Northumbria University. An environment with 16% atmospheric FiO2 (2134 m above sea 
level), 40% humidity and a temperature of 23oC was simulated for the hypoxic condition. 
The normoxic condition adopted the same humidity and temperature but employed an 
FiO2 level imitating sea level (20.93% available O2). All baseline measures were 
conducted at normoxia and the relevant O2 status was set / initiated at the beginning of 
the absorption period. For testing sessions in the normoxic condition the O2 status 
remained unchanged.  
 
4.2.5 Cognitive tasks 
A cognitive battery of tasks was delivered via COMPASS and consisted of seven tasks. 
With the exception of the memory tasks (which were omitted from the NIRS analysis), 
all other tasks have shown in previous neuroimaging studies to activate the prefrontal 
cortex (Drummond et al. 1999; Lawrence et al., 2002; Coull et al., 1996; Kazui et al., 
2000). The battery lasted approximately 12 minutes and was employed to tax the 
participant sufficiently to increase demand for neural substrates. The cognitive battery 
comprised (in order of appearance): Immediate word recall, Serial subtractions (3 & 7), 
RVIP, 3back, Delayed word recall and Delayed word recognition.  
 
4.2.6 Procedure 
Participants were required to attend the laboratory on five separate occasions. The first of 
these visits was a familiarisation session, which involved briefing the participant and 
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receiving their informed consent before screening them against the exclusion criteria. 
Training on the individual tasks in the cognitive battery was then provided to ensure the 
participants were competent and confident to complete all tasks on the battery without 
assistance; here, participants completed two full repetitions of the cognitive battery. The 
remaining 4 visits were testing sessions, in which participants arrived at the testing facility 
at 8 am, fully fasted for 12 hours (except for water). Upon arrival, participants were 
screened to ensure that they still complied with the exclusion criteria, before taking a brief 
rest. Participants were then led to the environmental chamber and connected to the NIRS 
device; this was worn throughout the full testing procedure. A baseline measurement of 
the cognitive battery was then completed and followed immediately by a 10-minute rest 
(while watching a non-stimulating video). The treatment for the day was then consumed. 
At this point, the chamber was then set to the appropriate O2 level (blind to the participant) 
and the participant remained at rest for a further 45 minutes (continuing with the video) 
to allow for adequate absorption. The participant was then required to complete 3 full 
series of the cognitive battery consecutively (Figure 4.0).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.0 A timeline of the second experimental study testing day. A baseline 
measure of the cognitive tasks was first established. After completing a 10-minute rest 
period, treatment was administered before participants rested for a 45-minute absorption 
period. Participants then completed 3 repetitions of the cognitive battery. Near-Infrared 
spectroscopy (NIRS) was worn for the full session and data collected throughout. All 
NIRS data was baseline adjusted from the first minute of the absorption period.  
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4.3 Statistical Approach 
All behavioural data was analysed using SPSS version 22 for windows (IBM SPSS 
Statistics Armonk, NY), while all NIRS analysis was analysed using Minitab 17 (State 
College, PA: Minitab, Inc.). 
4.3.1 Main NIRS analysis 
All raw data was first graphed (prior to any analysis) to determine the existence of 
potential outliers (prior to any analysis or un-blinding of treatments). In the first instance, 
a ±2.5 standard deviation of the mean was applied to the data to provide a rough guide to 
identify outliers, yet the removal of data was left to the researcher’s discretion. Although 
an arbitrary measure, this allowed for a certain amount of flexibility to permit for 
individual differences in natural CBF levels. This data clearing method was applied to all 
NIRS data in all studies within this thesis; with the means and standard deviations 
calculated for each individual study. After the removal of errors and outliers, the final 
sample for NIRS analysis was N=21. In the first instance, NIRS data was analysed with 
hemisphere (left & right) as a factor, although, no effect of hemisphere was found here or 
in any other chapter in this thesis. Therefore, the data from both the left and right 
hemispheres were combined and averaged for analysis. This was also done for the two 
remaining studies in this thesis. 
All NIRS data was converted to change from baseline (the baseline being the first minute 
of the absorption period) and averaged into 2-minute epochs across the remaining 
absorption and subsequent post dose task period. Due to the artefacts created by the 
movement associated with pen and paper responses within the NIRS data, memory task 
performance was removed from the analysis. The initial analysis of the averaged NIRS 
data was performed via within-subjects’ ANOVAs with treatment (500 mg × Placebo) 
analysed against O2 status (hypoxia × normoxia) and Epoch (comprising the thirty-seven 
2-minute epochs, covering both the absorption and post task period). Upon the emergence 
of a significant interaction effect, subsequent planned comparisons were conducted, 
comparing resveratrol to placebo at each epoch, within the relevant environmental 
condition; such t-tests were calculated using the MS error values from the initial ANOVA.  
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4.3.2 Behavioural data analysis 
All raw cognitive data was inspected for potential outliers and for missing data points 
prior to analysis. Participants with missing data were removed from behavioural analysis 
for the relevant task. One participant was excluded due to a data catchment error (missing 
several complete data sets), resulting in a sample of N=23 for analysis6 . Cognitive 
performance data was analysed as change from pre-dose baseline performance for all task 
sub-measures in the cognitive battery. This comprised a total of 14 within subjects’ 
ANOVAs investigating Treatment (500 mg resveratrol & placebo) × Repetition (×3) × 
O2 status (hypoxia & normoxia), followed, where appropriate, by Bonferroni corrected 
post-hoc pairwise comparisons between resveratrol and placebo (within the relevant O2 
status only).  
4.3.3 The analysis of overall cognitive domains across treatments and hypoxic 
conditions  
In accordance with the aims of the current study, subsequent analysis was carried out to 
determine the success of the hypoxic model. ANOVAs were conducted for the 3 NIRS 
data outcomes (oxy-Hb, deoxy-Hb & total-Hb) comparing only the placebo conditions to 
isolate the influence of the O2 status itself.  
Regarding cognitive performance, Z scores were compiled through change from baselines 
scores and combined for the complete sets of behavioural data (N=19), to represent the 
cognitive domains assessed in the cognitive battery. Mean scores were calculated for each 
task outcome measure (regardless of repetition). Each individual change from baseline 
score was then subtracted from the mean overall score and then divided by the standard 
deviation to produce a Z score. Scores for each task outcome were compiled for the 
following cognitive domains: accuracy (correct responses from: Serial subtractions tasks, 
RVIP & 3Back), speed of processing (correct reaction time scores from: 3back, RVIP & 
word recognition) errors (incorrect responses from: Serial subtractions tasks, RVIP & 
3Back) and secondary memory (correct recall responses from: both recall tasks & 
delayed word recognition). These were then analysed in a within subjects’ ANOVA (Rep 
× Treatment × O2 status) to ascertain any overall effects of hypoxia on the cognitive 
domains. Only main effects of O2 status and treatment or subsequent interaction with each 
other or repetition from the initial ANOVA will be reported.  
                                                          
6 Removal of participants from individual tasks was done due to either missing baseline data and / or data 
catchment errors (namely due to data responses failing to register for specific tasks). See appendix 2.0 for 
the sample size of individual tasks.  
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4.4 Results 
4.4.1 Near-Infrared Spectroscopy (NIRS) data 
 
Deoxygenated haemoglobin (deoxy-Hb): 
The ANOVA revealed a significant main effect of hypoxia/normoxia [F (1, 660) = 44.67, 
p<.001] along with a complementary interaction with epoch [F (33, 660) = 32.56, p<.001], 
indicating a significant increase in concentrations of deoxy-Hb in the hypoxia condition 
in comparison to the normoxia condition. The ANOVA also revealed a significant 
treatment × hypoxia × epoch interaction [F (33, 660) = 1.75, p = .006] demonstrating that 
administration of 500 mg resveratrol evinced significantly higher concentrations of 
deoxy-Hb, in comparison to placebo, during the absorption period within hypoxia. As can 
be seen from figure 4.1, planned comparisons showed that this was significant during 
epochs 5-23 (5-9, 11, 13, 15-17, 20-22 (p <.05); 12-13, 18-19 (p <.01) with the exception 
of the epochs 10 and 14 (trending at p= .070 p =.056 respectively). Within normoxia, the 
resveratrol/normoxia condition evinced a significant reduction during the absorption 
period in comparison to the placebo/normoxia condition, at epochs 18, 20, 22 (p <.05), 
and trending at epochs 17, 19, 21 (at p =.062, p =.077 & p =.059 respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 - The acute cerebral haemodynamic effects following administration of 
500 mg resveratrol and placebo in the prefrontal cortex in hypoxic and normoxic 
conditions. Figure displays average changes to deoxygenated haemoglobin 
concentrations (with SEM error bars), throughout the absorption and post dose tasks. 
**p<.01, *p<.05 and t = trend.  
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Oxygenated haemoglobin (oxy-Hb): 
The ANOVA revealed no significant main effect of treatment nor subsequent treatment 
related interaction with epoch and or hypoxia for changes in concentrations of oxy-Hb. 
 
Total haemoglobin (total-Hb): 
The ANOVA revealed no significant main effect of treatment nor subsequent treatment 
related interaction with epoch and or hypoxia for changes in concentrations of total-Hb. 
 
4.4.1.1 Cerebral haemodynamic response to hypoxia 
Oxygenated haemoglobin (oxy-Hb): 
The initial ANOVA revealed a significant hypoxia × epoch interaction [F (33, 660)=  2.45, 
p <.001] indicating significantly lower concentrations of oxy-Hb within the 
placebo/hypoxia condition in comparison to the placebo/normoxia condition. Planned 
comparisons revealed a reduction (nearing significance) at epoch 2 (p =.078) and 20 (p  
=.90), whilst revealing significant reductions at epochs 5, 19, 21 (p <.05) and 22 (p <.01) 
in oxy-Hb concentrations within the placebo/hypoxia condition, during the absorption 
period, in comparison to the placebo/normoxia condition. A similar pattern was found 
during the post-dose task period where a significant reduction in oxy-Hb concentrations 
was found within the placebo/hypoxia condition at epochs 23 (p <.01), 24-26 (p <.05), 28 
(p <.01), 31-33 (p <.01) and trending reductions at 29 (p =.089) and 34 (p =.063), in 
comparison to the placebo/normoxia condition. 
 
Deoxygenated haemoglobin (deoxy-Hb): 
The ANOVA revealed a significant main effect of hypoxia/normoxia [F (1, 660)= 18.19, 
p<.001] along with a complementary interaction with epoch [F (33, 660)= 17.13, p<.001], 
indicating a significant increase in concentrations of deoxy-Hb in the hypoxia condition, 
in comparison to normoxia. Follow up planned comparisons showed a significant increase 
in deoxy-Hb concentrations in the placebo/hypoxia condition in comparison to the 
placebo/normoxia condition, starting at epoch 10 which then continued to the end of the 
testing session (p <.01) (Figure 4.5).  
 
Total haemoglobin (total-Hb): 
The ANOVA revealed no significant main effect of treatment nor subsequent interaction 
with epoch for changes in concentrations of total-Hb. 
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Figure 4.2 - The acute cerebral hemodynamic effects following administration of 
placebo within the prefrontal cortex in hypoxic and normoxic conditions.  Figure 
displays average changes to oxygenated and deoxygenated haemoglobin concentrations 
(with SEM error bars), throughout the absorption and post dose tasks after administration 
with placebo, across both hypoxia and normoxia. **p<.01, *p<.05 and t = trend (nearing 
significance). 
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4.4.2 Behavioural data 
Baseline analysis – Prior to any analysis, a series of one-way ANOVAs was conducted 
on all baseline scores for each cognitive outcome sub-measure. The results showed that 
there was a significant difference between baseline scores for Serial 3 errors [F (3, 88) = 
3.159, p =.029], revealing that the resveratrol hypoxia condition had a significantly higher 
baseline in comparison to the placebo hypoxia (p =.004), placebo normoxia (p= .047) and 
resveratrol normoxia (p = .034) conditions. All other baseline scores for the rest of the 
cognitive outcome sub-measures showed to be statistically non-significant from one 
another (p >.10). 
 
Serial 3 subtractions: 
A significant main effect of treatment was found for the number of incorrect responses 
entered during performance of the Serial 3 subtraction task [F (1, 22) =4.813, p= .039]. 
This revealed that administration with resveratrol (M= .058) significantly reduced the 
number of errors made in comparison to placebo (M= 1.26) (Figure 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 The main effect of treatment for 500 mg resveratrol and placebo 
administration on number of error responses on the Serial 3 subtraction task. Figure 
displays change from baseline means (with SEM error bars), of number of Serial 
subtraction incorrect responses after administration with 500 mg resveratrol or placebo 
irrespective of the environmental condition (*p<.05). 
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Serial 7 subtractions: 
A significant main effect of treatment was found for the number of incorrect responses 
made on the Serial 7 subtraction task [F (1, 22) =5.447, p= .029]. This showed that 
administration of resveratrol (M= -.230) significantly reduced the number of errors made 
in comparison to placebo (M= .710) (Figure 4.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 The main effect of treatment for 500 mg resveratrol and placebo 
administration on number of error responses on the Serial 7 subtraction task. Figure 
displays change from baseline means (with SEM error bars), of number of Serial 
subtraction incorrect responses after administration with 500 mg resveratrol or placebo 
irrespective of the environmental condition (*p<.05).  
 
4.4.2.1 Overall cognitive domain performance 
Accuracy – A significant treatment × rep interaction was found for overall accuracy 
performance across the tasks [F (6, 108) =4.441, p= .019]. Further investigation into this 
interaction via Bonferroni corrected post-hoc t tests revealed a significant reduction (p 
=.017) in accuracy in the placebo condition in repetition 2 (M = -.137) in comparison to 
the placebo condition during repetition 1 (M =.06), while trending (p = .059) a reduction 
in comparison to the resveratrol condition during rep 2 (M =.093). 
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Figure 4.5 The treatment × repetition interaction effect of treatment for 500 mg 
resveratrol and placebo administration on overall task accuracy. Figure displays 
change from baseline Z score means (with SEM error bars), on overall accuracy (% / 
number correct) across Serial 3 & 7 subtraction, RVIP and 3back tasks irrespective of the 
environmental condition (*p<.05, t= trend). 
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Table 4.0 The effects of 500 mg resveratrol and placebo on Serial subtraction performance in both hypoxic and normoxic conditions. Table displays baseline and change 
from baseline scores (with SEM values in brackets) for significant results across the 3 post-dose battery repetitions after placebo and 500 mg resveratrol for 23 healthy, young 
adults. Table also displays ANOVA F and P values for main effects of treatment (T), oxygen status (OS) the interaction between the two (T*OS), repetition (T*R) all three 
(T*OS*R). *<.05, **<.01 and t= trend (nearing significance). 
 
 
 
Measure 
 
Treatment 
 Task Battery ANOVA 
N Baseline 1 2 3 Effect F P 
 
3’s Correct 
(number) 
Placebo Hypoxia 
23 48.04 
(2.95) 
.09 
(1.15) 
.48 
(1.59) 
-2.13 
(1.84) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.858 
 
2.585 
 
1.431 
 
.029 
 
2.145 
.364 
 
.122 
 
.250 
 
.866 
 
.129 
Placebo Normoxia 
23 44.87 
(3.04) 
1.22 
(1.83) 
.35 
(1.50) 
1.43 
(1.96) 
Resveratrol 
Hypoxia 
23 45.78 
(2.52) 
-1.00 
(1.45) 
2.17 
(1.35) 
.22 
(1.54) 
Resveratrol 
Normoxia 
23 44.70 
(3.05) 
2.78 
(1.32) 
3.39 
(1.91) 
1.09 
(1.87) 
 
3’s Incorrect 
(number) 
Placebo Hypoxia 
23 1.09 
(.29) 
.91 
(.50) 
.96 
(.42) 
2.61 
(.73) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
4.813 
 
2.261 
 
.489 
 
.067 
 
3.321 
.039* 
 
.147 
 
.617 
 
.798 
 
.062t 
Placebo Normoxia 
23 1.65 
(.50) 
.22 
(.59) 
1.52 
(.59) 
1.35 
(.59) 
Resveratrol 
Hypoxia 
23 2.87 
(.42) 
-.26 
(.38) 
.48 
(.67) 
1.00 
(.62) 
Resveratrol 
Normoxia 
23 1.57 
(.47) 
-.91 
(.62) 
-1.00 
(.50) 
1.04 
(.65) 
 
7’s Correct 
(number) 
Placebo Hypoxia 
23 26.43 
(1.97) 
1.61 
(1.10) 
1.35 
(1.24) 
3.00 
(1.14) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.355 
 
.732 
 
2.284 
 
3.266 
 
1.526 
.257 
 
.401 
 
.114 
 
.084t 
 
.229 
 
Placebo Normoxia 
23 25.61 
(1.97) 
1.26 
(1.41) 
.22 
(1.42) 
1.17 
(1.44) 
Resveratrol 
Hypoxia 
23 26.04 
(1.97) 
.00 
(1.23) 
3.17 
(1.32) 
.87 
(1.84) 
Resveratrol 
Normoxia 
23 25.48 
(2.30) 
3.57 
(.93) 
3.65 
(1.04) 
4.57 
(1.01) 
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7’s Incorrect 
(number) 
Placebo Hypoxia 
23 2.17 
(.54) 
.43 
(.73) 
1.83 
(.47) 
.65 
(.63) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
5.447 
 
.773 
 
.933 
 
.066 
 
.940 
.029* 
 
.389 
 
.401 
 
.799 
 
.398 
Placebo Normoxia 
23 2.39 
(.43) 
.04 
(.46) 
.52 
(.53) 
.78 
(.55) 
Resveratrol 
Hypoxia 
23 2.65 
(.66) 
-.17 
(.66) 
.00 
(.62) 
.04 
(.73) 
Resveratrol 
Normoxia 
23 2.91 
(.44) 
-.65 
(.45) 
-.17 
(.47) 
-.26 
(.42) 
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4.4.2.2 Cognitive performance in hypoxia 
There was no significant main effects of hypoxia or hypoxia related interactions on 
cognitive performance in the current study.  
4.4.2.3 Overall cognitive domain performance in hypoxia 
There was no significant main effects of hypoxia or hypoxia related interactions on 
overall cognitive domains in the current study.  
 
Cognitive results for individual tasks in this chapter are reported in full in Appendix 2.0, 
while results for overall cognitive domains are reported in Appendix 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
 
4.5 Discussion 
The aims of current study were two-fold: The first was to assess the efficacy of employing 
mild hypoxia as a representative, experimental model of cognitive ageing. Here, it was 
hypothesized that cognitive performance would decrease within the hypoxia condition as 
a result of a reduction in O2 supply. Secondly, the present study also aimed to evaluate 
the efficacy of resveratrol to induce increases in CBF, and, in turn, attenuate any 
reductions in cognitive performance induced by the hypoxic condition. 
The results here demonstrated significantly lower oxy-Hb concentrations during the final 
stages of the absorption period and across the full post dose task period in the hypoxia 
condition, confirming that the hypoxic level employed was capable of reducing cerebral 
oxygenation. Despite this, the hypoxia condition failed to induce any significant 
reductions in cognitive performance. Additionally, significantly higher concentrations of 
deoxy-Hb were present across both the absorption and post task period from exposure to 
hypoxia; which may signify an increase in O2 extraction too offset the hypoxic condition. 
Although, it is noteworthy the anticipated increase in CBF (as indexed by higher 
concentrations of total-Hb) was not observed here. The lack of an adaptive CBF response, 
in the face of no clear cognitive deficits, would suggest that the hypoxic level employed 
here was simply not sufficient to disrupt the high neurocognitive efficacy of the young, 
healthy sample.   
Indeed, it remains unclear whether mild hypoxia can deteriorate cognitive performance 
in healthy cohorts (Bartholomew et al., 1999) as most investigations only document 
consistent domain specific cognitive deficits at >3000 m above sea level (Bahrke & 
Shukitt-Hale, 1993). Ambiguity lies in the use of different tasks and the varying durations 
of exposure employed by previous investigations, making it difficult to ascertain what 
level of hypoxia would be appropriate to initially model cognitive ageing. Although 
reductions in mental performance have been observed at levels as low as 1524 m above 
sea level (Denison et al., 1966) most decreases to performance at these lower levels of 
hypoxia are most commonly found when measured during physical exertion (Bahrke & 
Shukitt-Hale, 1993). The increase in demand for O2 brought about by physical exertion, 
exacerbates the reduced access to O2 which may exaggerate the cognitive deficits reported 
at mild levels of hypoxia. The results of the current study would certainly support the 
notion that mild hypoxia is insufficient to disrupt cognitive performance in young, healthy 
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individuals. It is therefore proposed that a more disruptive hypoxic level is required to 
model the effects of the ageing brain.  
With regards to treatment related differences, the results showed that a single 500 mg 
dose of resveratrol was able to amplify the hypoxia-induced increases in O2 utilization 
across the absorption period, as indexed by significantly higher deoxy-Hb concentrations 
in comparison to placebo. However, in contrast to predictions, no significant modulation 
of CBF by resveratrol was found during the post dose task performance period during 
hypoxia. The findings here suggest that resveratrol was unable to promote an adaptive 
cerebral hemodynamic response of hypoxia during task performance. Alternately, this 
may simply highlight that the young cohort of participants did not require any additional 
modification to neural fuel access after consuming resveratrol. Although, to add further 
ambiguity, resveratrol also showed no effect on cerebral hemodynamics across the post 
dose task period in the normoxia condition relative to placebo, which is at odds with 
previous investigations (Kennedy et al., 2010; Wightman et al., 2014; Wightman et al., 
2015).  
In an attempt to explain these anomalous findings, it is noteworthy that ascent to 
moderate-high altitude has been found to induce a wide range of adverse psychological 
changes. This includes increased feelings of anxiety, depression, aggression and fatigue 
alongside reduced feelings of vigour and happiness (Shukitt-Hale & Lieberman, 1996; 
Shukitt-Hale et al., 1998; Bardwell et al., 2005). Further, despite the chamber being 
equipped with silencers to blunt the noise of air regulation, a certain and constant level of 
noise is continually present due to the regulation of air in both hypoxic and normoxic 
conditions, which may have been disconcerting to the participants. Moreover, as the O2 
status was blind to the participant, even the perceived reduction in O2 may have further 
exacerbated an anxiogenic effect. Interestingly, anxiety has been found to produce local 
and global changes in CBF that are unrelated to regional neuronal activation and, 
therefore, may confound the interpretation of neuroimaging data (Giardino et al., 2007). 
Consequently, the anxiogenic environment of the chamber may have caused such a level 
of noise in the neuroimaging data that this may have dissipated the well-established CBF 
effects of resveratrol in normoxia.  
With regards to cognitive performance, a significant effect was observed on the analysis 
of overall cognitive domains in the form of a treatment × rep interaction for task accuracy. 
However, upon further analysis, no consistent pattern revealed itself between the two 
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treatments, with the effect being likely exaggerated by the large difference within 
treatments across the post dose repetitions. However, in contrast to previous 
investigations, this is perhaps the first study to demonstrate that acute resveratrol 
administration can enhance cognitive performance in young, healthy cohorts. A 
significant reduction in the number of errors made on both subtraction tasks was found 
after administration of resveratrol alone, relative to placebo. It is also noteworthy, that the 
baseline differences for the Serial 3 subtraction task errors sub-measure showed that the 
resveratrol hypoxia baseline was significantly higher to all other scores, which may have 
influenced this result. Moreover, to contextualise the magnitude of the cognitive 
enhancement observed here, this was a single reduction in the error response rate across 
both Serial subtraction tasks; representing a single improvement across a variety of 
cognitive tasks / domains.   
In the absence of a resveratrol-mediated increase in CBF during task performance, it is 
unclear what mechanism may have contributed towards this improvement in reduced 
errors on the Serial subtraction tasks. It is conceivable, that the cognitive benefits of 
resveratrol observed here may be the result of mood enhancement or more specifically 
anxiolytic effects; whereby resveratrol may have attenuated the aforementioned 
anxiogenic nature of the testing environment. Indeed, administration of resveratrol (15 
mg/kg per day for 16 days) has been found to exert antidepressant and antianxiety effects 
in subclinical hypothyroidism rats (Ge et al., 2016). In terms of mechanisms, resveratrol 
has been found to inhibit MOA activity in a dose dependent manner, whilst increasing 
serotonin and noradrenaline levels, following 7 days supplementation in rodents (Xu et 
al., 2010).  
Although evidence in humans is lacking, berry polyphenols have been identified as 
inhibitors of MOA-A activity in human trials (Watson et al., 2015). In addition, a single 
dose of 300 mg EGCG has been shown to significantly improve self-reported calmness 
and stress (Scholey et al., 2012) while a 500 mg dose of cocoa polyphenols has been 
found to significantly improve self-rated calmness and contentedness following 30 days 
of supplementation (Pace et al., 2013). Although the latter study does not detail anxiolytic 
effects specifically, it is postulated that polyphenols may provide a benefit in situations 
where a calm or content temperament is advantageous, i.e. under conditions of high stress 
or anxiety (Pace et al., 2013). Of course, in the absence of any mood measures, it is not 
possible to state categorically that resveratrol has induced an anxiolytic effect or indeed, 
that the chamber was deemed anxiogenic by the participants. It is important therefore that 
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further investigation into the hypoxia model of cognitive ageing should be done so with 
a corresponding measurement of mood states such as self-reported anxiety.  
The current study has revealed that a mild hypoxic environment can reduce cerebral 
oxygenation in the prefrontal cortex, but this was not disruptive enough to induce 
cognitive deficits. It is proposed that a higher level of hypoxia is required to model the 
decreases in CMRO2 observed in ageing populations and, in turn, age-related cognitive 
deficits. In addition, this is perhaps the first investigation to observe cognitive 
improvements, albeit tentative, following a single dose of resveratrol in young, healthy 
individuals. However, in the absence of significant modulation to CBF, it is unclear what 
mechanism may have contributed to this effect. 
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Chapter 5 
The cerebral hemodynamic response and cognitive effects of acute resveratrol 
administration in young, healthy adults in moderate hypoxic and normoxic 
conditions. 
 
5.1 Introduction 
The results of the preceding chapter revealed that a mild hypoxia could decrease cerebral 
oxygenation within the prefrontal cortex but not significantly reduce cognitive 
performance on any individual task outcome or overall cognitive domain. It is noteworthy 
that deficits in cognitive performance at rest have been found more consistently at 
altitudes of >3000 m above sea level (Bahrke & Shukitt-Hale, 1993; Petrassi et al., 2012). 
Indeed, it has been proposed that the ‘critical zone’ for cognitive reductions is between 
4000-5000 m above sea level (12.7-11.2% atmospheric O2) (Nelson, 1982). This is 
supported further by a series of reviews reporting significant reductions in cognitive 
functioning at greater levels of hypoxia (Asmaro et al., 2013; Aquino Lemos et al., 2012; 
Bjursten et al., 2010; Petrassi et al., 2012).  
Contrary to predictions, the previous chapter also showed that acute administration of 
resveratrol was unable to modulate CBF during task performance in either the hypoxia or 
normoxia condition. It was proposed that the perceived reduction in O2 and the enclosed 
nature of the environmental chamber, might have contributed towards potential 
anxiogenic effects, and consequently, noise within the neuroimaging data. It is 
noteworthy that exposure for more than 1 hour at moderate-high altitude can provoke a 
negative impact on mood states in healthy individuals (Li et al., 2000); which seems to 
be further exacerbated with an increasing level of altitude (Shukitt, & Banderet, 1987). 
As the same chamber will be employed again in the current study, in addition to an 
increasing hypoxic level, it may be prudent to measure self-reported mood across the 
testing sessions. Interestingly, self-reported reductions in mood have been restored when 
supplemented with additional O2 during exposure to hypoxia (Legg et al., 2016). This 
potentially supports the reciprocal role of decreasing O2 and deterioration of mood 
parameters, but perhaps offers a further therapeutic role for vasodilators that can mediated 
CBF effects in hypoxia.   
In a recent study, Davranche et al. (2016) exposed 11 healthy males to 4350 m altitude 
for 4 days, measuring cognitive performance and CBF (via NIRS) at initial ascent (3-5 
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hours exposure), then after 2 and 4 days’ exposure respectively. Upon initial exposure to 
hypoxia, the researchers observed poorer reaction times and an increased number of errors. 
Interestingly however, the researchers also found that increased CBF within the prefrontal 
cortex significantly correlated with better reaction times, implying that the greater the 
CBF response, the more superior attenuation of the hypoxia induced cognitive deficit. 
Such results provide support for further exploration into the efficacy of resveratrol as a 
cognitive enhancer at a higher level of hypoxia.  Indeed, as an inverse relationship exists 
between hypoxia and maximal O2 uptake (Babbar & Agarwal, 2012) hypoxia will 
naturally reduce CMRO2, however, as an increased CBF response has been found to 
correlate with improved cognitive functioning in hypoxia; the capacity of resveratrol to 
enhance CBF should function to attenuate the reductions in O2 supply and consequently 
cognitive performance.  
The current study aims to build upon the results of the previous chapter and employ a 
more severe level of hypoxia (FiO2 = 12.7%), to model age-related cognitive impairment. 
This higher level of hypoxia is hypothesized to sufficiently compromise O2 delivery to 
induce relative decreases in cognitive performance and negatively impact self-reported 
mood in comparison to normoxia. It is also hypothesized that resveratrol will induce 
significant increases in cerebral perfusion, irrespective of O2 status. However, the 
increase in CBF within the hypoxic condition will function to attenuate the hypoxia-
induced reductions to behavioural performance.  
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5.2 Method 
5.2.1 Participants  
The current study sample comprised 24 healthy adults aged between 19-33 years (16 
female, mean age = 23, SD = 4.20, right handed = 23) with good or corrected vision. No 
participant reported to suffer from colour blindness. The current study recruited 
participants based upon the same inclusion / exclusion criteria as the previous chapter 
(see section 4.2.1 for details).  
 
5.2.2 Cognitive battery 
The current study maintained the continuous task design employed by the previous 
investigations in this thesis. The tasks, in order of appearance in the cognitive battery 
were as follows: Immediate word recall, Serial 3s, Serial 7s, Choice Reaction Time 
(CRT), RVIP, Delayed word recall, Stroop task and Word Recognition. The inclusion of 
the CRT and Stroop tasks was in an attempt to better match the tasks used by other studies 
that have observed cognitive deficits at hypoxia (Leifflen et al., 1997; Asmaro et al., 2013; 
Petrassi et al., 2011; Petrassi et al., 2012). Five mood VAS scales were also employed 
upon completion of each repetition of the task battery at both baseline and post dose 
repetitions. The current study measured self-reported: ‘Difficulty’, ‘Mental-fatigue’, 
‘Anxiety’, ‘Friendliness’ and ‘Aggression’. Refer to section 2.4 for VAS task description.  
 
5.2.3 Treatments 
During the four testing study visits, participants received a single-dose treatment in 
compliance with a previously randomised allocation to a (Latin Square) counterbalanced 
order. Treatments were administered on separate days, with each testing session being 
conducted no more than 48 hours before, and no more than 14 days after, the previous 
session. Two capsules were consumed by participants on each testing day being either: 
 
1) ×2 placebo capsules (CABOT MP5 fumed silica). 
2) ×2 250 mg resveratrol capsules (equating to a 500 mg dose).  
 
Again, all treatments were prepared by the lead investigator, before being coded by a third 
party who had no further involvement in any aspect of the study. No member of the 
investigational team was aware of the contents of the capsules until the statistical analysis 
of the current study was complete.  
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5.2.4 Environmental Chamber  
The environmental conditions remained constant with those of the previous chapter, with 
the exception that the O2 status of the hypoxic condition was increased from 16% FiO2 
(2134 m) to 12.7% FiO2 (4000 m). This was in response to previous studies which have 
found more consistent cognitive deficits at this simulated altitude. Furthermore, in 
contrast to the previous chapter, the initiation of the O2 status was set at the start of the 
testing session, rather than at the beginning of the absorption period. The rationale behind 
this change was twofold: firstly, the chamber required 2 hours to achieve the above 
detailed hypoxic level, making it impossible to achieve the required environmental 
condition prior to engaging in the post dose repetitions if the level was set at the end of 
the absorption period as with the previous chapter. Secondly, it could be argued that 
allowing the participants to stay inside the chamber, while the change in O2 status 
progressively occurs, could aid in the adaptation to the reduced availability of O2. This is 
perhaps supported by the progressive increase in deoxy-Hb concentrations during the 
latter stages of the absorption period in Chapter 4 and the lack of hypoxia related effects 
on cognitive performance. Despite the participants being immediately exposure to 
hypoxia, this was not predicted to influence baseline performance; analysis was 
conducted to verify this claim (see section 5.3.2).  
 
5.2.5 Near-Infrared spectroscopy (NIRS) 
CBF was monitored in the prefrontal cortex by NIRS throughout all four testing sessions. 
The same procedure and system was adopted as the previous chapter (refer to section 2.1 
for further information on this technique and the system used). 
 
5.2.6 Procedure 
Participants were required to attend the laboratory on five occasions. The first visit was a 
screening / training session, where participants declared themselves to be in line with the 
inclusion criteria and provided informed consent. Participants received training on the 
individual tasks in the cognitive battery to ensure they were competent and confident to 
complete all tasks on the battery without assistance; participants were required to 
complete two full repetitions of the cognitive battery. For the 4 subsequent testing visits, 
participants arrived at the environmental chamber at 8 am, fully fasted for 12 hours 
(except for water). After confirmation of their continued compliance to the inclusion 
119 
 
criteria, participants were then connected to the NIRS device; this was worn throughout 
the full testing procedure. After a brief rest, participants completed a baseline 
measurement of the cognitive battery before watching a non-stimulating video (Grand 
designs) for 10-minutes. Upon completion of the baseline rest measure, the treatment for 
the day was administered and the participant remained at rest for a further 45 minutes 
(continuing with the video), to allow for absorption of the treatment. After, the participant 
then completed 3 full consecutive repetitions of the cognitive battery (Figure 5.0). On 
completion of the final session, participants were fully debriefed. Participants were 
offered £65 upon completion of the study.   
 
 
 
 
 
 
 
 
 
Figure 5.0 A timeline of the third experimental study testing day.  
 
 
5.3 Statistical approach 
All behavioural data was analysed using SPSS version 22 for windows (IBM SPSS 
Statistics Armonk, NY), while all NIRS analysis was analysed using Minitab 17 (State 
College, PA: Minitab, Inc.).   
 
5.3.1 NIRS analysis 
The current study adopted the same analysis plan and approach to data cleaning as 
Chapter 4 (see section 4.3.1). After data cleaning, the final sample for NIRS data was 
N=19.  
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5.3.2 Behavioural data analysis 
The same approach to data cleaning and statistical analysis, as carried out in Chapter 4, 
was adopted for the cognitive data here (see Chapter 4.3.2 for details). No participants 
were removed from the data set as a result of the data cleaning (N = 24).  A series of 
ANOVAs and independent t-tests were carried out on each of the baseline task and mood 
outcome sub-measures to assess for any potential differences between baselines, and to 
evaluate if the immediate exposure to hypoxia at baseline had had any influence on 
behavioural performance (Lefferts, 2015). 
With regards to mood, all VAS data for ‘Difficulty’, ‘Mental-fatigue’, ‘Anxiety’, 
‘Friendliness’ and ‘Aggression’ were converted to change from baseline (utilising the 
score submitted after completion of the baseline repetition of the cognitive tasks, as a 
baseline measure) before individually being analysed in a 2 (treatment) × 3 (repetition) × 
2 (O2 status) repeated measures ANOVA.  Upon the emergence of a significant F test, 
these were follow up with Bonferroni corrected post-hoc analysis. In addition, to examine 
the claims made in the previous chapter regarding the potential negative impact of the 
chamber on mood, analysis was carried on all mood scores submitted prior to undertaking 
baseline mood outcome task (with the exception of difficulty) for each day via a 4 (day) 
× 2 (O2 status) ANOVA.  
 
5.3.3 The analysis of overall cognitive domains across treatments and hypoxic 
conditions 
In accordance with the preceding chapter, Z scores were compiled and combined for the 
complete sets of behavioural data (N=23) to represent the cognitive domains assessed in 
the cognitive battery: accuracy (correct responses from: Serial subtractions tasks, CRT 
RVIP, & Stroop), speed of processing (correct reaction time scores from: CRT, RVIP & 
Stroop) errors (incorrect responses from: Serial subtractions tasks & RVIP) and 
secondary memory (correct recall responses from: both recall tasks & delayed word 
recognition). These were then analysed in a within subjects’ ANOVA (Rep × Treatment 
× O2 status) to ascertain any overall effects of hypoxia on the cognitive domains. Only 
main effects of O2 status and treatment or subsequent interaction with each other or 
repetition from the initial ANOVA will be reported. 
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5.4 Results 
5.4.1 NIRS data 
Oxygenated haemoglobin (oxy-Hb): 
The initial ANOVA demonstrated a significant treatment × hypoxia/normoxia × epoch 
interaction [F (36, 612) = 1.49, p = .035] indicating higher concentrations of oxy-Hb 
during the hypoxia conditions in comparison to the normoxia conditions. In addition, the 
resveratrol/normoxia condition showed a significant increase in oxy-Hb concentrations 
in comparison to the placebo/normoxia condition. This indicates a higher cerebral 
oxygenation across the post dose task period following resveratrol in comparison to 
placebo during the normoxia condition. With reference to planned comparisons, the 
placebo/hypoxia condition showed an increase (nearing significance) in concentrations 
of oxy-Hb within the absorption period at epoch 8 (p =.075) and 18 (p =.066) in 
comparison to the resveratrol/hypoxia condition. No significant differences were found 
between treatments during hypoxia across task performance. During normoxia, planned 
comparisons revealed an increase in oxy-Hb index after placebo consumption, in 
comparison to resveratrol, by a significant increase at epoch 5 (p = .039) and trending 
increases at 19 (p = .077) and 21 (p = .065) within the absorption period. However, this 
shifted during performance of the post dose tasks, revealing a significant increase of oxy-
Hb concentrations after resveratrol, at all time points 23-37 (p <.01) in comparison to 
placebo (Figure 5.1). 
Total haemoglobin (total-Hb): 
The within subjects ANOVA revealed a significant treatment × epoch [F (36, 612) = 2.98, 
p <.001] and a treatment × hypoxia × epoch [F (36, 612) = 0.74, p <.001] interaction. 
Planned comparisons revealed an increase (nearing significance) in concentrations of 
total-Hb within the absorption period at epoch 8 (p =.075) within the placebo/hypoxia 
condition relative to the resveratrol/hypoxia condition. In addition, a significant increase 
in total-Hb concentrations was found at epochs 31 (p =.025) and 37 (p =.035), whilst 
trending an increase at epoch 32 (p =.081) and 35 (p =.080) in the placebo/hypoxia 
condition, in comparison to the resveratrol/hypoxia condition, during the post dose task 
period. With regards to normoxia, resveratrol induced significantly higher total-Hb 
concentrations across all epochs (23-37) of the post dose task period [all p <.01; except 
for epoch 25-26 (p <.05)] in comparison to placebo (Figure 5.2). 
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Deoxygenated haemoglobin (deoxy-Hb): 
The ANOVA revealed no significant main effect of treatment nor subsequent related 
interaction with epoch or hypoxia for changes in concentrations of deoxy-Hb. 
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Figure 5.1 - The acute cerebral hemodynamic effects to oxygenated haemoglobin 
following administration of 500mg resveratrol and placebo in the prefrontal cortex 
within the hypoxic and normoxic conditions. Figure displays average changes in 
oxygenated haemoglobin concentrations (with SEM error bars), throughout the 
absorption and post dose tasks. **p<.01, *p<.05 and t = trend (nearing significance).  
 
 
 
2D Graph 2
X Data
0 10 20 30 40
Y
 D
a
ta
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
 Placebo Normoxia 
 Resveratrol Normoxia 
*
**
**
**
* * **
**
*
*
**
**
**
**
**
2D Graph 1
X Data
0 10 20 30 40
Y
 D
a
ta
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
2.0
 Placebo Hypoxia 
 Resveratrol Hypoxia 
t
t
C
o
n
ce
n
tr
at
io
n
 c
h
an
g
e 
(μ
m
o
l/
L
) 
Epoch 
Absorption Post dose tasks 
Oxygenated haemoglobin 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 - The acute cerebral hemodynamic effects of total haemoglobin following 
administration of 500 mg resveratrol and placebo in the prefrontal cortex within the 
hypoxic and normoxic conditions. Figure displays average changes in total 
haemoglobin concentrations (with SEM error bars), throughout the absorption and post 
dose tasks. **p<.01, *p<.05 and t = trend (nearing significance). 
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5.4.1.1 Cerebral haemodynamic response to hypoxia 
Oxygenated haemoglobin (oxy-Hb): 
The initial AVOVA revealed a significant hypoxia × epoch interaction [F (36, 648) = 
1.77, p = .004] indicating significantly higher concentrations of oxy-Hb within hypoxia 
in comparison to normoxia. Planned comparisons demonstrated a significant increase at 
epochs 15 and 18 (p <.05), whilst trending an increase at 16 (p= .089) and 21 (p= .055) 
respectively, during the absorption period in hypoxia, in comparison to normoxia. 
Moreover, a significant increase in oxy-Hb concentrations within the placebo/hypoxia 
condition was observed across the entire the post-dose task period (epochs 23-37, p<.01; 
epoch 23 p<.05) in comparison to the placebo/normoxia condition.  
 
Total haemoglobin (total-Hb): 
The within subjects ANOVA revealed a significant hypoxia × epoch F (33, 660) = 1.80, 
p < .001] interaction effect indicating higher concentrations of total-Hb in the 
placebo/hypoxia condition in comparison to the placebo/normoxia condition. Post hoc 
comparisons revealed a trending increase in total-Hb concentrations within the 
placebo/hypoxia condition in comparison to placebo/normoxia at epochs 19 (p =.056) and 
21 (p =.050) and significant increases at epochs 15-16 and 18 (p <.05), across the 
absorption period. This increase in total-Hb concentrations continued within the 
placebo/hypoxia condition across all epochs of the post dose task period, demonstrating 
a trending increase at epoch 23 (p =.052) and a significant increase in all subsequent 
epochs (24-37 p<.01), in comparison to the placebo/normoxia condition (Figure 5.6).  
Deoxygenated haemoglobin (deoxy-Hb): 
The ANOVA revealed no significant main effect of hypoxia or subsequent interaction 
with epoch for changes in concentrations of deoxy-Hb.  
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Figure 5.3 - The acute cerebral hemodynamic effects following administration of 
placebo in the prefrontal cortex in hypoxic and normoxic conditions. Figure displays 
average changes to total and oxygenated haemoglobin concentrations (with SEM error 
bars), throughout the absorption and post dose tasks. **p<.01, *p<.05 and t = trend 
(nearing significance). 
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5.4.2 Behavioural data 
Assessment of baseline – A series of ANOVAs and independent t-tests were conducted 
for each task outcome, to comparing differences between the baselines and to ensure there 
was no effect of hypoxia on the baseline scores. All differences between baselines were 
statistically non-significant (p >.10).  
Serial 3 subtractions – A significant treatment × hypoxia / normoxia × repetition 
interaction [F (2, 46) = 3.467, p =.040] was found for correct responses entered during 
the Serial 3 subtraction task (Figure 5.4). However, follow up post-hoc t tests revealed no 
significant differences between either treatment (during hypoxia & normoxia 
respectively) at any of the three post-dose repetitions. However, within treatments, the 
resveratrol normoxia condition showed to score significantly higher on the number of 
correct entries on the Serial 3 subtraction task in comparison to the resveratrol hypoxia 
condition across all 3 repetitions of the post dose tasks (p =.012; p =.011; p =.047 
respectively). Moreover, the number of correct responses in the placebo normoxia 
condition at repetition 3, revealed to be significantly higher than that of repetition 1 (p 
=.005) and 2 (p =.019). 
 
 
 
 
 
 
 
o2 
 
 
Figure 5.4 The treatment × hypoxia / normoxia × repetition interaction effect of 500 
mg resveratrol and placebo administration on the number of correct responses on 
the Serial 3 subtraction task. Figure displays change from baseline means (with SEM 
error bars), of number of Serial subtraction correct responses after 500 mg resveratrol or 
placebo, in hypoxia and normoxia, across the three post dose repetitions. 
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CRT – A significant main effect of treatment was found for correct reaction time [F (1, 
23) = 4.827, p =.038], revealing that supplementation with resveratrol (M= 13.64) 
increased reaction time in comparison to placebo (M= -6.93) (Figure 5.5).  
 
 
 
 
 
 
 
 
 
Figure 5.5 The main effect of treatment for 500 mg resveratrol and placebo 
administration on reaction time on the choice reaction time task. Figure displays 
change from baseline means (with SEM error bars), of correct reaction time on the choice 
reaction time task after administration of 500 mg resveratrol or placebo (*p<.05). 
 
RVIP – A significant treatment × hypoxia / normoxia × repetition interaction for RVIP 
correct reaction time was observed [F (2, 44) = 5.406, p =.016]. Follow up post-hoc 
student t tests revealed no significant differences between either of the treatments or at 
any of the three post-dose repetitions (Figure 5.6). Although a trending improvement 
(decrease) in reaction time was found in the resveratrol normoxia in comparison to the 
placebo normoxia condition (p =.065) during the first repetition, no other difference 
between treatment were found across the environmental condition or repetition. While, a 
similar improvement was observed for the resveratrol hypoxia condition in contrast to the 
placebo hypoxia condition (p =.074) during the second repetition. Within treatments, the 
placebo hypoxia condition during repetition 2 showed to have a significantly worse 
(higher) reaction time in comparison to the same condition during repetition 1 (p =.009) 
and 3 (p =.004). 
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Figure 5.6 The treatment × hypoxia/ normoxia × repetition interaction effect of 500 
mg resveratrol and placebo administration on RVIP reaction time. Figure displays 
change from baseline means (with SEM error bars), of reaction time (ms) from the correct 
responses on the RVIP task. This was following 500 mg resveratrol or placebo, in hypoxia 
and normoxia, across the three post dose repetitions.  
 
 
5.4.2.1 Overall cognitive domain performance 
No significant treatment or subsequent treatment related interaction with repetition was 
found on any of overall cognitive domains.  
 
5.4.3 Mood data 
No significant treatment or subsequent treatment related interaction with repetition was 
observed for any of the self-reported mood parameters.  
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Table 5.0 The effects of 500 mg resveratrol against placebo on cognitive performance in both hypoxic and normoxic conditions. Table displays baseline and change 
from baseline scores (with SEM values in brackets) for the 3 post-dose battery repetitions after placebo and 500 mg resveratrol for 24 healthy, young adults. Table also displays 
ANOVA F and P values for main effects of treatment (T), oxygen status (OS) the interaction between the two (T*OS), repetition (T*R) and all three (T*OS*R). *<.05, **<.01 
and T= trend. 
 
 
Measure 
 
Treatment 
 Task Battery ANOVA 
N Baseline 1 2 3 Effect F P 
 
3’s Correct 
(number) 
Placebo Hypoxia 24 
48.29 
(3.37) 
.92 
(1.34) 
-.58 
(1.11) 
1.08 
(1.40) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.603 
 
5.872 
 
2.344 
 
.628 
 
3.467 
.445 
 
.024* 
 
.107 
 
.436 
 
.040* 
Placebo Normoxia 24 
46.88 
(3.87) 
-.04 
(1.39) 
1.79 
(1.64) 
4.92 
(1.72) 
Resveratrol Hypoxia 24 
49.12 
(4.10) 
-1.58 
(1.26) 
-1.21 
(1.12) 
-.96 
(1.11) 
Resveratrol Normoxia 24 
48.25 
(3.76) 
2.38 
(1.23) 
2.79 
(1.16) 
2.04 
(1.30) 
 
3’s Incorrect 
(number) 
Placebo Hypoxia 24 
2.00 
(.48) 
.71 
(.54) 
.83 
(.45) 
1.04 
(.70) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.015 
 
11.797 
 
1.108 
 
.102 
 
.624 
.904 
 
 .002** 
 
.328 
 
.753 
 
.540 
Placebo Normoxia 24 
1.63 
(.31) 
.13 
(.48) 
-.21 
(.40) 
.00 
(.47) 
Resveratrol Hypoxia 24 
1.63 
(.39) 
.71 
(.41) 
1.00 
(.47) 
1.17 
(.42) 
Resveratrol Normoxia 24 
2.46 
(.45) 
-.83 
(.53) 
-.04 
(.44) 
.25 
(.52) 
Choice Reaction 
Time % Correct 
Placebo Hypoxia 24 
96.46 
(1.01) 
-.10 
(.68) 
.83 
(.78) 
.42 
(.84) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.326 
 
1.424 
 
.861 
 
.309 
 
.342 
.573 
 
.245 
 
.429 
 
.583 
 
.712 
Placebo Normoxia 24 
96.46 
(.94) 
1.67 
(.76) 
1.67 
(.78) 
.42 
(.78) 
Resveratrol Hypoxia 24 
97.08 
(.65) 
-.31 
(.63) 
-.10 
(.57) 
.94 
(.69) 
Resveratrol Normoxia 24 
97.08 
(.76) 
.83 
(.36) 
.94 
(.49) 
.10 
(.65) 
Placebo Hypoxia 24 
428.05 
(17.22) 
-15.02 
(10.65) 
-13.44 
(8.68) 
-1.72 
(14.64) 
T 
 
4.827 
 
.038* 
 
131 
 
Choice Reaction 
Time % Correct 
RT (msecs) 
Placebo Normoxia 24 
430.02 
(19.63) 
-14.80 
(15.29) 
.17 
(12.21) 
-1.56 
(9.51) 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.189 
 
.530 
 
.024 
 
1.581 
.668 
 
.602 
 
.861 
 
.243 
Resveratrol Hypoxia 24 
409.23 
(12.44) 
9.51 
(6.57) 
11.06 
(6.91) 
9.77 
(7.10) 
Resveratrol Normoxia 24 
422.21 
(10.70) 
8.69 
(7.98) 
9.25 
(7.19) 
17.60 
(9.70) 
 
 
RVIP % Correct 
Placebo Hypoxia 23 
72.56 
(12.44) 
.82 
(3.30) 
-.82 
(3.13) 
-6.79 
(3.13) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.108 
 
4.221 
 
1.325 
 
.550 
 
.831 
.746 
 
.052t 
 
.276 
 
.466 
 
.442 
Placebo Normoxia 23 
72.28 
(3.85) 
1.09 
(2.74) 
-.54 
(3.31) 
1.63 
(3.95) 
Resveratrol Hypoxia 23 
78.26 
(2.99) 
-1.90 
(2.79) 
-5.98 
(3.32) 
-8.42 
(3.44) 
Resveratrol Normoxia 23 
70.38 
(3.67) 
6.52 
(2.68) 
-.27 
(2.41) 
1.63 
(2.92) 
 
RVIP Correct 
RT 
(msecs) 
Placebo Hypoxia 23 
463.38 
(12.98) 
14.44 
(7.07) 
33.34 
(9.43) 
3.68 
(9.15) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.079 
 
.000 
 
2.781 
 
.109 
 
5.406 
.310 
 
.983 
 
.073t 
 
.745 
 
.016* 
Placebo Normoxia 23 
471.36 
(12.72) 
17.58 
(10.21) 
13.89 
(12.06) 
13.03 
(13.45) 
Resveratrol Hypoxia 23 
468.77 
(10.87) 
5.00 
(9.23) 
3.47 
(10.50) 
14.74 
(11.22) 
Resveratrol Normoxia 23 
469.85 
(11.49) 
1.03 
(8.61) 
13.69 
(11.35) 
14.17 
(12.17) 
RVIP Errors 
(number)  
Placebo Hypoxia 23 
1.48 
(.63) 
-.83 
(.55) 
-.52 
(.53) 
-.48 
(.59) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.150 
 
2.225 
 
.058 
 
1.720 
 
1.333 
.871 
 
.437 
 
.398 
 
.203 
 
.274 
Placebo Normoxia 23 
.87 
(.30) 
.39 
(.23) 
.17 
(.20) 
.35 
(.36) 
Resveratrol Hypoxia 23 
1.17 
(.31) 
-.30 
(.24) 
-.13 
(.22) 
.04 
(.24) 
Resveratrol Normoxia 23 
1.13 
(.28) 
-.30 
(.30) 
-.04 
(.29) 
-.04 
(.33) 
 
 Placebo Hypoxia 24 5.94 -2.54 -2.54 -1.44 
T 
 
.106 
 
.748 
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Delayed Word 
Recall Correct 
(number) 
(.09) (.48) (.61) (.60) OS 
 
T*R 
 
T*OS 
 
T*OS*R 
4.787 
 
1.946 
 
1.192 
 
1.946 
.039* 
 
.410 
 
.286 
 
.154 
Placebo Normoxia 24 
5.78 
(.45) 
-1.17 
(.42) 
-.65 
(.47) 
-.98 
(.54) 
Resveratrol Hypoxia 24 
6.06 
(.46) 
-1.21 
(.55) 
-2.75 
(.45) 
-2.02 
(.62) 
Resveratrol Normoxia 24 
6.17 
(.55) 
-1.56 
(.38) 
-1.23 
(.47) 
-1.40 
(.40) 
Delayed Word 
Recall Incorrect 
(number) 
Placebo Hypoxia 24 
.33 
(.12) 
.42 
(.22) 
.62 
(.24) 
.46 
(.21) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.874 
 
.008 
 
.850 
 
2.552 
 
.952 
.359 
 
.929 
 
.410 
 
.124 
 
.394 
Placebo Normoxia 24 
.50 
(.14) 
-.08 
(.24) 
.42 
(.31) 
.25 
(.30) 
Resveratrol Hypoxia 24 
.75 
(.23) 
-.29 
(.20) 
.13 
(.27) 
.21 
(.23) 
Resveratrol Normoxia 24 
.21 
(.09) 
.13 
(.09) 
.33 
(.17) 
.42 
(.16) 
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5.4.4 Cognitive performance in hypoxia 
Serial 3 subtractions – A significant main effect of hypoxia / normoxia was found [F (1, 
23) = 5.872, p =.024] demonstrating a significant reduction in the number of correct 
responses on the Serial 3 subtraction task within the hypoxia condition (M= -.389) in 
comparison to the normoxia condition (M= 2.312) (Figure 5.7).  
 
 
 
 
 
 
 
 
 
 
Figure 5.7 The main effect of hypoxia/normoxia on the number of correct responses 
on Serial three subtraction tasks. Figure displays change from baseline means (with 
SEM error bars), on correct Serial subtraction responses in hypoxia and normoxia 
(*p<.05). 
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A significant main effect was also found of hypoxia/normoxia [F (1, 23) = 11.797, p 
=.002] demonstrating a significant increase in the number of errors entered within the 
hypoxia condition (M= .910) in comparison to the normoxia condition (M= -.118) (Figure 
5.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 The main effect of hypoxia/normoxia on the number of error responses 
on Serial three subtraction tasks. Figure displays change from baseline means (with 
SEM error bars), of incorrect responses on the Serial subtraction task whilst in hypoxia 
and normoxia (*p<.05). 
 
Delayed word recall – A significant main effect of hypoxia/normoxia was found on the 
number of correctly recalled words on the delayed word recall task [F (1, 23) = 4.787, p 
=.039]. This demonstrated a significant reduction in the number of correct responses 
within the hypoxic condition (M= -.2.083) in comparison to the normoxic condition (M= 
-1.163) (Figure 5.9).  
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Figure 5.9 The main effect of hypoxia / normoxia on overall number of words 
correctly recalled on the delayed word recall task. Figure displays change from 
baseline means (with SEM error bars), of correct words recalled in hypoxia and normoxia 
(*p<.05). 
 
5.4.4.1 Overall cognitive domain performance in hypoxia 
Accuracy – A significant main effect of hypoxia/normoxia was found for overall accuracy 
performance across tasks [F (1, 22) =7.324, p= .013] which showed lower accuracy within 
the hypoxic condition (M= -.041) in comparison to the normoxic condition (M= .041) 
(Figure 5.10).  
 
 
 
 
 
 
 
 
 
Figure 5.10 The main effect of hypoxia / normoxia on overall accuracy (number of 
correct responses) across task performance. Figure displays change from baseline Z 
score means (with SEM error bars), on overall accuracy (% / number correct) across Serial 
3 & 7, CRT, RVIP and Stroop tasks in both hypoxia and normoxia (*p<.05). 
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5.4.5 Mood in hypoxia 
 Mental fatigue – A significant main effect of hypoxia/normoxia was found on self-
reported levels of mental fatigue [F (1, 23) = 25.326, p <.001] revealing that hypoxia (M 
= 12.37) significantly increased mental fatigue in comparison to normoxia (M = 2.65) 
(Figure 5.11). 
 
 
 
 
 
 
 
 
Figure 5.11 The main effect of hypoxia / normoxia self-reported levels of mental 
fatigue. Figure displays change from baseline means (with SEM error bars), of self-
reported mental fatigue (mm) in normoxia and hypoxia (**p<.01). 
 
5.4.5.1 The effect of the environmental chamber on mood 
No significant main effect of day, hypoxia / normoxia nor subsequent interaction effect 
was found for any of the self-reported mood parameters (p >.80). 
 
Cognitive results for all individual tasks (and their subsequent outcomes measures) in this 
chapter are reported in full in Appendix 3.0, while results for overall cognitive domains 
are reported in Appendix 3.2. Mood data can be found reported in full in Appendix 3.1. 
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5.5 Discussion 
The current study aimed to build upon the results of the preceding chapter by employing 
a more disruptive level of hypoxia (12.7% FiO2) to model the role of age-related decline 
in cognitive performance. It was hypothesized that this higher level of hypoxia would 
induce significant decline on several individual tasks and overall cognitive domains. 
Moreover, it was also predicted that a single 500 mg dose of resveratrol would be capable 
of modulating CBF, irrespective of the environmental condition and that this would be 
exaggerated further within hypoxia; serving to attenuate any hypoxia induced cognitive 
deficits. 
In contrast to Chapter 4, the results here showed that the hypoxia condition significantly 
increased CBF in the prefrontal cortex, as indexed by significantly higher concentrations 
of total-Hb, relative to the normoxia condition. Consequently, significantly increased 
concentrations of oxy-Hb were observed across both the absorption and post dose task 
performance during hypoxia relative to normoxia. This is perhaps unsurprising, as the 
brain will continually combat reductions to cerebral oxygenation with increased cerebral 
perfusion to avoid potential damage to the CNS (Reis et al., 1994; Harris et al., 2013). 
Despite this adaptive response, as anticipated, the current study did find that exposure to 
hypoxia significantly reduced cognitive performance across several task outcomes.  
Indeed, significant reductions were observed in both the number of correct and incorrect 
entries on the Serial 3 subtraction task during hypoxia in comparison to normoxia. This 
was further complemented by a significant reduction in the number of correctly identified 
words on the delayed word recall task in the hypoxia condition relative to the normoxia 
condition. Moreover, on analysis of the composite cognitive Z scores, overall accuracy 
was found to significantly decrease across task performance. Such decreases in cognitive 
performance are consistent with previous research into both hypoxia (Petrassi et al., 2012; 
McMorris et al., 2017) and ageing populations (Harada et al., 2013); providing firm 
evidence of the overall success of hypoxia as a representative, experimental model of the 
cognitive ageing process.  
Interestingly, participants also reported to experience significantly higher levels of mental 
fatigue within hypoxia in comparison to normoxia. This provides further confirmation 
that exposure to a reduced O2 supply can also impact mood, although, contrary to the 
suggestions of the previous chapter, no significant main effect or relevant interaction with 
O2 status was found for self-reported ratings of anxiety. However, these findings may 
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actually support claims for the aforementioned anxiogenic nature of the testing 
environment, as this may infer that the nature of the environment itself / the perceived 
nature of the reduction in O2 was anxiety inducing, rather the reduction in O2 itself. 
Although, additional analysis of the baseline mood scores showed that there was no 
significant main effect of day, O2 status or subsequent interaction between the two factors 
for any of the mood measures. It is reasonable to assume that the increased exposure to 
the chamber over the 4 testing sessions would naturally reduce any negative effect on 
mood, yet this was not supported by the results here.  
With regards to treatment related effects on cognition, a significant treatment × hypoxia 
/ normoxia × repetition interaction effect was found for both Serial 3 correct responses 
and RVIP correct reaction time. However, the series of follow up student t-tests provided 
no interpretable pattern between the treatments and hypoxia / normoxia conditions across 
the 3 post-dose repetitions. A single significant main effect on reaction time on the CRT 
task which revealed resveratrol increased (worsened) reaction time relative to placebo; 
however, as this represents 1 / 17 task outcomes, this is likely to be a type I error. 
Moreover, on further observation of the difference between the two treatments, the 
resveratrol condition showed an increased reaction time of less than 20 ms in comparison 
to the placebo condition; thus, it would be difficult to argue that such a small decrease 
could indeed impact cognitive performance.  
The results here demonstrated that a single 500 mg dose was capable of inducing CBF 
changes in the prefrontal cortex within the normoxic condition, in line with previous 
investigations (Kennedy et al., 2010; Wightman et al., 2014; Wightman et al., 2015). This 
was indexed by significant increases in both total-Hb and oxy-Hb concentrations in 
comparison to placebo, across the post dose task period. However, contrary to the initial 
hypothesis, resveratrol was again unable to significantly increase CBF during hypoxia 
when compared to placebo. The lack of resveratrol-mediated modulation of CBF during 
hypoxia is somewhat unanticipated. Of course, it is noteworthy that the insult of hypoxia 
is global across the brain and therefore the measurement of oxygenation of the prefrontal 
cortex here may not be representative of the oxygenation status of additional brain 
regions.  
However, as the vasodilatory response to acute hypoxia is NO mediated, it is possible 
that further stimulation of NO synthesis is not possible by any exogenous means, 
resveratrol or otherwise. In support, a small but growing body of research has shown that 
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administration of other nutritional NO-dependent vasodilators have also demonstrated 
poor success in increasing cerebral oxygenation in hypoxic conditions. In a randomized, 
double-blind, crossover investigation, Lefferts et al. (2015) found that acute 
supplementation of dietary nitrates was unable to promote increased neurovascular 
coupling or cognitive performance in moderate-high hypoxia (11.6% O2). Additionally, 
Masschelein et al. (2012) found that 6 days of nitrate loading prior to each testing session 
improved arterial and muscle oxygenation status, but not cerebral oxygenation during 
exercise in high hypoxia (11% O2). Querido and Sheel (2007) note that, as the 
autoregulation of the CBF response operates to protect the CNS from hypoxic damage, it 
is only interrupted once capillary O2 saturation (SaO2) reaches <60%, therefore any 
attempt to exaggerate this response above this level may be redundant (Masschelein et 
al., 2012). As <60% capillary O2 saturation could not have been achieved by the hypoxic 
level employed in the current study, it is clear that the CBF effects of resveratrol here 
may have been unable to modulate the heightened CBF response further.  
It appears therefore, that the use of the hypoxic model employed here may have been a 
doubled edged sword. Despite clear reductions in cognitive performance in the current 
chapter, the adaptive CBF reflex to hypoxia may have masked any potential CBF benefit 
of resveratrol. As hypoxia naturally induces increases in CBF, which cannot be increased 
further by resveratrol, this has hindered the exact mechanism by which resveratrol is 
hypothesized to increase cognitive performance. Moreover, it could be argued that 
assessing the ability of resveratrol to increase CBF further in an already augmented CBF 
response, is not representative of the ageing population the model was intended to mimic. 
As naturally ageing cohorts typically experience a reduction in both peripheral and 
cerebral blood flow, evaluating the capacity of resveratrol to indirectly enhance an already 
heightened vasodilatory response is not necessarily directly comparable. Therefore, it is 
clear research directly into ageing cohorts is still warranted.  
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Chapter 6  
The cerebral hemodynamic response and cognitive effects of acute resveratrol 
administration in a healthy, 50-70yrs cohort: A double blind, crossover 
investigation. 
6.1 Introduction  
The hypothesis underpinning this thesis is that acute administration of resveratrol will be 
capable of exerting CBF and cognitive benefits in naturally ageing adults. As natural 
ageing results in reductions to rCBF and CMRO2, it is proposed that the CBF effects of 
resveratrol will provide an increased benefit to an ageing/ older cohort and subsequently 
improve cognitive performance via attenuation of the reduction in CMRO2. This 
hypothesis has hitherto been examined through the ability of resveratrol to mitigate 
cognitive reductions induced by hypoxia. However, the results of the previous two 
chapters have revealed that a single dose of resveratrol was unable to significantly 
increase CBF and/or subsequently attenuate cognitive reductions induced by hypoxia 
(Chapter 5 only).  
Despite the inauspicious performance of resveratrol thus far, research directly into 
naturally ageing adults is still warranted. Not only is resveratrol unable to increase blood 
flow further due to a tight regulation of CBF in hypoxia, examining the ability of 
resveratrol to enhance an already heightened vasodilatory response does not fully 
represent the reduction in both cerebral and peripheral blood flow experienced by 
naturally ageing samples.  Therefore, further study is needed to evaluate the efficacy of 
resveratrol to increase a vasodilatory response in an ageing cohort that naturally suffer a 
reduction in blood flow capacity. In support, despite a lack of success in amplifying the 
CBF response in hypoxia, acute nitrate administration has been observed to increase 
cerebral perfusion alongside cognitive enhancement in older adults (Presley et al., 2011; 
Kelly et al., 2013). Resveratrol has shown greater success in inducing an increased 
vasodilatory response within individuals who directly suffer a reduction in eNOS 
expression, such as those with endothelial dysfunction (Wong et al., 2011; Wong et al., 
2013). Additionally, a small but growing body of evidence has demonstrated that 
administration of other vasoactive polyphenols, such as fruit flavanones and cocoa-
flavanols, can increase cerebral perfusion (Lamport et al., 2016; Sorond et al., 2008; 
Lamport et al., 2015) and cognitive performance (Kean et al., 2015; Mastroiacovo et al., 
2015; Brickman et al. 2014) in healthy, older adults.  
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To date, only one study has examined the efficacy of an acute dose of resveratrol in 
improving cognitive functioning in naturally ageing populations. Scholey et al. (2014) 
examined the behavioural effects of a resveratrol-enriched wine, within a cohort of older 
adults (mean age = 70.44 years). The results showed that wine infused with 200 mg of 
resveratrol evinced a significant improvement in Serial 7 subtraction performance at post 
dose repetitions two and four in comparison to wine alone. These findings should be 
interpreted with caution however; with the study failing to compare the results to a 
dealcoholized control. Moreover, in the absence of monitoring blood flow parameters, it 
is difficult to attribute these results to increases in CBF. In a recent double blind, placebo 
controlled investigation, Evans et al. (2017) examined the efficacy of smaller (75 mg) and 
more frequent administrations (twice daily for 14 weeks) of resveratrol on cerebral 
responsiveness in a cohort of postmenopausal women (mean age = 61.5); a population 
acknowledged to suffer a reduction in CBF. The authors reported that the resveratrol 
group demonstrated significantly augmented cerebral responsiveness during the cognitive 
test battery (comprising memory and interference tasks), which correlated with an overall 
increase in cognitive performance. The results of this study provide support for the ability 
of resveratrol to directly increase cerebral perfusion in cohorts who suffer a reduction in 
CBF and the subsequent capacity to improve cognitive performance.  
Significant age-related decline in cognition has been estimated to begin at approximately 
50 years (Aartsen et al., 2002; Rönnlund, et al., 2005), coinciding with initial reductions 
observed in rCBF and CMRO2 (Lu et al., 2010; De Vis et al., 2015; Aanerud et al., 2012). 
It is proposed, therefore, that healthy individuals aged >50 years will possess a small but 
significant decline in rCBF and cognitive performance and that this will be sensitive 
enough for the vasodilatory effects of resveratrol to be beneficial to cognitive functioning. 
However, cognitive ageing is thought to accelerate from >70 years (Filley & Cullum, 
1994), with individuals beyond this age showing a greater risk of pathological and 
neurodegenerative decline (Howieson, 2015). Additionally, given the extremes of the 
ageing process, substantial differences within cognitive functioning can be observed in 
individuals over this age (Letenneur et al., 2007). Consequently, it may be more prudent 
to examine the efficacy of resveratrol as a cognitive enhancer between the ages of 50-70 
years; thus, reducing the impact of other unforeseen variables in those older than this 
threshold. With this in mind, this final chapter aimed to investigate whether a single 500 
mg dose of resveratrol was capable of increasing CBF, and consequently improving 
cognitive performance in healthy, ageing adults aged 50-70 years. 
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6.2 Method 
6.2.1 Participants  
The current study recruited 24 healthy older adults, aged 50-69 years (18 female, mean 
age = 59.36, SD 6.00, 22 right handed), who reported themselves to be free of any 
diagnosed developmental or neurological disorders or who had suffered head trauma. 
Participants reported themselves to be in good health, free from any food allergies, 
intolerances or digestive problems and possessed good or corrected vision. All 
participants abstained from social drugs (including tobacco), herbal / food supplements, 
and were not taking part in any other intervention study during the full course of their 
involvement in the study. Female participants taking hormonal replacement for 
menopause were still eligible to participate. In addition, participants who were pregnant 
(or seeking to be) smoked, or consumed excessive caffeine (<six cups of coffee or 
equivalent / daily) were excluded from the current study. Due to the requirements of the 
tasks, participants were also excluded if English was not their first language, if they 
suffered from colour blindness, or a relevant learning difficulty.  
6.2.2 Standardised diet  
Prior to each testing day, participants were required to follow a standardised diet, which 
required the participants to abstain from polyphenol containing foods and beverages for 
24 hours. This included the avoidance of all alcoholic beverages, fruit (fresh, dried, tinned 
or otherwise), vegetables (including processed products with vegetables) or sauces that 
included any of the above (e.g. tomato based sauces). Moreover, participants were 
required to avoid all cocoa containing products including chocolate (white, milk or dark), 
chocolate confectionery, biscuits and baked goods whilst also abstaining from all soy 
containing products (e.g. soy beans), nuts or nut based food items. Finally, this diet 
included avoiding liquorice, honey or herbs, including their extracts, and foods or 
beverages containing these ingredients (including herbal teas). In addition to the 
standardised diet, participants were required to fast for 2 hours (except water), abstain 
from caffeinated foods and beverages for 18 hours prior to arrival and also refraining 
from taking oral antihistamines and over the counter medications (such as paracetamol & 
ibuprofen) for 48 hours before testing commenced. The rationale behind implementing 
these dietary restrictions was to remove the need for these older participants to fast for an 
extended period (i.e. 12 hrs) while still avoiding the interference from the consumption 
of other phenolics, caffeine and/or alcohol. 
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6.2.3 Treatments 
The individual treatments were administered on the two separate testing days, with each 
testing session being conducted no more than 48 hours before, and no more than 14 days 
after, the previous session. During the two study visits participants received a single-dose 
treatment in a counterbalanced (Latin square) order, dictated by random allocation: 
 
1) ×2 capsules containing 250 mg resveratrol (equating to a 500 mg dose).  
2) ×2 capsules both containing placebo 
The treatments were administered in identical, size 0 vegetable capsules, which were 
prepared by the lead researcher and coded by a third party who had no further involvement 
in any aspect of the study. Again, no member of the investigational team was aware of 
the contents of the capsules until the analysis was completed. 
6.2.4 Cognitive battery 
For consistency and direct comparison to the hypoxic model, the cognitive tasks remained 
the same as Chapter 5 (see section 5.2.3 for details).  
6.2.5 Frequency Domain Near-Infrared Spectroscopy (FD-NIRS) 
The OxiplexTS Frequency Domain Near-Infrared Tissue Oximeter (model 99200), with 
OxiTS software version 3.1, was employed for the current study. Refer to section 2.2.2 
for full specification of this device.  To maintain a light noise-free operation, all testing 
took place in a darkened room, with minimal artificial or natural light. Additionally, upon 
placement of the two NIRS optodes to the participant’s forehead, an adhesive bandage 
was also applied to prevent the interference of any remaining penetrating light. Markers 
were inserted throughout the recording of the NIRS data to time stamp specific epochs 
corresponding to individual cognitive tasks. Data collected during the memory tasks was 
excluded from the analysis due to artefacts caused by the physical movement associated 
with the paper and pencil responses. 
6.2.6 Procedure 
For consistency across the thesis, the same testing paradigm employed in Chapters 4 and 
5 was also adopted for this final study, with the exception that a different NIRS device 
was utilized. Participants were required to attend the laboratory on three occasions. The 
initial visit was a screening / training session, where participants declared themselves to 
be in line with the inclusion criteria after providing informed consent. Participants were 
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then trained on the tasks of the cognitive demand battery (this comprised 3 repetitions of 
shortened version of each task and then 2 full repetitions of the cognitive battery) before 
the compliance requirements for the following visits were explained. The following two 
visits were testing sessions, where participants arrived at the testing facility at 1 pm, 
having adhered to the standardised diet for 24 hours, and fasted for 2 hours (except for 
water). After confirmation of their continued compliance to the inclusion criteria, 
participants were connected to the NIRS device. After a brief rest, participants completed 
a baseline measure of the cognitive battery before watching a non-stimulating video for 
10 minutes. Upon completion of the baseline rest measure, the treatment for the day was 
administered and the participant remained at rest for a further 45 minutes (continuing to 
watch the same non-stimulating video), to allow for absorption. The participant then 
completed 3 consecutive repetitions of the cognitive battery. On the final testing visit 
participants were thanked for their time and fully debriefed. The participants received £30 
compensation upon completion of the study. 
 
 
 
 
 
 
 
 
 
Figure 6.0 A timeline of the fourth experimental study testing day. 
 
6.3 Statistical analysis 
All behavioural data was analysed using SPSS version 22 for Windows (IBM SPSS 
Statistics Armonk, NY), and all NIRS analysis was analysed using Minitab 17 (State 
College, PA: Minitab, Inc.).  
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6.3.1 Main NIRS analysis  
Prior to any analysis, raw data was graphed and cleaned for the existence of potential 
outliers / artefacts with the data set. This led to the removal of 5 participants (N=19). 
Consistent with the previous investigations in this thesis both left and right hemispheres 
were combined and averaged for analysis. All subsequent NIRS data was converted to 
change from baseline (utilising the first minute of the absorption period as the baseline) 
and averaged into 2-minute epochs across the remaining 44-minutes of the absorption and 
~40-minute post-dose task periods. Again, due to the artefacts in the data created by the 
gross movements involved in completing the pen and paper memory tasks, both 
immediate and delayed word recall tasks were removed from the NIRS analysis. The 
averaged NIRS data was analysed via within-subjects’ ANOVAs, analysing Treatment 
(resveratrol × placebo) against Epoch (×37 two-minute averaged time points across both 
the absorption and post task period). Upon significance of the initial F test, subsequent 
planned comparisons were conducted, using t tests calculated with the MS error values 
from the initial ANOVAs. 
 
6.3.2 Behavioural analysis 
No data was removed during the cleaning process, resulting in a final sample of N=24. 
Post dose cognitive data and its task sub-measures were then converted to change from 
baseline performance. For each task sub measure, a Treatment (resveratrol × placebo) by 
Repetition (×3) repeated measures ANOVA was conducted, followed up by Bonferroni 
corrected post-hoc pairwise comparisons (on the emergence of significant interaction 
effects). To provide an indication of the relative cognitive ability of the older cohort, 
differences in cognitive task performance between the young sample used in Chapter 5 
and the older cohort employed here were analysed. A series of independent sample t-tests 
were conducted on each task outcome for baseline scores from visit 1 for both studies.  
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6.4 Results 
6.4.1 NIRS Data 
The ANOVA revealed no significant main effect of treatment nor subsequent interaction 
with epoch for changes in concentrations of oxy-Hb, deoxy-Hb or total-Hb.  
 
6.4.2 Behavioural data 
Baseline analysis – Prior to any analysis, a series of independent sample t-tests were 
carried out on all baseline scores for each cognitive sub-measure. All other differences 
between baseline scores showed to be statistically non-significant (p >.094). 
RVIP correct – A significant main effect of treatment was found for correct responses on 
the RVIP task [F (1, 23) = 9.514, p= .005], demonstrating that administration of 
resveratrol (M= -4.080) led to a lower percentage of correct responses in comparison to 
administration with placebo (M= 5.12) (Figure 6.1). 
 
 
 
 
 
 
 
 
Figure 6.1 The main effect of 500 mg resveratrol and placebo administration on 
percentage correct responses on the RVIP task. Figure displays change from baseline 
means (with SEM error bars), of percentage correct responses after 500 mg resveratrol 
and placebo on the RVIP task (**p<.01). 
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RVIP reaction time (RT) – A significant main effect of treatment was also found for 
correct RT on the RVIP task [F (1, 23) = 6.991, p= .015], showing that administration of 
resveratrol (M= 26.19) led to slower correct responses in comparison to placebo (M= -
14.20) (Figure 6.2).  
 
 
 
 
 
 
 
 
 
Figure 6.2 The main effect of 500 mg resveratrol and placebo administration on 
RVIP correct response time. Figure displays change from baseline means (with SEM 
error bars), of time (in ms) taken to register a correct response following 500 mg 
resveratrol or placebo on the RVIP task (*p<.05). 
 
 
Measure 
 
Treatment 
 Task Battery ANOVA 
N Baseline 1 2 3 Effect F P 
RVIP 
% 
Correct 
Placebo 24 
56.77 
(5.16) 
.52 
(2.68) 
6.51 
(2.42) 
8.33 
(2.37) 
R 
 
T 
 
T*R 
1.579 
 
9.514 
 
3.026 
.217 
 
.005** 
 
.058t Resveratrol 24 
63.28 
(5.00) 
-2.86 
(3.19) 
-6.77 
(3.49) 
-2.60 
(2.98) 
RVIP 
Correct 
RT 
(msecs) 
Placebo 24 
529.73 
(14.81) 
-28.32 
(23.46) 
-5.73 
(10.40) 
-8.55 
(10.67) 
R 
 
T 
 
T*R 
.026 
 
6.991 
 
1.352 
.935 
 
.015* 
 
.265 Resveratrol 24 
494.05 
(14.72) 
38.72 
(13.69) 
20.59 
(9.59) 
19.23 
(12.42) 
No other significant treatment related effects were found for cognitive performance. See 
Appendix 4.0 for the full reporting of cognitive results.  
 
Table 6.0 The effects of 500 mg resveratrol and placebo on cognitive performance. Table displays 
baseline and change from baseline scores (with SEM values in brackets) for significant treatment related 
results across the three post-dose battery repetitions after placebo and 500 mg resveratrol for 24 healthy, 
older adults. Table also displays ANOVA F and P values for main effects of treatment (T) and repetition 
(R) and an interaction between the two (T*R) with *<.05, **<.01.  
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6.4.3 Analysis comparing the cognitive performance of the young and older 
cohorts 
Only significant differences between cohorts are reported here. See Appendix 4.1 for the 
full reporting of the comparisons between the young (18-35 years) and older (50-70 years) 
cohorts. 
Serial 3: The t test revealed the young cohort (M = 41.17) scored a significantly higher 
number of correct entries on the Serial 3 subtraction task [t (46) = 4.329, p <.001] in 
comparison to the older cohort (M = 23.83). 
 
 
 
 
 
 
 
Figure 6.3 The difference between average correct responses entered on the Serial 3 
subtraction task for both the young and older cohort. Figure displays the baseline 
means (with SEM error bars) of the correct number of entries for the Serial 3 subtraction 
task for the young cohort of Chapter 5 and older cohort of Chapter 6 at baseline of visit 1 
(**p<.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2D Graph 1
Y
 D
a
ta
0
10
20
30
40
50
Serial 3 corr 
Serial 3 corr: 23.83 
Young Older 
** 
N
u
m
b
er
 o
f 
co
rr
ec
t 
re
sp
o
n
se
s 
149 
 
 
Serial 7: The t test revealed the young cohort (M = 27.17) scored a significantly higher 
number of correct entries on the Serial 7 subtraction task [t (46) = 2.086, p = .044] in 
comparison to the older cohort (M = 18.04). 
 
 
 
 
 
 
 
Figure 6.4 The difference between average correct responses entered on the Serial 7 
subtraction task for both young and older cohorts. Figure displays the baseline means 
(with SEM error bars) of the correct number of entries for the Serial 7 subtraction task 
for the young cohort of Chapter 5 and older cohort of Chapter 6 at baseline of visit 1 
(*p<.05). 
 
CRT: The t test revealed the young cohort (M = 441.47) responded significantly quicker 
for correct responses on the choice reaction time task [t (46) = 2.102, p = .041] in 
comparison to the older cohort (M = 501.57).   
                                                                                             
 
 
 
 
 
 
Figure 6.5 The difference between average reaction time to correct responses 
entered on the CRT task for both young and older cohorts. Figure displays the 
baseline means (with SEM error bars) for reaction time (in ms) for the young cohort of 
Chapter 5 and older cohort of Chapter 6 at baseline of visit 1 for the CRT task (*p<.05). 
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RVIP: The t test revealed the young cohort (M = 448.58) responded significantly quicker 
to responses on the RVIP task [t (46) = 2.047, p = .046] in comparison to the older cohort 
(M = 504.67). 
 
 
 
 
 
Figure 6.6 The difference between average reaction time to correct responses 
entered on the RVIP task for both young and older cohorts. Figure displays the 
baseline means (with SEM error bars) for reaction time (in ms) for the young cohort of 
Chapter 5 and older cohort of Chapter 6 at baseline of visit 1 for the RVIP task (*p<.05). 
 
Stroop: The t test revealed the young cohort (M = 702.65) responded significantly quicker 
for correct responses on the Stroop task [t (46) = 4.872, p <.001] in comparison to the 
older cohort (M = 962.93). 
 
 
 
 
 
 
 
Figure 6.7 The difference between average reaction time to correct responses 
entered on the Stroop task for both young and older cohorts. Figure displays the 
baseline means (with SEM error bars) for reaction time (in ms) for the young cohort of 
Chapter 5 and older cohort of Chapter 6 at baseline of visit 1 for the Stroop task (**p<.01). 
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6.5 Discussion 
This final experimental chapter assessed whether an acute dose of resveratrol could 
induce significant increases in CBF and cognitive performance in healthy, older adults. It 
was argued that the CBF effects of resveratrol would provide increased utility in ageing 
populations, above and beyond those in hitherto utilized younger samples; leading to 
improved cognitive functioning. The findings here do not support this. Indeed, contrasting 
with all previous literature (Kennedy et al., 2010; Wightman et al., 2014; Wightman et 
al., 2015), and Chapter 5 of this thesis, a single dose of 500 mg resveratrol was unable to 
modulate CBF in the prefrontal cortex during either the absorption period or task 
performance. In addition, cognitive performance was found to decrease following a single 
dose of resveratrol, relative to placebo.  
Two key methodological factors of the current trial differ from those in previous chapters 
and may explain these unanticipated findings, particularly the lack of CBF effects; 1, the 
use of a different NIRS device and 2, the older sample of participants. As little evidence 
exists to support the use of FD NIRS in the measurement of CBF from nutritional 
interventions, it is possible that the use of the current FD NIRS device may have 
contributed to the abovementioned unanticipated findings. This device has been noted to 
produce a greater level of noise within the data in comparison to its CW counterpart 
(Davies et al., 2016), whilst also being unable to provide depth specific measurements 
(Bakkers et al., 2004). It is therefore unlikely that the current study has reliably measured 
the same area of the prefrontal cortex as recorded in previous investigations; making it 
difficult to provide an accurate comparison between studies. The benefits of this device 
(see section 2.2.2) make it particularly practical for the measurement of CBF with the 
prefrontal cortex in older cohorts but further research is clearly required to confirm the 
efficacy of the measure of this NIRS in the field.  
The second explanation, is that it is also possible that the CBF effects reported here reflect 
differences emanating from the older sample themselves. Although rCBF has been found 
to decline with age in areas such as the prefrontal cortex (Lu et al., 2010), it has been 
proposed that older adults who score highly on cognitive tasks, may be counteracting such 
age-related neural declines through a plastic reorganisation of neurocognitive networks 
(Cabeza et al., 2002). Indeed, changes in CBF across the brain are not uniform, with 
subcortical regions remaining relatively unaffected by reduced blood flow (Chen et al., 
2011), which may contribute to neural reorganisation. To add further ambiguity, the 
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diversity of rCBF reductions are still subject to debate, with several researchers reporting 
large variance in the extent of rCBF decline, which may result from several individual 
differences (Sonntag et al., 2007). Despite the uncertainty surrounding the 
cerebrovascular efficacy of the current sample, it is noteworthy that the older cohort 
employed within this study were found to perform significantly poorer on several the 
cognitive tasks in comparison to the young (18-35 years) sample of Chapter 5. Indeed, 
the current sample were found to score significantly fewer correct entries on both Serial 
subtraction tasks, while displaying significantly poorer reaction time on CRT, RVIP and 
Stroop tasks in comparison to the younger participants of Chapter 5. These results support 
the notion that the participants did indeed possess the anticipated reduction to cognitive 
performance. 
With regards to treatment related effects on cognition, resveratrol was found to 
significantly worsen cognitive performance in this cohort. This was indexed by 
significantly poorer accuracy and reaction time on the RVIP task in comparison to 
placebo. In the face of no effect on cerebral haemodynamics, this may actually point 
towards a high, acute dose of resveratrol being detrimental in older adults. Interestingly, 
decreases in executive functioning following long term polyphenol consumption 
(catechins, proanthocyanidins & flavonols) have been reported previously (Kesse-Guyot 
et al., 2011). Despite this evidence stemming from a longitudinal study, the authors do 
highlight that, certain polyphenols, under certain conditions, may exert pro-oxidant 
effects that may explain the inverse relation in performance (Kesse-Guyot et al., 2011). 
Similarly, recent evidence would imply a potential hormesis dose effect of resveratrol 
where by high doses may induce pro-oxidant effects (Plauth et al., 2016); this may (albite 
tentatively) suggest a high dose of resveratrol may result in a negative impact on cognitive 
performance.  
Building on the above, the CBF and subsequent cognitive benefits of resveratrol may be 
observed more consistently following smaller doses. Indeed, Wong et al. (2016) 
examined a range of acute doses of resveratrol (75, 150, and 300 mg) in individuals with 
type 2 diabetes mellitus (aged 49-78 years); a disorder acknowledged to reduce the ability 
of cerebral vessels to supply blood to brain regions during local metabolic demand 
(Janson et al., 2016). All 3 doses showed significantly increased blood flow velocity in 
the middle cerebral arteries. However, only the lower 75 mg dose was found to 
additionally increase blood flow velocity in the posterior cerebral arteries. Moreover, 
when this dose was supplemented for an extended period (14 weeks), Evans et al. (2017) 
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found significant overall improvements in cognition which correlated with increased 
cerebral vasodilatory responsiveness in menopausal women. Two further studies have 
also demonstrated cognitive benefits from resveratrol following 23 weeks of 
supplementation in dosages of ≤200 mg (Witte et al., 2014; Kobe et al., 2017) in older 
adults. Taken together, the above evidence may point towards prolonged supplementation 
of resveratrol in smaller doses to obtain maximal benefit; especially in the age group 
utilized here. 
Additionally and alternatively, it is finally postulated that the standardised diet may have 
also contributed to the unanticipated findings in this chapter. As all participants were 
asked to refrain from phenolic containing foods for 24 hours prior to testing, this would 
have naturally lowered their circulating polyphenol levels and, consequently, may have 
reduced cognitive performance and attention. This is supported by the notion that 
polyphenols may not accumulate over time and only reflect the last meal (Rendeiro et al., 
2015).  Higher intake of polyphenols has been found to lead to significantly better 
cognitive functioning in comparison to lower intake (Letenneur et al., 2007). Indeed, 
although average polyphenol intake was not officially monitored, several participants 
reported the diet to be ‘unpleasant’ or ‘difficult’, due to having to avoid regularly 
consumed foods such as fruit and vegetables. Lamport et al. (2012) report that restriction 
in habitual phenolic intake may impact a polyphenol intervention and its underlying 
mechanisms of action. As withdrawal may lead to a relative deficit, it is postulated that 
additional supplementation within trials may only serve to attenuate the effects of 
polyphenols removed from the diet; much in the same way that acute caffeine 
supplementation, following short-term abstinence, simply removes withdrawal effects 
rather than exerting net effects on the consumer. It is therefore suggested that future acute 
investigations may be better served recruiting individuals who regularly consume low 
quantities of polyphenols, in order to obtain the optimum benefits of resveratrol and avoid 
interference from withdrawal effects.  
In conclusion, the current study aimed to investigate whether an acute dose of resveratrol 
was capable of augmenting CBF and, in turn, cognitive performance in healthy, ageing 
adults. The results of this study revealed that a single dose of resveratrol was unable to 
improve CBF and lead to worsened cognitive performance in this cohort. Both findings 
are surprising; given the consistent CBF findings observed in previous investigations, and 
the small, but growing literature pointing towards cognitive enhancement following 
resveratrol supplementation. 
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Chapter 7 
 General discussion 
The current PhD thesis aimed to assess the potential cognitive enhancing effects of the 
polyphenol resveratrol, in young and ageing adults. This was in response to a growing 
body of research which had demonstrated that oral supplementation of resveratrol could 
induce NO-dependent vasodilation and, consequently, increases in CBF. Despite 
consistent previous observations of increased CBF and O2 extraction, no study at the time 
of undertaking this thesis had found these in conjunction with any consistent modulation 
of cognitive performance. It was proposed that the young, healthy samples employed in 
previous studies may have been unable to benefit from increased CBF for two reasons. 
Firstly, such cohorts are hypothesised to be the in the peak of their cognitive abilities. 
Secondly, they are also likely able to maintain an effective CBF response during cognitive 
demand; leaving any improvements from resveratrol to be so small as to be unobservable.  
As naturally ageing populations are noted to suffer a reduction in rCBF, CMRO2 and / or 
a subsequent decline in cognitive performance, it was proposed that the CBF effects of 
resveratrol could attenuate this decline and therefore improve cognitive performance. 
However, given the multifactorial nature of cognitive ageing, it was suggested that a 
model of cognitive ageing would be more appropriate to first test this hypothesis. Indeed, 
it was proposed that an acute bout of hypoxia to reduce cognitive functioning in young, 
healthy populations would sufficiently model the age-related decline in neural O2 delivery 
and extraction. By first compromising cognitive functioning in young, healthy 
populations, this would create a clearer picture of the capacity of resveratrol to mitigate 
a reduced CMRO2, via an enhanced CBF response. This could then be established in 
healthy, older cohorts directly.  
The current thesis therefore, primarily aimed to assess the metabolic, cerebral-
haemodynamic and cognitive effects of resveratrol administration in healthy, young and 
(naturally) ageing cohorts. The ancillary aim of this thesis was to examine the efficacy of 
a hypoxic model as a representative, experimental model of cognitive ageing. 
 
 7.1 Summary of empirical findings 
The first empirical chapter (Chapter 3) was a double-blind, placebo-controlled, crossover 
investigation, which employed ICa to provide a proxy for cerebral metabolism during 
high cognitive demand. Here, the aim was to establish whether administration of 
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resveratrol could induce a dose (250 mg, 500 mg) dependent increase in metabolic and 
substrate expenditure during rest and cognitive performance, within a sample of 27 
healthy, young (M age = 22 years) participants. The results here showed that 500 mg 
resveratrol was capable of evincing significant increases in CHO oxidation during 
cognitive performance (as indexed by higher RER), 45 minutes and 3 hours post 
administration, relative to placebo. However, cognitive performance and metabolic / 
substrate expenditure at rest were unaffected by either dose. The overall conclusion of 
this chapter was that resveratrol is capable of influencing substrate oxidation during 
cognitive performance and this provides evidence for its effect on cerebral metabolism. 
Although, as resveratrol failed to improve cognitive functioning in a young, healthy 
cohort, it was proposed that administration may be more beneficial in populations who 
suffer a reduction in the supply of neural fuel substrates; such as naturally ageing 
populations.   
The second empirical study (Chapter 4), a double-blind, placebo-controlled, crossover 
investigation, aimed to address the conclusions of the previous chapter by employing mild 
hypoxia (16% FiO2) to model the role of decreased rCBF and subsequent CMRO2, in 
naturally ageing populations from a sample of 24 young (M age = 22 years), healthy 
participants. It was proposed that a reduction in O2 would lead to impaired cognitive 
performance and that administration of a single 500 mg dose of resveratrol would 
attenuate this decline with an increase in CBF (monitored throughout the session via CW 
NIRS). Cerebral oxygenation was found to decrease in the hypoxia condition, as indexed 
by significantly lower concentrations of oxy-Hb relative to the normoxia condition. 
However, this did not lead to any decline in cognitive performance. As increased O2 
extraction (indexed by significantly higher concentrations of deoxy-Hb) was present 
throughout the absorption and post dose task period, it was postulated that this may have 
naturally mitigated the hypoxic environment and the subsequent decreases in cognitive 
functioning. This suggests that the hypoxic level employed in this chapter was not 
disruptive enough to model the age-related decline in cognitive functioning. 
Administration of resveratrol exaggerated the increase in deoxy-Hb concentrations across 
the absorption period, but was unable to modulate CBF during the post dose task period 
in either hypoxia or normoxia. Strikingly however, administration of resveratrol was 
found to significantly reduce the number of errors entered on both the Serial 3 and 7 
subtraction tasks, irrespective of the environmental condition (O2 status); suggesting an 
effect of resveratrol itself. This is perhaps the first study to identify cognitive 
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improvements resulting from a single dose of resveratrol in healthy, young humans. 
However, in the absence of any modulation of CBF, it was proposed that the ability of 
resveratrol to offer anxiolytic effects (via modulation of MOA), may have offset the 
potential anxiogenic environment of the environmental chamber and subsequently 
provided cognitive enhancement.  
The following investigation (Chapter 5); a double-blind, placebo-controlled, crossover 
investigation, took note of the preceding findings and employed a more disruptive (12.7% 
O2) hypoxic environment, in order to model the age-related regional reductions to 
CMRO2 and consequential deficits in cognitive functioning more effectively. It was 
hypothesised again that the lower O2 availability would induce cognitive deficits which 
resveratrol would then mitigate with an increased CBF response. In keeping with the 
previous chapter, a further sample of 24 young (M age = 23) healthy participants were 
employed. Contrasting with the previous chapter, the results showed a significant increase 
in cerebral oxygenation within the prefrontal cortex (evidenced by significantly higher 
oxy-Hb concentrations) across both the absorption and post dose task period within 
hypoxia, in comparison to normoxia. This may have been as a result of the CNS protecting 
itself from the insult of hypoxia with an exaggerated CBF response. 
Despite this, exposure to the hypoxia condition did reveal clear reductions in cognitive 
functioning and mood. Performance was found to decrease on individual tasks (Serial 
subtractions & Delayed word recall), while composite cognitive Z score analysis revealed 
a significant decrease in overall accuracy performance across the tasks. Moreover, 
participants reported significantly higher levels of mental fatigue when in hypoxia in 
comparison to normoxia. This provided confirmation of the success of the hypoxic model 
of cognitive ageing.  
In keeping with previous investigations, a single 500 mg dose of resveratrol was found to 
significantly increase total-Hb and oxy-Hb concentrations in the prefrontal cortex during 
post dose task performance in the normoxia condition. However, in contrast to the initial 
hypothesis, resveratrol administration was unable to exaggerate the CBF response to 
hypoxia across both the absorption and task periods. As the same dose of resveratrol has 
been shown to clearly increase CBF in normoxia, it is more likely that the hypoxic 
condition itself must have contributed to the current findings, rather than a lack of efficacy 
of resveratrol to enhance CBF. It was surmised that, as the sole purpose of the 
autoregulatory response to hypoxia is to protect to the CNS from hypoxic damage, this 
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restricts any exogenous factors from increasing this reflex further, blunting any effect of 
resveratrol.   
A single treatment related difference to cognitive performance was observed in Chapter 
5. However, this showed that administration with resveratrol significantly worsened 
reaction time on the correct responses of the choice reaction time task, in comparison to 
placebo. As this represented only 1 of 17 outcome measures, it was deemed likely a type 
I error. Moreover, on further inspection of the difference between the means, the 
worsening in reaction time during the task was so minimal, it would be difficult to 
attribute this as a cognitive enhancing effect. Despite the lack of modulation of CBF and 
cognitive performance by resveratrol, investigation into its effect on ageing populations 
was still deemed to be warranted. The hypoxic model may have inadvertently interfered 
with the vascular mechanism of resveratrol. Further, exaggerating an already increased 
CBF response does not fully compare to attenuating reductions in blood flow capacity 
observed consistently in ageing populations. The success and the constraints of the use of 
hypoxia as a representative, experimental model of cognitive ageing will be discussed 
further in section 7.5. 
The final empirical study (Chapter 6), also a double-blind, placebo-controlled, crossover 
investigation, utilized a sample of 24 (M age = 59 years) naturally ageing adults. It was 
hypothesized that a single dose of resveratrol would be capable of inducing significant 
increases in CBF and, in turn, improve cognitive functioning. However, the results of 
Chapter 6 showed no significant resveratrol-mediated modulation of CBF nor of 
cognitive performance. In fact, resveratrol lead to a decrease in cognitive performance.  
This loss of the previously observed resveratrol-mediated CBF effects was proposed to 
have been the result of the constraints of the FD NIRS apparatus, which may not have 
measured the same area of the prefrontal cortex as monitored previously. The advantages 
and constraints of both NIRS devices will be discussed in section 7.6.2. Contrary to 
previous predictions, resveratrol was found to significantly worsen both accuracy and 
correct response reaction time on the RVIP task, relative to placebo. However, the 
requirement to abstain from phenolic containing foods for 24 hours prior to testing, may 
have only served to contribute to the unpredictable impact on cognitive performance. A 
summary of the findings across the four experimental chapters can be found below in 
Table 7.0.
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Chapter 3 
Chapter 4 Chapter 5 
 
Chapter 6 
Normoxia Hypoxia Normoxia Hypoxia 
 
Cognition 
 
No significant 
effects. 
 
↑Improved error rate (S3 & S7 
subtractions) 
 
 
↓RT (CRT) 
 
 
↓RT (RVIP) 
↓Accuracy (RVIP) 
 
Total-Hb 
  
No significant 
effects. 
 
No significant 
effects. 
 
↑During post 
dose task 
performance 
 
No significant 
effects. 
 
No significant 
effects. 
 
Oxy-Hb 
  
No significant 
effects. 
 
No significant 
effects. 
 
↑During post 
dose task 
performance 
 
No significant 
effects. 
 
No significant 
effects. 
 
Deoxy-Hb 
  
No significant 
effects. 
↑During 
absorption 
period 
 
No significant 
effects. 
 
No significant 
effects. 
 
No significant 
effects. 
 
RER 
↑RER (45 mins 
& 3hrs) 
     
Table 7.0 The summary of effects of 500 mg resveratrol against placebo on cognitive performance, cerebral haemodynamics and metabolism across the 4 experimental 
chapters. Abbreviations: ↑increase in performance or physiological measure; ↓decreases in performance or physiological measure. A diagonal line denotes that this measure was 
not an outcome in this chapter. 
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7.2 The metabolic profile of resveratrol  
The rationale behind investigating the metabolic effects of resveratrol in Chapter 3, was 
to provide insight into the capacity of resveratrol to enhance cerebral metabolic and 
substrate utilisation during cognitive demand. It was noted that previously observed 
increases in CBF and O2 extraction during both task performance and at rest (Kennedy et 
al., 2010; Wightman et al., 2014) only reflect the pattern of cerebral metabolic activity 
and therefore do not quantify the extent of cerebral metabolic change or cerebral EE (Al 
Naher et al., 2016). Given that the brain is the most metabolic organ in the body, the 
monitoring of whole body metabolism, via ICa, provided a proxy of resveratrol-mediated 
increases in blood flow capacity in response to cerebral metabolic change from increased 
substrate delivery and utilisation. The use of ICa and the methodological restraints of its 
use will be discussed further in section 7.6.1. 
The results of Chapter 3 revealed that both 250 mg and 500 mg doses of resveratrol could 
significantly increase the oxidation of CHO during task performance in a dose dependent 
manner. This was evidenced by significant increases in RER and subsequent percentage 
of CHO of EE during Serial 3 and 7 subtraction performance. This was seen 45 minutes 
and 3 hours post administration. Although there was no resveratrol-mediated increase in 
EE, the results still provided interesting confirmation that a single dose of resveratrol can 
evince a subtle, yet significant, shift in fuel utilization during cognitive demand. Although 
this was attributed to the CBF effects of resveratrol, it is notable that the shift in oxidation 
of CHO from resveratrol may also have been as a result of its ability to modulate AMPK; 
a key regulator in energy sensing procedures (Kulkarni & Cantó, 2015), glycaemic 
response and energy homeostasis (Hardie et al., 2012). In support, resveratrol has 
previously been shown to activate AMPK and subsequently stimulate insulin signalling 
and glucose uptake in both skeletal muscle and neuronal cells in vitro (Patel et al., 2011). 
Two previous investigations have also reported that acute doses of resveratrol can 
increase RER at rest (Williams et al. 2013; Scribbans et al., 2014). However, as neither 
investigation measured cognitive performance, it remains unclear whether this has been 
beneficial. Indeed, due to the novelty of the paradigm, no clear consensus exists within 
the literature as to whether an increase in RER during cognitive demand correlates with 
improved performance. Only two investigations at the time of writing have reported 
modulation of RER during cognitive performance, with one reporting a significant 
increase (Delistraty et al., 1991) and the other a significant decrease (Troubat et al., 2009) 
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in RER across cognitive demand. In a recent review, Grassman et al. (2016) note that the 
excretion of CO2 is the only capnographic measure which has shown sensitivity to 
increasing task difficulty. This is particularly interesting as this implies that cognitive 
effort not only involves additional EE, but also that increased CO2 excretion may provide 
a proxy for increased exertion. As RER is characterised by an increased ratio of CO2 : O2, 
it may be that resveratrol can increase the rate of glucose metabolism during cognitive 
demand and, consequently, may offer a means to boost cognitive performance.  
The increase in glucose utilisation observed here may also imply an additional method of 
enhancement by resveratrol. Other polyphenols have been credited with the regulation of 
blood glucose and it is proposed that the capacity for polyphenols to do so may allow for 
a plausible mechanism of cognitive enhancement; given the importance of glucose for 
cellular function and cognitive performance (Bell et al., 2015). It is hypothesized that the 
availability of glucose can be enhanced when consumed in a polyphenol-rich food / 
beverage, as polyphenols may slow the rate of absorption of sugar which consequently 
results in a greater availability of glucose over an extended period (Bell et al., 2015). In 
support, polyphenol rich blackcurrant extract has been found to increase blood glucose 
levels and cognitive performance (Watson et al., 2015), while ~40% and ~17% of the 
cognitive benefits of cocoa-flavanols observed in elderly adults were attributed to insulin 
resistance respectively (Desideri et al., 2012; Mastroiacovo et al., 2015).  
The ability of resveratrol to shift to a higher CHO fuel utilisation during cognitive 
performance may imply a possible interaction with glucose utilisation and insulin 
regulation, and thus, provide an alternative means of physiological effects. Although, as 
the effects of resveratrol were observed under fasted conditions in Chapter 3, it is 
interesting to consider that resveratrol could also influence glucose utilisation in 
conjunction with the consumption of glucose; which may have potentially beneficial 
ramifications for cognitive performance. Moreover, such resveratrol-meditated 
modulation of glucose could exist outside of CBF effects and, therefore, warrants further 
study, particularly in older cohorts who are acknowledged to suffer a reduction in glucose 
tolerance; an established cause of age-related cognitive decline (Lamport et al., 2009).  
Regarding the metabolic effects of resveratrol during rest, previous investigations had 
observed increased concentrations of deoxy-Hb, 35 minutes following administration 
(Kennedy et al., 2010) while pharmacokinetic evidence suggests the metabolites of 
resveratrol peak within ~30 minutes of consumption (Walle, 2011), suggesting that the 
161 
 
onset of resveratrol effects may emerge around this time point; even at rest. This led to 
the tentative suggestion that the metabolic effects of resveratrol may also be apparent 
prior to engagement in task performance. However, no treatment related differences were 
observed 35 minutes following consumption of either the 250 mg or 500 mg dose relative 
to placebo. It is possible that relative changes in metabolism are subtle and, as this data 
was not a change from baseline measure, it is likely that this has greatly reduced the 
sensitivity of the assessment, blunting any potentially measurable treatment related 
effects.  
 
7.3 The cerebral haemodynamic effects of resveratrol  
The premise that acute administration of resveratrol would be capable of exerting an 
amplified CBF response and increased O2 extraction / utilization was supported by 
Chapter 5 and (albeit to a weaker extent) Chapter 4 respectively. However, the additional 
hypotheses that resveratrol would be able to (1) exaggerate the CBF response and O2 
extraction induced by a hypoxic condition and (2) enhance CBF in samples which 
experience a reduction in CBF during cognitive performance, were not supported by any 
study in this thesis. All studies which measured CBF in the current thesis monitored 
changes in cerebral haemodynamics across both the absorption and post dose cognitive 
task periods. Chapter 4 revealed that 500 mg resveratrol could enhance O2 extraction at 
rest in hypoxia (as indexed by significantly higher concentrations of deoxy-Hb) after only 
10 minutes of administration. This was observed to continue until the end of the 45 minute 
absorption period. However, this effect was seen to diminish immediately upon the start 
of the post dose cognitive task performance period (see Figure 4.1). Chapter 5 observed 
that the same dose significantly increased both oxy-Hb and total-Hb concentrations 
during task performance when in normoxia, indexing an increase in CBF and cerebral 
oxygenation. However, this finding was not reproduced during task performance within 
hypoxia (see Figure 5.2 & Figure 5.3). Finally, Chapter 6 saw no treatment related change 
in cerebral haemodynamics across the absorption or post dose task period in a cohort of 
older, naturally ageing volunteers.  
The resveratrol-mediated increase in both total-Hb and oxy-Hb concentrations in the 
prefrontal cortex reported in Chapter 5 demonstrated the CBF mechanism of resveratrol; 
supporting its capacity to increase the availability of neural fuel substrates during 
cognitive performance. Moreover, as the CBF effects of resveratrol were observed during 
cognitive performance only, and not during resting / absorption periods, this supports the 
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notion that resveratrol can increase the NO-mediated endothelial vasodilatory response 
to neural demand specifically. Although significant increases in O2 extraction were seen 
throughout the absorption period in Chapter 4, this was within hypoxia only, and an 
explanation for this is offered below. The findings of Chapter 5 are broadly in line with 
that of previous investigations into resveratrol (Wightman et al., 2015) and research into 
other vaso-active polyphenols (Francis et al., 2006; Sorond et al., 2008). Distinctions can 
be made however where, despite also finding significant increases in concentrations of 
total-Hb, both Kennedy et al. (2010) and Wightman et al. (2014) reported complementary 
increases in deoxy-Hb alongside oxy-Hb concentrations from resveratrol administration. 
Why the additional increase in deoxy-Hb concentrations has not been replicated here is 
unclear.  
The lack of CBF modulation during cognitive performance in both hypoxia and normoxia 
in Chapter 4 was unanticipated. The explanation offered was that the anxiogenic nature 
of the environmental chamber may have added a level of noise to the neuroimaging data 
when recorded by the NIRS device. Why this has occurred in Chapter 4 and not Chapter 
5, is not clear and will be discussed further below. The results of Chapter 4 did 
demonstrate that 500 mg of resveratrol could enhance the natural increase in O2 extraction 
and utilisation (as indexed by increases in deoxy-Hb concentrations) and this started after 
only 10 minutes following administration. As the hypoxic level was set at the start of the 
absorption period in Chapter 4, this would demonstrate that resveratrol can respond to the 
slow but steady decrease to atmospheric O2 with increased O2 extraction; thus, offsetting 
the immediate hypoxic environment, and may suggest a beneficial adaptive effect of 
resveratrol. However, as this effect was seen to diminish at the end of the absorption 
period, which consequently was also the time that the hypoxic level would have reached 
the prescribed mild hypoxic level, this is unlikely to have any bearing on neurocognitive 
performance in the young sample employed.  
Regarding the CBF response during task performance in hypoxia, resveratrol was unable 
to enhance CBF in either mild (Chapter 4) or moderate (Chapter 5) hypoxia. It is first 
important to note that the cerebral haemodynamic response during both investigations 
was measured within the prefrontal cortex only and, therefore, it is possible that 
resveratrol could have modulated CBF within areas not measured in either study. 
However, as the autoregulation of the CBF response operates to protect the CNS from 
hypoxic damage, it appears more likely that the natural vasodilatory reflex, induced upon 
exposure to hypoxia, cannot be exaggerated by exogenous means and this would likely 
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be tightly regulated across all areas of the brain. It has been proposed that this 
autoregulatory response only becomes disturbed once capillary O2 saturation reaches <60% 
(Querido & Sheel, 2007) and therefore attempting to augment CBF further, via resveratrol 
administration, may be redundant (Masschelein et al., 2012). To put this into perspective, 
the mild hypoxia (16% FiO2) employed in Chapter 4 would be the equivalent of a capillary 
O2 saturation of ~94%, while the moderate hypoxia of Chapter 5 (12.7% FiO2) would 
equate to ~86% capillary O2 saturation. Therefore, neither hypoxic level was sufficient to 
disrupt the autoregulatory response.  
This is supported by the observation that other potent vasodilators have been unable to 
enhance neurovascular coupling in hypoxia. Lefferts et al. (2015) found that acute 
supplementation of dietary nitrates was unable to promote increased neurovascular 
coupling or cognitive performance in moderate-high hypoxia (11.6% FiO2). Moreover, 6 
days of nitrate supplementation prior to exposure to high hypoxia (11% FiO2) has been 
found to improve arterial and muscle oxygenation status, but not cerebral oxygenation, 
during exercise (Masschelein et al., 2012). This would suggest that even nitrate or 
resveratrol ‘loading’ prior to exposure cannot modulate NO-dependent vasodilation. 
Despite the lack of CBF effects of nitrite supplementation in humans, an increased CBF 
response within hypoxia has been found in rodent models. However, this is only seen 
when normal NO bioavailability / production was compromised within the brain (Piknova 
et al. 2011). An alternative explanation could be that the CBF response of hypoxia is not 
solely mediated by NO. Indeed, the hypoxia-induced vasodilatory response has also been 
found to be uninterrupted even when in the presence of a NO inhibitor, questioning 
whether NO is the sole contributor to the vasodilatory response to hypoxia (Umbrello et 
al., 2013). A recent review has proposed that several other factors may play a role in the 
autoregulated CBF response to hypoxia; including adenosine and anaerobic neuronal 
metabolism (Willie et al., 2014).  This would certainly offer a reasonable explanation as 
to why resveratrol was able to increase deoxy-Hb concentrations in Chapter 4 and not in 
Chapter 5. However, this would question the use of hypoxia as a model for the ageing 
brain utilised in the current thesis (this will be discussed further in section 7.5) especially 
when investigating the use of NO-dependent vasodilators to overcome a compromised O2 
supply. 
Finally, the efficacy of resveratrol to augment CBF in naturally ageing populations was 
not supported in this thesis. This finding was certainly unanticipated and would contradict 
much previous literature which has seen resveratrol-mediated increases in cerebral 
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perfusion (Wong et al., 2016) and / or endothelial vasodilation (Wong et al., 2011, 2012) 
in older or vascular impaired cohorts. Given the consistent ability of resveratrol 
administration to induce vascular effects following both acute and chronic doses, the most 
plausible explanation for this observation here is methodological issues. In contrast to the 
other two studies which monitored CBF (Chapter 4 & 5), a FD NIRS was preferred to a 
CW device for Chapter 6 (the rationale for this device has been outlined in section 2.1.2) 
and it is therefore proposed that this may have contributed to the current findings (see 
section 7.6.2).  
 
7.4 Cognitive and mood effects of resveratrol  
The hypothesis of the current PhD thesis was that the engendered CBF effects of 
resveratrol would enhance cognitive performance via the increased access and utilisation 
of neural fuel substrates (namely O2 and glucose) as, when consumed alone, these have 
been previously found to improve several aspects of cognitive functioning (Scholey et al., 
1998; Moss et al., 1998; Sünram-Lea et al., 2001; Scholey et al., 2001). The resulting 
cognitive benefits of resveratrol however, were proposed to be more observable in 
populations with a notable reduction in CBF and subsequent CMRO2 e.g. ageing 
populations. This was also extended to a preceding model of ageing via acute hypoxia 
(where cerebral oxygenation would also be lower), as previous investigations have 
revealed an attenuation of behavioural performance following supplementation with 
additional O2 (Legg et al., 2016). However, in contrast to predictions, no cognitive 
benefits of resveratrol were seen in young, healthy participants within hypoxia (Chapter 
4 & 5), nor were any cognitive effects of resveratrol established in a sample of healthy, 
older (50-70 years) participants (Chapter 6). To add further ambiguity, the cognitive 
enhancing effects of resveratrol were observed, in the absence of any modulation of CBF, 
in Chapter 4. 
Chapter 3 saw no cognitive effects from either 250 mg or 500 mg doses of resveratrol in 
young, healthy populations on three Serial subtraction tasks in an increasing gradation of 
difficulty. Chapter 5 also observed no resveratrol-mediated modulation of cognitive 
functioning when assessed across 8 different tasks, with a combined total of 17 outcome 
measures, in both hypoxia or normoxia, in a similar cohort.7 This is perhaps unsurprising 
                                                          
7 A single treatment related increase in performance was observed, where administration of resveratrol was 
found to significantly worsen reaction time on the choice reaction time task relative to placebo. However, 
as this represented 1 of 17 outcome measures, this was deemed more likely to be a type I error. 
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given that no investigation previously had observed consistent improvements in cognitive 
performance resulting from an acute or chronic dose of resveratrol in young, healthy 
cohorts. However, Chapter 6 utilized the same battery of cognitive tasks as Chapter 5 in 
a healthy, older sample and found that 500 mg resveratrol had a negative impact on 
performance, in the form of slower reaction time and reduced accuracy on the RVIP task 
in comparison to placebo (see Figure 6.3). Interestingly, despite no modulation of CBF 
during task performance, administration of 500 mg resveratrol was found to significantly 
reduce the number of incorrect responses entered during both the Serial 3 and 7 
subtraction tasks (see Figure 4.5 & Figure 4.6). As this was a main effect of treatment, 
and not an interaction with O2 status, it was proposed this was an effect of resveratrol in 
and of itself. 
The absence of modulation of cognitive functioning in young, healthy samples observed 
in 2 out of 3 studies is consistent with the previous studies investigating the cognitive 
effects of resveratrol prior to undertaking this thesis (Kennedy et al., 2010; Wightman et 
al., 2014; Wightman et al., 2015). Further still, this would also generally correspond with 
the majority of investigations into the cognitive effects of other vaso-active polyphenols 
such as cocoa-flavanols (Francis et al., 2006; Decroix et al., 2016). The current thesis 
therefore, has provided further confirmation that the CBF mechanism underpinning the 
proposed mechanism of action of resveratrol, and indeed many other polyphenols (Bell 
et al., 2015), is unable to provide consistent cognitive improvements in young, healthy 
cohorts. As proposed initially, and supported by the increase in fuel utilisation and 
cerebral oxygenation from resveratrol in Chapters 3 and 5 respectively, this is due to the 
already superior supply of CBF beyond that of the demand for CMRO2 and ATP 
consumption (Raichle & Gusnard, 2002; Leithner & Royl, 2014) in the young, healthy 
samples employed; which are more than likely at the peak capacity of their cognitive 
functioning (Rönnlund et al., 2005). Although some authors have proposed that the lack 
of cognitive improvements seen in this population are due to inadequate cognitively 
demanding paradigms (Massee et al., 2015), the weight of so many investigations, would 
suggest otherwise.   
The enhancement of cognitive performance in the young, healthy sample observed in 
Chapter 4 was unanticipated. In the absence of the CBF mechanism and / or any 
interaction with the O2 status, the results here were attributed to the anxiolytic effects of 
resveratrol, which may have functioned to offset the potential anxiogenic environment of 
the environmental chamber. Although most evidence stems from rodent models, 
166 
 
resveratrol has been found to inhibit MOA activity in a dose dependent manner; 
increasing serotonin and noradrenaline levels (Xu et al., 2010). Moreover, although the 
body of evidence to support this claim is small, single doses of other polyphenols such as 
EGCG have been found to significantly improve self-reported stress and calmness 
(Scholey et al., 2012). Interestingly, a 30 day supplementation of 500 mg cocoa 
polyphenols was found to significantly improve self-rated calmness and contentedness 
(Pace et al., 2013). Although this does not imply anxiolytic effects specifically, the 
authors of this study proposed that polyphenols may prove beneficial in situations of high 
stress or anxiety (Pace et al., 2013). Such claims could be supported by the findings of 
Chapter 4 yet, as the majority of evidence for polyphenol-mediated mood enhancement 
comes predominately from chronic (>28 days) supplementation, and no significant 
treatment related finding was found on self-reported anxiety in Chapter 5, this finding 
remains ambiguous and could be the result of an unseen / unknown mechanism of 
resveratrol.  
The cognitive enhancement observed in Chapter 4 is the first to be seen in a young, 
healthy population from 3 published studies (Kennedy et al., 2010; Wightman et al. 2014; 
Wightman et al., 20158) and a further unpublished study (Wightman, 2013). Moreover, 
the findings represent 1 less error across both Serial subtraction tasks; representing only 
a single improvement across a variety of cognitive tasks / domains. The above is not 
intended to take away from the significant finding here, but instead contextualises the 
cognitive enhancement. Additionally, as this finding was observed within a hypothesized 
anxiogenic environment, it is also emphasised that the effects of resveratrol observed here 
in a young, healthy cohort were a result of anxiolytic properties rather than direct 
cognitive enhancement per se.  
Due to the relative novelty of the hypoxic model employed in the current thesis, there is 
little previous polyphenol research to shed light on the lack of cognitive improvements 
seen within hypoxia in both Chapter 4 and 5. However, a number of trials have been 
performed to examine the efficacy of vaso-active nitrate supplementation. Lefferts et al. 
(2015), for example, found that an acute dose of dietary nitrate was unable to promote 
increased neurovascular coupling or cognitive performance during exposure to hypoxia. 
More recently, Shannon et al. (2017) found that nitrate rich beetroot juice was able to 
increase exercise performance but not cognition in either moderate (~14% O2) or high 
                                                          
8 Wightman et al. (2014) did observe a single resveratrol-mediated increase on 3back performance but the 
authors attributed this as a type I error. 
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(~11% O2) hypoxia. It is also noteworthy that the lack of cognitive enhancement seen in 
hypoxia in both Chapter 4 and 5 from resveratrol, were not found in conjunction with any 
increase in CBF or O2 extraction during task performance. As the mechanism 
underpinning the cognitive enhancing effect of resveratrol appeared to be thwarted within 
hypoxia (see section 7.3), the findings here perhaps suggest a recurring trend for all vaso-
active polyphenols that interact with NO signalling.  
The lack of cognitive performance modulation by resveratrol within the naturally ageing 
populations (Chapter 6) would conflict with the small, but growing, body of literature 
which has found cognitive improvements following consumption of other vaso-active 
polyphenols; including fruit flavanones (Lamport et al., 2015; Kean et al., 2015) and 
cocoa-flavanols (Desideri et al., 2012; Mastroiacovo et al., 2015; Brickman et al., 2014). 
However, the cognitive benefits reported from these investigations appear to be evident 
following chronic doses (≥8 weeks)9. As the current study only investigated the efficacy 
of a single, bolus acute dose, this may suggest that the cognitive effects of resveratrol will 
be more apparent following prolonged supplementation, especially in older adults. Indeed, 
3 studies to date have observed significant improvements in cognitive performance 
following prolonged resveratrol supplementation (14-23 weeks) (Witte et al., 2014; Kobe 
et al., 2017) with one investigation demonstrating cognitive enhancement in direct 
conjunction with enhanced CBF responsiveness (Evan et al., 2017). However, this does 
not totally undermine the benefit of single doses. Scholey et al. (2014) found significant 
modulation of cognitive performance in a cohort of older adults (mean age = 70.44 years) 
following acute supplementation of resveratrol enhanced wine. These results should be 
viewed with caution however, as there was no dealcoholized control, nor measurement 
of CBF. Finally, it is possible that there is simply a lack of research into acute doses rather 
than a lack of efficacy from acute resveratrol administration.  
The results of Chapter 6 revealed that resveratrol worsened aspects of cognitive 
performance in healthy, older participants. Although no immediate explanation presents 
itself for this, it was proposed that the dietary requirements of the study may have 
contributed to these ambiguous cognitive effects. All participants were asked to refrain 
from consuming phenolic containing foods for 24 hours prior to testing. Lamport et al. 
(2012) argue against such dietary restrictions of habitual phenolic intake, as this would 
naturally lower circulating levels of polyphenols and, in turn, may impact the polyphenol 
                                                          
9 With the exception of Mastroiacovo et al. (2015), who found significant improvements in cognitive 
functioning following an acute dose of (both 993 mg & 520 mg) cocoa-flavanols. 
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intervention and its underlying mechanisms of action. This could be the result of 
withdrawal from regular circulating levels of polyphenols which would mean that 
subsequent polyphenol administration would serve only to attenuate any withdrawal-
induced deficits. In the case of Chapter 6, such deficits could pertain to cognition and 
may have produced the abovementioned unanticipated results.  
In addition, it could be argued seeking out samples that are particularly healthy do not 
represent ‘normal’ ageing as the natural ageing process is co-morbid with several other 
health complaints; including a diminishing efficacy of the cardiovascular system. In fact, 
it is more likely that, given the strict inclusion / exclusion criteria, the current cohort 
possessed a higher than normal cerebrovascular functioning. Despite this, the older adults 
employed in Chapter 6 did possess the anticipated deficits to cognition, as indexed 
significantly less correct entries on the Serial subtraction tasks and poorer reaction time 
on the CRT, RVIP and Stroop tasks in contrast to the younger adults of Chapter 5. 
However, it is noteworthy that the average task scores of the older cohort do meet norms 
associated with high cognitive functioning for within this age group, and given the 
cohort’s superior (particularly cardiovascular) health, it is unlikely this would allow scope 
for improvements to cognitive performance via resveratrol-mediated increases to CBF. 
Both the above points raise an interesting questions for the methodological rigour of 
future investigations (see section 7.8).  
 
7.5 Discussion of the success of the hypoxic model of ageing 
The rationale behind the use of hypoxia to model the cognitive ageing process was based 
on the premise that ageing is commonly characterized by a decrease in O2 supply due to 
diminishing functionality of the human vasculature (Valli et al., 2015). Therefore, the use 
of hypoxia has been suggested as an experimental model sufficient for studying ageing 
processes (Cataldi & Di Giulio, 2009). In support of this, altitude induced hypoxia has 
been found to induce cognitive deficits (Petrassi et al., 2012; McMorris et al., 2017) which 
interestingly coordinate with those observed during cognitive ageing (Glisky, 2007; 
Harada et al., 2013).  
Due to the multifactorial nature of cognitive ageing, and the various extraneous variables 
that can exacerbate cognitive decline, it was proposed that the above model would be an 
appropriate first step. By first modelling these reductions, this would provide a clearer 
representation of the role of CMRO2 and cognitive decline. The anticipated deficits from 
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this model would then be more controlled and allow investigation of the capacity of 
resveratrol to attenuate such deficits; hypothesized to be via increased CBF.  
The success of the model was analysed by comparing the placebo conditions to assess the 
differences in cerebral haemodynamics between hypoxia and normoxia. The impact of 
hypoxia on cognitive performance was assessed via composite Z scores, representing the 
cognitive domains assessed in the cognitive batteries: accuracy, speed of processing, 
errors and secondary memory. All of these domains had previously shown reductions 
during bouts of altitude induced hypoxia (Petrassi et al., 2012). Chapter 4 employed a 
mild (16% FiO2 = 2134 m above sea level) hypoxia and observed a significant reduction 
in cerebral oxygenation within the prefrontal cortex. However, this was not found in 
conjunction with any significant reductions in cognitive performance across individual 
tasks or overall task domains. Chapter 5 induced a moderate hypoxia (12.7% FiO2 = 4000 
m above sea level) and successfully demonstrated significant reductions in behavioural 
performance. This was evidenced by decreases in the performance of individual tasks, 
including Serial 3 subtractions and delayed word recall, and overall accuracy across tasks. 
Additionally, participants reported significantly higher levels of mental fatigue when in 
hypoxia in comparison to normoxia. Contrasting to the previous chapter however, 
oxygenation and CBF were found to increase when in hypoxia relative to normoxia. 
Before undertaking the investigation in Chapter 4, it remained ambiguous as to what level 
of hypoxia should be used to model age-related cognitive decline. Previous research had 
only found consistent reductions in cognitive performance at altitudes of >3000 m 
(Bahrke & Shukitt-Hale, 1993); potentially due to the efficacy of the body to successfully 
adapt to milder bouts of hypoxia. However, it was also proposed that the inconsistency 
of results found at mild hypoxia was the result of the durations (1-24 hours) employed, 
and a lack of control over extraneous variables (e.g. physical exertion). It was suggested 
therefore, that a short period of exposure to a hypoxic condition would still evince 
cognitive deficits due to immediate exposure allowing for minimal adaptations (Petrassi 
et al., 2012). The lack of cognitive reductions observed in Chapter 4 would certainly 
support the notion that mild hypoxia is unable to induce cognitive deficits at rest. This 
was proposed to be the result of the high efficacy of young, healthy populations in 
addition to inability of mild hypoxia to induce cognitive deficits.  
The moderate hypoxic level of Chapter 5 induced several convincing reductions to 
performance both in individual tasks and overall accuracy of performance. However, 
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these cognitive deficits were not observed in conjunction with a significant decrease in 
cerebral oxygenation, rather an increase. The increases observed may reflect the cerebral 
perfusion reflex of the brain which aims to avoid potential damage to the CNS (Reis et 
al., 1994; Harris et al., 2013).  This also potentially lends further support to the argument 
that the mild hypoxia was not sufficient to induce neurocognitive deficits in Chapter 4, as 
no comparative adaptive CBF response was induced during the lower hypoxia condition. 
The significant reductions observed in cognitive performance in chapter interestingly 
correspond to that of age-related deficits. Therefore, the results of Chapter 5 do provide 
confirmation that hypoxia could be used to model cognitive ageing.  
Despite such convincing reductions in cognitive performance during hypoxia, 
administration of resveratrol was unable to modulate either cognitive functioning or CBF. 
The explanation behind the latter has already been discussed in more detail (see section 
7.3) but it is logical to hypothesize that the lack of effects in the former is due to the latter. 
The results of both studies, therefore, beg the question whether the use of hypoxia is an 
appropriate model of age-related impairment of the cerebral vasculature and subsequent 
cognitive performance. It would appear from the above discussed results that the use of 
hypoxia has been a double-edged sword. Firstly, the adaptive NO-dependant vasodilatory 
response to hypoxia appears unmodifiable by resveratrol (or other NO-dependant 
vasodilators), which could have nullified the CBF mechanism of cognitive enhancement 
under investigation in this thesis. Moreover, it could be argued that resveratrol-induced 
exaggeration of an already heightened CBF response does not fully reflect the reduction 
in blood flow capacity experienced during ageing.  
Indeed, the whole basis of the rationale behind utilizing resveratrol in ageing cohorts was 
based on its efficacy to induce an enhanced vasodilatory response within individuals who 
directly suffer a reduction in eNOS expression or an impaired vasodilatory response. For 
example, individuals who suffer from endothelial dysfunction (and therefore an impaired 
NO response), such as obese or hypertensive cohorts have been shown to have an 
increased vasodilatory response from acute doses of resveratrol (Wong et al., 2011; Wong 
et al., 2013). However, by assessing the capacity to further increase CBF during an event 
of already heightened blood flow, rather than impaired CBF, does not allow for a fair 
comparison.  
In summary, the results here suggest that the use of hypoxia for an experimental model 
of cognitive ageing can induce age-related cognitive deficits in a young, health cohort. 
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However, the interference from the natural protective increase in CBF, induced to protect 
the CNS during bouts of hypoxia, has inadvertently muddied the interpretation of the CBF 
effects of resveratrol in hypoxia. Therefore, it becomes difficult to argue for the suitability 
of hypoxia as a model for the ageing brain when investigating the effects of vaso-active 
compounds to overcome such reductions; especially those which rely on the interaction 
with NO signalling to exert their effects. Moreover, the comparison to sea level was also 
arguably compromised by potential anxiogenic effects induced by the use of an 
environmental chamber. Given that anxiety has been found to interfere with 
neuroimaging data, this also makes it difficult to compare the findings within the chamber 
to previous studies. However, this should not deter further investigation of resveratrol in 
ageing cohorts directly, nor should it discourage the use of hypoxia as a model for the 
ageing brain external to the field of nutritional neuroscience.  
7.6 Discussion of methodologies 
7.6.1 Indirect Calorimetry (ICa)  
ICa is a non-invasive method which monitors pulmonary gases to provide an accurate 
estimate of whole body EE and fuel substrate utilisation. Before now, this method has 
predominantly been used in sporting and exercise contexts (Westerterp & Plasqui, 2004). 
However, a small number of studies have employed ICa to evaluate changes to whole 
body metabolism during cognitive demand. The rationale behind the use of ICa was to 
build upon the growing CBF evidence of resveratrol measured previously by NIRS which, 
despite reflecting the overall pattern of cerebral metabolic activity, does not quantify the 
extent of cerebral metabolic change, nor the relative change of EE as a whole (Al Naher 
et al., 2016). Therefore, the use of ICa was to gain an insight to any resveratrol mediated 
changes in fuel utilization and EE during cognitive demand, providing further insight into 
the CBF effects under investigation in the current thesis.  
Previous investigations have demonstrated that ICa can examine subtle changes in EE 
during cognitive task performance and even during varying task demand (Al Naher et al., 
2016). Although the measurement of metabolic changes from nutritional interventions 
during cognitive performance remains novel, support did stem from a previous 
investigation which has demonstrated that ICa was sensitive enough to detect subtle 
changes in fat oxidation from acute and chronic multivitamin supplementation during task 
performance (Kennedy et al., 2016). ICa was only employed in Chapter 3 of this thesis, 
but it was capable of detecting resveratrol-mediated increases in RER during task 
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performance, 45 minutes and 3 hours post administration. Although, again, it remains 
unclear whether this increase in RER was beneficial (see section 7.2). 
As first outlined in section 7.2, no consensus exists within the literature as to what a 
‘typical’ response to cognitive demand entails beyond that of an increase in EE. The 
direction of results from Chapter 3 demonstrated that RER gradually decreased across the 
3 post-treatment task intervals (45 min, 2hr & 3hrs). This would support the findings of 
Troubat et al. (2009), who reported an initial higher RER upon starting a cognitively 
demanding game of chess, which then gradually decreased throughout the match. As the 
cerebral haemodynamic response to cognitive demand typically elevates levels of total-
Hb and oxy-Hb (Obrig & Villringer, 1997) and, in turn, lowers deoxy-Hb concentrations 
(Obrig & Villringer, 2003), ICa data seen in this study and by Troubat et al. (2009) would 
therefore complement the natural CBF response measured previously by NIRS.  
 
7.6.2 Near-Infrared Spectroscopy (NIRS) 
NIRS is a non-invasive neuroimaging technique that is capable of monitoring cerebral 
haemodynamics in response to varying neural demand on different cognitive tasks (Cui 
et al., 2011). Typically, the CBF response to neural activation is greater than that of 
CMRO2 (Leithner & Royl, 2014). Thus, neural demand evinces an increase in both total-
Hb and oxy-Hb concentrations and, consequently, lowers deoxy-Hb concentrations 
(Obrig & Villringer, 1997; Obrig & Villringer, 2003). NIRS is also sensitive to the CBF 
effects of nutritional interventions during cognitive performance (Jackson & Kennedy, 
2013). This is supported by the observation that NIRS can detect both increases in CBF 
(as indexed from higher levels of total-Hb) from DHA-rich fish oil (Jackson et al., 2012a) 
and multivitamins (Kennedy et al., 2016) and reductions in CBF from caffeine (Kennedy 
& Haskell, 2011) and low doses of the polyphenol EGCG (Wightman et al., 2012). The 
current thesis employed the use of the two different NIRS devices: CW NIRS (the device 
used in all the above-referenced research) and the novel FD NIRS. The former is the most 
commercially available of the two, and allows for the observation of concentration change 
in regional CBF (Hoshi, 2003). The latter however, measures the quantification of the 
CBF response; thus, permitting the measurement of absolute concentrations of cerebral 
haemodynamics.  
The CW NIRS device has demonstrated previously to be an appropriate instrument to 
detect the CBF effects of resveratrol including the novel observation of resveratrol-
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mediated increases in oxy-Hb, deoxy-Hb and total-Hb concentrations at rest and during 
cognitive performance (Kennedy et al., 2010; Wightman et al., 2014; Wightman et al., 
2015). The same NIRS was also detected CBF effects of resveratrol in response to neural 
demand (Chapter 5), and at rest, in hypoxia (Chapter 4) within this thesis, adding further 
support for its use in intervention studies. Moreover, consistent with other investigations 
(Davies et al., 2016), the CW device also effectively measured the CBF response to 
hypoxia in the prefrontal cortex; as indexed by decreased oxygenation and increased O2 
extraction (Chapter 4). The consistency of this device across previous trials supports the 
assertion that CBF measurements were scuppered in the final study which investigated 
older participants (aged 50-70 years). However, it is likely that the issue here was not 
with the NIRS per se, but rather the change in NIRS device which was implemented in 
this age group for 2 key reasons: (1) the standard formula utilised by the CW NIRS is 
based upon those recommended Duncan et al. (1995), which are only valid for the 
measurement of brain tissue in individuals aged 17-50 years. (2) The CW device must 
remain attached throughout the course of a full testing session, making the restrictive 
nature of the equipment difficult to commit to an extended testing session (~2 ¼ hours). 
The measurement of absolute haemoglobin concentrations obtained by the FD device 
overcame both of these constraints and offered an alternative method of measuring CBF 
in the prefrontal cortex. Despite the sensitivity of FD NIRS to measure the cerebral 
haemodynamic effects of nutritional interventions being unestablished prior to its 
employment in Chapter 6, such FD devices have been reported capable of monitoring 
neural demand on certain of cognitive tasks (Power et al., 2010). However, as outlined in 
section 7.3, the efficacy of the FD device to measure the CBF effects of resveratrol is 
questionable, as no significant treatment-related changes to cerebral haemodynamic were 
observed in the naturally ageing cohort. In the absence of any data into the CBF effects 
of resveratrol with the CW NIRS in this age group, it is not possible to determine whether 
this lack of effect seen here is due to this age-group, the FD NIRS device or, indeed, a 
combination of the two.  
The multi-distance principle of FD NIRS (see section 2.1.2) has been reported to produce 
a greater level of noise within the data set in comparison to its CW counterpart (Davies 
et al., 2016). This may result in the measure of superficial tissue, as the device is unable 
to provide depth specific measurements (Bakkers et al., 2004). The 4 cm separation 
distance between transmitter and receiver of the CW NIRS has been credited with 
sufficient spatial resolution reach a depth of 0.5-2 cm (Fukui et al., 2003). This depth is 
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sufficient to reach the blood vessels and capillaries of the prefrontal cortex (Haque et al., 
1998) and reflects neural activity of the prefrontal cortex; as evidenced by the wealth of 
supporting evidence outlined above and the results of Chapter 5 of this thesis. However, 
it is unclear whether this precise depth has been replicated with the FD device; therefore, 
it is unclear whether the same cortical area of the prefrontal cortex has been recorded in 
comparison to that of previous investigations and those in Chapter 4 and 5 of this thesis. 
On the face of such results it appears likely the use of CW NIRS is more appropriate for 
acute, single dose investigations due to its superior sensitivity to nutritional interventions. 
This does not discount the use of FD NIRS for future research, rather that its use appears 
to be better suited to chronic investigations where changes over time can be better 
measured. Further research is of course needed to understand the efficacy of the FD 
device and its use in measuring the cerebral haemodynamic response of nutritional 
interventions. To this researcher’s knowledge, several ongoing investigations are 
currently utilizing the same FD device to examine the CBF response of DHA-rich fish 
oils, iron and phenolic-rich tea. The results of these forthcoming studies certainly will 
provide further insight into the use of FD NIRS in the field of nutritional neuroscience.  
 
7.6.3 Environmental chamber 
In order to deliver a hypoxic model of aging, the current thesis employed the use of the 
state of the art environmental chamber at Northumbria University. The use of an 
environmental chamber was preferred over other methods of inducing hypoxia as this 
allowed for control over the extraneous environmental factors that can impact cognitive 
performance in addition to hypoxic conditions (Taylor et al., 2015). Moreover, other 
artificial methods of inducing hypoxia (i.e. hypoxic gases via face masks) may have 
provided discomfort to the participant due to the constrains of already wearing a 
neuroimaging (NIRS) device.  
The results of Chapter 4 and 5 demonstrated that the chamber could provide an effective 
method of inducing hypoxia and the desired effects to mental functioning. This was 
evidenced by reductions in cerebral oxygenation in the prefrontal cortex (Chapter 4) and 
cognitive performance (Chapter 5) from the hypoxic condition. Interestingly, some 
unanticipated results also took place within the chamber, in both environmental 
conditions, suggesting a psychological influence of the chamber in and of itself. For the 
first time, clear resveratrol-mediated increases in cognitive performance were observed 
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in a young, healthy cohort, irrespective of the O2 status. Moreover, the previously 
observed resveratrol-mediated increases in CBF at rest, and during task performance, 
were not observed in the normoxic condition of Chapter 4 10 .  These unanticipated 
cognitive and CBF effects observed within the chamber have raised some interesting 
questions surrounding its potential anxiety-inducing nature, and whether this may have 
influenced the neuroimaging and cognitive data measured during the testing sessions. It 
is noteworthy that exposure to altitude-induced hypoxia (artificial or otherwise) has been 
found to induce a wide range of adverse psychological changes; including increased 
feelings of anxiety (Shukitt, & Banderet, 1987). Although, as declining mood states have 
only been consistently observed at higher levels of hypoxia (>2800 m altitude; ~14.7% 
FiO2) it is unclear why this could have occurred in Chapter 4, which employed a mild 
hypoxia, but not in Chapter 5 where a moderate hypoxia was used.  
In both investigations, participants were introduced to the chamber briefly at the initial 
training session. This was to familiarise subjects with the testing environment and 
consequently reduce any physiological and psychological noise that may occur from the 
anticipation and/or anxiety of the first testing visit. Despite this, it was proposed that an 
anxiogenic effect induced by the chamber may have played a role in the results of Chapter 
4. Although the environmental chamber possesses hypoxic silencers, a continuous level 
of noise was still present as a result of the regulation of air in both hypoxia and normoxia 
conditions. Additionally, as the O2 status was blind to the participant, even the perceived 
reduction in O2 may have induced feelings of tension and anxiety. Finally, the laboratory 
itself is a 20 m2 space which may have added a further claustrophobic or confining nature 
to the testing procedure. These factors may all have contributed to the facilitation of an 
anxiogenic effect, perhaps even more so in individuals who are of a nervous disposition 
(Roth et al., 2002).  
Anxiety induced in simulated altitude can lead to hyperventilation and consequently 
hypocapnia (vasoconstriction). This can then be exacerbated further by individuals who 
misinterpreted symptoms of the hypoxia for ‘dangerous’ side effects (Roth et al. 2002). 
Interestingly, however, Asmaro et al. (2015) reported that participants were unaware of 
their behavioural decline during exposure to hypoxia in a hypobaric chamber. In fact, 
participants reportedly believe that they had continued to perform well on a cognitive 
battery even at 5334 m and 7620 m stimulated altitude. This may suggest that the hypoxic 
                                                          
10 Why resveratrol was unable to increase CBF during hypoxia in the same study has been discussed 
previously in section 7.3. 
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conditions employed in the current thesis were sufficiently blind to the participants and 
that the chamber itself may have induced anxiety. This is further supported by the 
observation that no differences in self-reported anxiety were noted between the hypoxia 
and normoxia conditions in Chapter 5. As higher hypoxic levels like those induced in 
Chapter 5 (12.7% FiO2) have been seen to induce anxiety and tension, the fact that self-
reported anxiety did not increase in the hypoxic condition, in comparison to the normoxic 
condition, would certainly suggest that the chamber itself was anxiety inducing. It may 
just be that a greater number of participants were sensitive to this in Chapter 4 than in 
Chapter 5. 
The solution going forward appears to be that more extensive prior exposure to the 
environmental chamber itself is needed before testing (i.e. all training/ familiarisation 
sessions to be undertaken within the chamber). Monitoring breathing rate in hypoxia and 
normoxia also appears essential to further understand and interpret the cerebral 
haemodynamic response within hypoxic conditions. However, at this time it is not clear 
how this could be achieved without the potential claustrophobic addition of a mask over 
the mouth.  
 
7.6.4 Cognitive tasks 
The rationale behind the cognitive tasks employed in this thesis was four-fold. Firstly, all 
tasks employed across the chapters have previously shown sensitivity to nutritional 
interventions. Secondly, all tasks (with the exception of memory tasks) employed across 
Chapters 4-6 were capable of activating the prefrontal cortex and were sensitive enough 
to be detected by NIRS (CW NIRS only) (Wightman et al., 2012; Jackson et al., 2012). 
Thirdly, the tasks used in Chapters 4 and 5 reflected cognitive domains that were sensitive 
to reductions in O2, whilst also being directly relevant to the cognitive domains that see a 
decline in naturally ageing adults. Finally, the use of these tasks was also proposed to 
induce sufficient cognitive demand to require additional neural fuel resources which 
resveratrol was hypothesized to provide. 
With reference to the first and third rationale, no previous cognitive improvements had 
been observed directly from resveratrol consumption, thus an expansive battery of tasks 
and cognitive domains was used in Chapters 4-6. This included the use of the three tasks 
in the cognitive demand battery (CBD; which comprises Serial 3 and 7 subtractions and 
RVIP); all of which were completed for 2 minutes each. The use of these tasks has shown 
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sensitivity to cognitive improvements following consumption of polyphenol-rich 
supplements such as cocoa-flavanols (Scholey et al., 2010) and ginkgo biloba (Scholey 
& Kennedy, 2002) in young, healthy samples. Improvements (on Serial subtractions only) 
have also been seen following administration with resveratrol-enriched red wine (Scholey 
et al., 2014) in ageing cohorts. As these tasks are considered to measure working memory 
and executive functioning, the employment of these tasks across the final 3 chapters was 
appropriate given that both cognitive domains have shown to decline in hypoxia (Aquino 
et al., 2013) and during ageing (Peters, 2006). This was also supported by the significant 
reductions in performance observed on the Serial subtraction tasks in both hypoxia 
(Chapter 5) and the older adults (Chapter 6). The resveratrol-mediated improvement in 
the number of incorrect responses entered during both Serial subtraction tasks in Chapter 
4 demonstrates that resveratrol may enhance working memory performance.  
Memory is particularly subject to decline during ageing (John & Cole, 1986); as 
evidenced by poorer recall performance in naturally ageing samples (Howieson, 2015). 
Recall tasks are sensitive to improvements from additional supplementation of O2 in 
young adults (Moss et al., 1998) whilst being particularly susceptible to declining 
performance in response to a reduction in O2 supply from a hypoxic condition (Aquino et 
al., 2013). Thus, Chapters 4-6 included immediate and delayed word recall and word 
recognition; involving the encoding, storage and retrieval of 12 words per repetition of 
the cognitive battery. No resveratrol-mediated improvements were found on memory 
performance within the older cohort of Chapter 6, nor were any observable reductions in 
memory performance found in the older cohort of Chapter 6 in comparison to the younger 
adults of Chapter 5. Despite this, the moderate hypoxic condition of Chapter 5 did show 
significantly reduced performance on delayed word recall, in comparison to the normoxic 
condition, supporting previous findings.  
The final task employed in the cognitive battery of Chapter 4 was the 3back task. The 
3back task was replaced with CRT and the Stroop task in Chapter 5 and 6 and the aim 
here was to utilize tasks / cognitive domains that were sensitive to a reduction in FiO2. 
Indeed, Stroop and reaction time tasks are all sufficiently sensitive to observe the 
reductions in executive functioning and speed of processing within hypoxic conditions 
(Atkinson, 2016; de Aquino Lemos et al., 2012). The results of Chapter 5 showed a 
significant reduction in accuracy across the Serial subtraction, Stroop, RVIP and CRT 
tasks, although, no significant main or interaction effect was found on reaction time / 
speed of processing. However, significantly poorer reaction times on Stroop, RVIP and 
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CRT tasks were observed in the older adults in Chapter 6, in contrast to the young adults 
of Chapter 5; supporting claims that older adults will exhibit slower reaction times / speed 
of processing (Filley & Cullum, 1994; Salthouse, 1996; Berardi et al., 2001). 
Regarding the final aforementioned rationale, all tasks were employed in a continuous 
demanding battery that was repeated 3 times to ensure that an adequate level of demand 
was implemented across all 4 studies. Although the use of these tasks, within this format, 
have not provided previous support for inducing sufficient to evince the benefits of 
resveratrol in young, healthy populations, this demanding paradigm was hypothesized to 
be sufficiently taxing to ageing populations in order to draw upon an increased demand 
for neural fuel resources.  
Finally, Chapter 3 utilized the Serial subtraction tasks (3, 7 & 17), each running for 5 
minutes each. The use of Serial subtraction tasks has been reported previously to be 
cognitively demanding by participants and demonstrated to increase both glucose 
utilisation and heart rate beyond that of peripheral mechanisms (Scholey et al., 2001; 
Kennedy & Scholey, 2004; Kennedy et al., 2016). As there was a main effect of time (pre 
vs post completion) on ‘mental fatigue’ across post-dose cognitive performance in 
Chapter 3, it can be argued that the young sample employed also found the subtraction 
battery sufficiently taxing and it may be deemed ‘cognitively demanding’. Moreover, 
Wightman (2013) proposed the objective increase in workload can be observable from 
the increase in the cerebral haemodynamic response across task performance (or in the 
case of Chapter 3, the increase in fuel oxidation) which details an increase in demand for 
neural resources; supporting this point further.  
 
7.7 Discussion of the statistical approach  
The statistical method adopted across this current thesis for physiological data (NIRS & 
ICa) was planned comparisons, but only upon the emergence of a significant F test from 
the initial ANOVA. Arguably, planned comparisons may be carried out irrespective of 
the significance of the initial ANOVA and to rely on this may even be deemed ‘overly 
conservative’ (Keppel, 1991). However, it could be argued that the CBF effects of 
resveratrol have now been established and, as such, a more conservative statistical 
approach should be utilized going forward.  
A case could be made to argue for a less conservative approach for Chapter 3 due to the 
novelty of the paradigm. Yet, as the small number of planned comparisons required was 
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so small (9 in total), the analysis of ICa data, regardless of the initial ANOVA, would 
have inflated the risk of a misinterpreting a pattern of significant results as a ‘true’ effect 
(Coolican, 2014). Despite this more rigorous approach, resveratrol was found to 
significantly increase cerebral haemodynamics and RER in the direction of previous 
investigations. Similarly, regarding behavioural data, given that there is more scope to 
observe a pattern of effects with large comparisons (i.e. the NIRS data), the small number 
of comparisons required across the cognitive and mood sub-measures (3 post dose 
repetitions per chapter) would again increase the risk of misinterpreting patterns of 
significant follow up t-tests, for true effects. Therefore, given the large number of sub 
measures and subsequent analysis undertaken, and to protect against this increase risk of 
a type I error, all cognitive and mood sub measures were analysed via Bonferroni 
corrected pairwise comparisons rather than planned comparisons.  
 
7.8 Future directions 
Upon starting this thesis, research investigating the use of polyphenols for cognitive 
enhancement was growing rapidly. What was surprising, however, was that only a small 
number of trials had supported the proposed CBF mechanism of vaso-active phenolics 
with appropriate physiological data (Bell et al., 2015). Hence, the current thesis aimed to 
employ a supporting measurement of cerebral activity during each investigation of this 
thesis. The number of trials investigating resveratrol within humans still remains 
relatively small; with research predominantly focusing on young, healthy populations. In 
the face of consistent increases in cerebral perfusion, alongside no subsequent modulation 
of cognitive performance, in younger cohorts, it appeared axiomatic that the benefits of 
resveratrol would be more pronounced in those who suffer a reduction in CBF; namely 
ageing populations. The current thesis aimed to investigate this gap, but with a specific 
focus on providing clear support for the proposed CBF mechanism for cognitive 
enhancement of resveratrol.  
The findings of the four investigations reported here do not support the argument that 
resveratrol can provide cognitive enhancement in healthy, naturally ageing populations. 
However, when taking this forward, if research is to continue in naturally ageing samples, 
studies should look to relax the extensive exclusion / inclusion criteria set out in the 
current thesis. Seeking out samples that are particularly healthy does not represent 
‘normal’ ageing as the natural ageing process itself, is co-morbid with several other health 
complaints. Although the older adults employed in Chapter 6 did possess the anticipated 
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deficits to cognition, it is noteworthy that the average task scores of the older cohort do 
meet norms associated with high cognitive functioning for this age group. Moreover, the 
reductions observed cannot be credited to a decrease in rCBF. In fact, it is more likely 
that given the strict inclusion / exclusion criteria and the lack of a resveratrol-mediated 
increase in CBF that the current cohort possess a higher than normal cerebrovascular 
functioning. Therefore, despite employing a cohort with adequate reductions to cognitive 
performance adopting an overly conservative approach to sample recruitment may not be 
representative of the wider population, nor allow any scope for improvement from 
resveratrol administration, due to the cohort’s superior (particularly cardiovascular) 
health. Nevertheless, this sample group was a key first step prior to investigating more 
varied cohorts.  
Further investigation may be better suited in populations that either self-report mild 
cognitive decline or possess evidence of an impairment in the cerebral vasculature; such 
as ageing individuals that are overweight or hypertensive. Indeed, the vasodilatory effects 
of resveratrol are found to be more pronounced in obese and hypertensive cohorts; as 
evidence by an increased vasodilatory response from both acute and chronic doses of 
resveratrol (Wong et al., 2011; Wong et al., 2013). Further, individuals with mild 
cognitive impairment are more likely than their younger counterparts to exhibit cognitive 
benefits from vaso-active cocoa-flavanols (Desideri et al., 2012). Although, it should be 
noted that this does not necessarily restrict the benefits of resveratrol to ‘unhealthy’ 
populations, but may also encompass cohorts who generally consume less phenolics in 
their diet. Indeed, as this thesis has shown, acute investigations may be better served 
recruiting individuals who regularly consume low quantities of polyphenols and, from a 
real-world perspective, these cohorts are probably more likely to reap the benefits of 
polyphenol supplementation yet are, by definition, not likely to receive them from the 
diet. Chapter 6 has evidenced that restricting phenolic consumption in regular consumers 
serves only to disrupt or interfere with the CBF / cognitive effects of resveratrol. 
Therefore, future investigations should be cautious of implementing ‘beige’ diets and may 
gain further understanding from measuring phenolic intake prior to enrolment and use 
this information as a covariate (Lamport et al., 2012).  
In addition, the cognitive enhancing effects of resveratrol do not seem confined to the 
ability to bolster NO-dependant vasodilation. Indeed, the results from Chapter 3 suggest 
that there may be merit in investigating the potential glucose-regulatory effects of 
resveratrol further (fasted or postprandial) particularly in older adults who are noted to 
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suffer a reduction in glucose tolerance; which has shown to be a contributor to cognitive 
decline.  Furthermore, the results of Chapter 4 propose that acute resveratrol 
administration may interact with mood, which may indirectly provide cognitive 
enhancement; particularly in events of high stress and or anxiety. Research into the mood 
enhancing effects of resveratrol (and indeed other polyphenols) is small but, on the face 
of promising evidence, further investigation is warranted to assess the extent to which 
resveratrol can improve mood parameters; especially under established stress paradigms. 
With regards to the future use of the hypoxic model, it is hoped that findings here spark 
further research into the use of hypoxia to investigate the cognitive ageing process. 
Although its use to measure reductions in cerebral vascular activity and the capacity of 
resveratrol to attenuate such deficits does appear to be flawed, this should not discourage 
the use of hypoxia to model cognitive decline of ageing populations outside the field or 
indeed other ‘hypoxic’ populations.   
 
7.9 Concluding remarks 
Previous research has observed consistent CBF effects of resveratrol, yet no subsequent 
cognitive improvements in young, healthy cohorts. The current thesis aimed to examine 
whether the CBF effects of resveratrol would provide cognitive enhancement in older 
adults, who are considered to suffer a reduction in rCBF, CMRO2 and consequently 
cognitive performance. Additionally, this series of investigations also aimed to examine 
the efficacy of employing hypoxia as a representative, experimental model of ageing in 
young, healthy populations. This hypoxic model was employed in order to provide a 
clearer picture into the potential CBF mechanism of cognitive enhancement by resveratrol; 
to directly attenuate reductions is CMRO2 in an otherwise healthy cohort. The 4 
intervention studies reported here demonstrated that an acute dose of 500 mg can increase 
fuel utilisation (Chapter 3) and CBF (Chapter 5) during cognitive demand in young, 
healthy cohorts in normoxia. However, no resveratrol-mediated CBF or cognitive benefits 
were found in hypoxia (Chapter 4 & 5) or in comparatively healthy older adults (Chapter 
6). Nevertheless, it was argued that the heightened CBF response in hypoxia may have 
inadvertently interfered with the CBF effects of resveratrol here, questioning the 
suitability of hypoxia as a representative model of ageing. Questions about the novel 
NIRS device utilized, offer potential explanations for the lack of resveratrol-mediated 
cognitive and CBF effects in this sample. Alternatively, it is possible high, acute doses of 
resveratrol may be detrimental to aspects of cognition in this cohort; although, further 
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research is needed to elucidate this claim. Interestingly, cognitive benefits (in the form of 
reduced error responses) were found irrespective of the previously observed CBF effects 
(Chapter 4). As this was found within a proposed anxiogenic environment, and 
irrespective of the O2 status, it is likely that this cognitive benefit is an indirect result of 
anxiolytic effects, rather than direct cognitive enhancement.  
In summary, the results here would suggest that resveratrol may be unable to evince 
cognitive enhancement within hypoxic conditions or in healthy, older cohorts. Future 
research may benefit from further exploration into unanticipated cognitive deficits seen 
here in older adults. Although this may be a result of the methods employed in this thesis, 
smaller, more frequent doses may unlock the cognitive benefits of resveratrol.  
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Appendix 
 
Appendix 1.0 The summary of the behavioural results of Chapter 3: the effects of 250 mg, 500 mg 
resveratrol and placebo on mood, with baseline scores and the three post-dose repetitions. Table 
displays baseline scores, and the change from baseline scores (with SEM values in brackets) for the 3 post-
dose repetitions after administration of treatment for 26 young, healthy adults. Scores were calculated 
change from baseline, using the post-baseline scores as a baseline. Table displays ANOVA’s F and P values 
for main effects of treatment (T), repetition (R), Time (PP) and their subsequent interactions (T*R) (*<.05, 
**<.01 and t= trend). 
 
  
 
Measure 
 
Treatment 
 Repetition ANOVA 
Baseline Time 1 2 3 Effect F P 
 
 
 
 
 
 
 
Mental 
Fatigue 
 
 
 
250 mg 
Resveratrol 
 
 
45.46 
(8.92) 
Pre -8.12 
(2.25) 
 
-
11.92 
(2.66) 
-9.08 
(3.95) 
 
 
 
R 
 
PP 
 
T 
 
T*R 
 
T*PP 
 
T*PP*R 
 
 
 
 
3.206 
 
10.711 
 
.850 
 
.580 
 
.618 
 
1.484 
 
 
 
 
.062t 
 
.003** 
 
.434 
 
.678 
 
.543 
 
.213 
 
Post -1.42 
(3.28) 
 
-5.73 
(3.30) 
1.27 
(3.08) 
 
 
500 mg 
Resveratrol 
 
 
46.15 
(9.05) 
Pre -6.00 
(3.66) 
 
-
11.46 
(3.96) 
-5.38 
(3.41) 
Post -4.12 
(4.06) 
 
-5.23 
(4.03) 
1.08 
(4.00) 
 
 
Placebo 
 
 
 
43.31 
(8.49) 
Pre -3.54 
(2.89) 
 
-
11.15 
(2.51) 
-3.92 
(2.76) 
Post -1.65 
(2.94) 
 
1.27 
(3.08) 
5.42 
(2.82 
 
 
 
 
 
 
 
 
Concentration 
 
250 mg 
Resveratrol 
 
53.85 
(10.56) 
 
Pre 
 
.08 
(2.50) 
 
4.38 
(3.42) 
6.04 
(3.47) 
 
 
 
R 
 
PP 
 
T 
 
T*R 
 
T*PP 
 
T*PP*R 
 
 
 
 
1.157 
 
4.073 
 
1.502 
 
1.391 
 
.519 
 
1.162 
 
 
 
 
.323 
 
.054t 
 
.233 
 
.243 
 
.598 
 
.329 
 
Post 5.65 
(2.63) 
 
6.73 
(4.42) 
6.81 
(3.98) 
 
500 mg 
Resveratrol 
 
57.38 
(11.25) 
 
Pre 
 
-1.96 
(3.76) 
 
-1.69 
(4.68) 
-1.46 
(4.58) 
Post 4.08 
(4.49) 
 
8.69 
(3.48) 
-1.04 
(5.53 
 
 
Placebo 
 
 
56.35 
(11.05) 
Pre 
 
-7.15 
(2.85) 
 
-1.62 
(3.27) 
-4.35 
(3.43) 
Post 1.58 
(2.93) 
.58 
(4.22) 
-1.88 
(3.82) 
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Appendix 1.1 The summary of the behavioural results of Chapter 3: the effects of 250 mg, 500 mg resveratrol and placebo on cognitive performance across baseline 
and the three post dose repetitions. Table displays baseline and change from baseline scores (with SEM values in brackets) for the 3 post-dose repetitions after administration 
of treatment for 27 young, healthy adults. Table also displays ANOVA’s F and P values for main effects of treatment (T), repetition (R) and their subsequent interactions (*<.05, 
**<.01 and t= trend (nearing significance)). 
 
Measure 
 
Treatment 
 Repetition ANOVA 
Baseline 1 2 3 Effect F P 
 
 
Serial 3’s 
Total 
250 mg 
Resveratrol 
110.88 
(8.18) 
7.58 
(2.06) 
8.65 
(2.33) 
14.04 
(2.69) 
R 2.458 .096 
500 mg 
Resveratrol 
112.15 
(8.18) 
10.19 
(1.86) 
9.46 
(2.79) 
9.85 
(2.27) 
T .145 .865 
 
 
 
Placebo 
 
112.65 
(9.00) 
9.42 
(3.83) 
10.58 
(2.26) 
13.23 
(2.41) 
T*R .974 .405 
 
 
Serial 3’s 
Correct 
250 mg 
Resveratrol 
107.35 
(8.18) 
6.19 
(2.13) 
7.38 
(2.80) 
12.15 
(2.96) 
R 2.251 .116 
500 mg 
Resveratrol 
108.58 
(8.21) 
7.77 
(2.07) 
7.27 
(2.94) 
7.92 
(2.33) 
T .612 .546 
 
 
 
Placebo 
 
107.00 
(8.99) 
8.69 
(3.93) 
9.54 
(2.24) 
12.88 
(2.41) 
T*R .734 .521 
 
 
Serial 3’s 
Errors 
250 mg 
Resveratrol 
3.54 
(.61) 
1.15 
(.85) 
1.27 
(.92) 
1.88 
(.75) 
R .029 .972 
500 mg 
Resveratrol 
3.58 
(.56) 
2.42 
(.90) 
2.19 
(.95) 
1.92 
(.76) 
T 1.557 .221 
 
 
 
Placebo 
 
5.65 
(.62) 
.73 
(.70) 
1.04 
(.81) 
.35 
(.89) 
T*R .499 .736 
 
 
Serial 7’s 
Total 
250 mg 
Resveratrol 
77.46 
(7.06) 
4.65 
(1.64) 
6.15 
(1.63) 
8.42 
(2.18) 
R 2.634 .082t 
500 mg 
Resveratrol 
78.50 
(7.71) 
8.00 
(2.02) 
7.88 
(2.10) 
7.77 
(2.13) 
T 1.059 .354 
 
 
 
Placebo 
 
76.04 
(7.65) 
7.85 
(1.78) 
9.19 
(2.17) 
11.54 
(2.46) 
T*R .839 .504 
 
 
250 mg 
Resveratrol 
72.35 
(7.29) 
3.50 
(1.66) 
5.73 
(1.75) 
8.12 
(2.05) 
R 2.108 .132 
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Serial 7’s 
Correct 
500 mg 
Resveratrol 
73.50 
(7.54) 
8.65 
(1.87) 
6.96 
(2.10) 
8.12 
(2.12) 
T .999 .376 
 
 
 
Placebo 
 
70.19 
(7.83) 
7.96 
(1.73) 
8.38 
(2.29) 
10.65 
(2.62) 
T*R 1.044 .388 
 
 
Serial 7’s 
Errors 
250 mg 
Resveratrol 
5.12 
(.94) 
1.15 
(.52) 
.42 
(.65) 
.31 
(.98) 
R .729 .487 
500 mg 
Resveratrol 
5.00 
(.64) 
-.65 
(.75) 
.92 
(.55) 
-.35 
(.75) 
T .468 .629 
 
 
 
Placebo 
 
5.85 
(.75) 
-.12 
(.70) 
.81 
(.82) 
.88 
(.79) 
T*R 1.531 .199 
 
 
Serial 17’s 
Total 
250 mg 
Resveratrol 
48.73 
(5.73) 
4.54 
(1.16) 
6.92 
(1.34) 
7.35 
(1.57) 
R 1.899 .160 
500 mg 
Resveratrol 
51.23 
(5.48) 
4.00 
(1.71) 
5.19 
(1.34) 
4.35 
(1.99) 
T 2.368 .104 
 
 
 
Placebo 
 
47.92 
(5.19) 
8.12 
(1.25) 
6.81 
(1.44) 
10.12 
(1.77) 
T*R 1.989 .102 
 
 
Serial 17’s 
Correct 
250 mg 
Resveratrol 
43.96 
(5.63) 
4.38 
(1.24) 
6.69 
(1.49) 
6.38 
(1.82) 
R 1.598 .212 
500 mg 
Resveratrol 
46.00 
(5.41) 
3.50 
(2.07) 
4.73 
(1.65) 
4.69 
(2.11) 
T 2.599 .084t 
 
 
 
Placebo 
 
42.31 
(5.19) 
8.65 
(1.45) 
7.96 
(1.67) 
10.27 
(1.89) 
T*R .772 .546 
 
 
Serial 17’s 
Errors 
250 mg 
Resveratrol 
4.77 
(.92) 
.38 
(.75) 
.23 
(.76) 
.96 
(.84) 
R .347 .708 
500 mg 
Resveratrol 
5.23 
(.52) 
.50 
(.68) 
.46 
(.64) 
-.35 
(.65) 
T .871 .425 
 
 
 
Placebo 
 
5.62 
(.73) 
-.54 
(.77) 
-1.15 
(.54) 
-.15 
(.61) 
T*R 1.244 .297 
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Appendix 2.0 The summary of the behavioural results of Chapter 4: the effects of 500 mg resveratrol and placebo on cognitive performance in both hypoxic and 
normoxic conditions. Table displays baseline and change from baseline scores (with SEM values in brackets) for the 3 post-dose battery repetitions after placebo and 500 mg 
resveratrol for 23 healthy, young adults. Table also displays ANOVA F and P values for main effects of treatment (T), oxygen status (OS) the interaction between the two 
(T*OS), repetition (T*R) all three (T*OS*R). *<.05, **<.01 and t= trend (nearing significance). 
 
 
Measure 
 
Treatment 
 Repetition ANOVA 
N Baseline 1 2 3 Effect F P 
 
3’s Correct 
(number) 
Placebo Hypoxia 
23 48.04 
(2.95) 
.09 
(1.15) 
.48 
(1.59) 
-2.13 
(1.84) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.858 
 
2.585 
 
1.431 
 
.029 
 
2.145 
.364 
 
.122 
 
.250 
 
.866 
 
.129 
Placebo Normoxia 
23 44.87 
(3.04) 
1.22 
(1.83) 
.35 
(1.50) 
1.43 
(1.96) 
Resveratrol 
Hypoxia 
23 45.78 
(2.52) 
-1.00 
(1.45) 
2.17 
(1.35) 
.22 
(1.54) 
Resveratrol 
Normoxia 
23 44.70 
(3.05) 
2.78 
(1.32) 
3.39 
(1.91) 
1.09 
(1.87) 
 
3’s Incorrect 
(number) 
Placebo Hypoxia 
23 1.09 
(.29) 
.91 
(.50) 
.96 
(.42) 
2.61 
(.73) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
4.813 
 
2.261 
 
.489 
 
.067 
 
3.321 
.039* 
 
.147 
 
.617 
 
.798 
 
.062t 
Placebo Normoxia 
23 1.65 
(.50) 
.22 
(.59) 
1.52 
(.59) 
1.35 
(.59) 
Resveratrol 
Hypoxia 
23 2.87 
(.42) 
-.26 
(.38) 
.48 
(.67) 
1.00 
(.62) 
Resveratrol 
Normoxia 
23 1.57 
(.47) 
-.91 
(.62) 
-1.00 
(.50) 
1.04 
(.65) 
 
7’s Correct 
(number) 
Placebo Hypoxia 
23 26.43 
(1.97) 
1.61 
(1.10) 
1.35 
(1.24) 
3.00 
(1.14) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.355 
 
.732 
 
2.284 
 
3.266 
 
1.526 
.257 
 
.401 
 
.114 
 
.084t 
 
.229 
Placebo Normoxia 
23 25.61 
(1.97) 
1.26 
(1.41) 
.22 
(1.42) 
1.17 
(1.44) 
Resveratrol 
Hypoxia 
23 26.04 
(1.97) 
.00 
(1.23) 
3.17 
(1.32) 
.87 
(1.84) 
Resveratrol 
Normoxia 
23 25.48 
(2.30) 
3.57 
(.93) 
3.65 
(1.04) 
4.57 
(1.01) 
 
7’s Incorrect 
Placebo Hypoxia 
23 2.17 
(.54) 
.43 
(.73) 
1.83 
(.47) 
.65 
(.63) 
T 
 
5.447 
 
.029* 
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(number) 
Placebo Normoxia 
23 2.39 
(.43) 
.04 
(.46) 
.52 
(.53) 
.78 
(.55) 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.773 
 
.933 
 
.066 
 
.940 
.389 
 
.401 
 
.799 
 
.398 
Resveratrol 
Hypoxia 
23 2.65 
(.66) 
-.17 
(.66) 
.00 
(.62) 
.04 
(.73) 
Resveratrol 
Normoxia 
23 2.91 
(.44) 
-.65 
(.45) 
-.17 
(.47) 
-.26 
(.42) 
 
 
RVIP % Correct 
Placebo Hypoxia 19 
55.92 
(5.71) 
5.92 
(2.89) 
-.99 
(4.44) 
4.93 
(3.96) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.231 
 
.001 
 
.593 
 
1.194 
 
.629 
.637 
 
.975 
 
.558 
 
.289 
 
.539 
Placebo Normoxia 
19 61.51 
(5.22) 
.33 
(3.22) 
1.97 
(3.38) 
-4.28 
(4.54) 
Resveratrol 
Hypoxia 
19 61.51 
(5.04) 
-.99 
(3.74) 
-1.32 
(4.16) 
-4.61 
(3.99) 
Resveratrol 
Normoxia 
19 60.53 
(6.48) 
3.29 
(4.26) 
4.28 
(4.51) 
-1.97 
(4.71) 
 
 
RVIP % Correct RT 
(msecs) 
Placebo Hypoxia 
19 494.77 
(10.66) 
3.36 
(10.42) 
-21.56 
(28.90) 
7.63 
(13.77) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.717 
 
.190 
 
2.867 
 
3.060 
 
.397 
.207 
 
.668 
 
.070t 
 
.097 
 
.675 
Placebo Normoxia 
19 485.10 
(8.63) 
18.69 
(14.04) 
13.78 
(13.50) 
24.32 
(11.15) 
Resveratrol 
Hypoxia 
19 484.92 
(11.30) 
-12.56 
(9.28) 
5.63 
(12.14) 
3.01 
(14.77) 
Resveratrol 
Normoxia 
19 511.03 
(11.87) 
-16.57 
(9.17) 
-4.50 
(12.79) 
-23.64 
(10.76) 
RVIP Incorrect 
(nmber) 
Placebo Hypoxia 19 .53 
(.18) 
-.26 
(.20) 
-.26 
(.17) 
-.05 
(.20) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.163 
 
1.138 
 
3.034 
 
.208 
 
.164 
.295 
 
.300 
 
.061t 
 
.654 
 
.775 
Placebo Normoxia 19 .47 
(.12) 
.00 
(.20) 
-.26 
(.19) 
.05 
(.21) 
Resveratrol 
Hypoxia 
19 .42 
(.16) 
-.11 
(.13) 
-.05 
(.16) 
-.16 
(.16) 
Resveratrol 
Normoxia 
19 .21 
(.10) 
.16 
(.12) 
.16 
(.12) 
.05 
(.12) 
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3 Back % Correct 
Placebo Hypoxia 21 
87.30 
(3.56) 
1.06 
(.85) 
-.32 
(1.48) 
.95 
(1.29) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.022 
 
.700 
 
1.227 
 
.616 
 
1.496 
.883 
 
.794 
 
.304 
 
.442 
 
.236 
Placebo Normoxia 
21 87.20 
(3.23) 
2.12 
(1.23) 
-.53 
(1.41) 
4.23 
(.93) 
Resveratrol 
Hypoxia 
21 87.09 
(3.30) 
1.48 
(1.25) 
.74 
(1.38) 
3.07 
(1.21) 
Resveratrol 
Normoxia 
21 88.57 
(3.33) 
.00 
(1.70) 
.95 
(1.71) 
1.90 
(1.20) 
 
3 Back Correct RT 
(msecs) 
Placebo Hypoxia 
21 766.24 
(58.72) 
-93.11 
(34.63) 
-62.84 
(35.33) 
-94.27 
(39.14) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.166 
 
.403 
 
.326 
 
.548 
 
1.297 
.293 
 
.533 
 
.724 
 
.468 
 
.285 
Placebo Normoxia 
21 764.52 
(63.22) 
-95.37 
(42.22) 
-128.20 
(43.69) 
-125.25 
(40.67) 
Resveratrol 
Hypoxia 
21 736.52 
(64.89) 
-69.54 
(30.02) 
-82.53 
(28.95) 
-75.59 
(39.06) 
Resveratrol 
Normoxia 
21 726.38 
(57.34) 
-55.59 
(25.36) 
-73.19 
(28.65) 
-88.32 
(30.18) 
 
Word Recognition % 
Correct 
Placebo Hypoxia 
22 84.09 
(2.10) 
-5.91 
(1.40) 
-2.27 
(2.18) 
-3.64 
(1.94) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.002 
 
3.078 
 
.303 
 
.037 
 
1.550 
.967 
 
.094 
 
.740 
 
.849 
 
.224 
Placebo Normoxia 
22 82.12 
(2.02) 
-1.36 
(2.25) 
-1.36 
(2.32) 
.30 
(2.71) 
Resveratrol 
Hypoxia 
22 81.97 
(1.69) 
-3.49 
(1.27) 
-3.64 
(2.38) 
-3.94 
(1.99) 
Resveratrol 
Normoxia 
22 82.57 
(1.83) 
-2.42 
(2.08) 
.30 
(2.14) 
-1.36 
(2.26) 
 
Word Recognition % 
Correct 
RT 
(msecs) 
Placebo Hypoxia 
22 798.45 
(52.87) 
-36.19 
(29.25) 
-22.97 
(34.66) 
-60.86 
(41.85) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.535 
 
1.291 
 
.406 
 
1.373 
 
.144 
.472 
 
.269 
 
.669 
 
.254 
 
.866 
Placebo Normoxia 
22 744.54 
(27.79) 
26.31 
(25.35) 
45.33 
(48.19) 
4.64 
(20.96) 
Resveratrol 
Hypoxia 
22 750.54 
(31.53) 
4.00 
(27.07) 
-22.45 
(24.60) 
-36.31 
(29.86) 
Resveratrol 
Normoxia 
22 772.73 
(47.55) 
-23.31 
(32.21) 
-12.34 
(38.39) 
-37.89 
(31.03) 
221 
 
 
Immediate Word 
Recall 
Placebo Hypoxia 
23 8.33 
(.39) 
-1.65 
(.48) 
-1.07 
(.43) 
-.174 
(.46) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.157 
 
.086 
 
.335 
 
.359 
 
1.758 
.696 
 
.772 
 
.717 
 
.555 
 
.184 
Placebo Normoxia 
23 7.67 
(.43) 
-.57 
(.43) 
-.50 
(.45) 
-.67 
(.41) 
Resveratrol 
Hypoxia 
23 8.33 
(.39) 
-.96 
(.37) 
-.94 
(.49) 
-.65 
(.41) 
Resveratrol 
Normoxia 
23 8.15 
(.46) 
-1.13 
(.54) 
-1.04 
(.50) 
-.67 
(.56) 
 
Delayed Word Recall 
Placebo Hypoxia 
23 6.43 
(.51) 
-2.35 
(.51) 
-2.59 
(.70) 
-1.76 
(.70) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.735 
 
.015 
 
1.864 
 
1.110 
 
.078 
.201 
 
.905 
 
.167 
 
.304 
 
.925 
Placebo Normoxia 
23 6.02 
(.50) 
-1.78 
(.43) 
-1.89 
(.53) 
-1.67 
(.57) 
Resveratrol 
Hypoxia 
23 5.63 
(.49) 
-1.07 
(.42) 
-1.20 
(.52) 
-1.41 
(.52) 
Resveratrol 
Normoxia 
23 
5.96 
(.52) 
-1.54 
(.58) 
-1.65 
(.54) 
-2.13 
(.51) 
 
 
 
 
 
 
 
 
 
222 
 
Appendix 2.1. The summary of the behavioural Z score analysis of Chapter 4: the effects of 500 mg resveratrol and placebo on overall cognitive domains in both 
hypoxic and normoxic conditions. Table displays change from baseline scores (with SEM values in brackets) for the 3 post-dose battery repetitions after placebo and 500 mg 
resveratrol for 19 healthy, young adults. Table also displays ANOVA F and P values for main effects of treatment (T), oxygen status (OS) the interaction between the two 
(T*OS), repetition (T*R) all three (T*OS*R). *<.05, **<.01 and t= trend (nearing significance). 
 
 
Measure 
 
Treatment 
 Repetition  ANOVA 
1 2 3 Effect F P 
 
 
 
 
Accuracy 
Placebo 
Hypoxia 
.092 
(.11) 
-.149 
(.14) 
-.010 
(.14) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.229 
 
2.163 
 
4.441 
 
.966 
 
1.148 
.638 
 
.159 
 
.019* 
 
.339 
 
.328 
Placebo 
Normoxia 
.028 
(.13) 
-.124 
(.12) 
.018 
(.11) 
Resveratrol 
Hypoxia 
-.206 
(.10) 
.012 
(.11) 
-.078 
(.13) 
Resveratrol 
Normoxia 
.155 
(.13) 
.174 
(.17) 
.087 
(.15) 
 
 
 
 
Speed 
Placebo 
Hypoxia 
-.055 
(.10) 
-.071 
(.22) 
-.103 
(.18) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.196 
 
.153 
 
.668 
 
1.474 
 
.699 
.663 
 
.701 
 
.226 
 
.240 
 
.511 
Placebo 
Normoxia 
.188 
(.16) 
.061 
(.16) 
.119 
(.11) 
Resveratrol 
Hypoxia 
.028 
(.09) 
.014 
(.10) 
.031 
(.15) 
Resveratrol 
Normoxia 
-.048 
(.13) 
.009 
(.14) 
-.173 
(.15) 
 
 
 
 
Error 
Placebo 
Hypoxia 
-.156 
(.14) 
.156 
(.11) 
.259 
(.19) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.461 
 
.043 
 
1.114 
 
.011 
 
.685 
.242 
 
.839 
 
.339 
 
.919 
 
.511 
Placebo 
Normoxia 
-.56 
(.15) 
.011 
(.15) 
.207 
(.18) 
Resveratrol 
Hypoxia 
-.151 
(.10) 
.023 
(.14) 
-.068 
(.10) 
Resveratrol 
Normoxia 
-.206 
(.11) 
-.112 
(.11) 
.092 
(.13) 
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Secondary 
Memory 
Placebo 
Hypoxia 
-.385 
(.14) 
-.259 
(.19) 
.044 
(.19) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.047 
 
3.637 
 
.530 
 
.489 
 
1.378 
.831 
 
.073t 
 
.593 
 
.493 
 
.265 
Placebo 
Normoxia 
.191 
(.16) 
.164 
(.18) 
.168 
(.19) 
Resveratrol 
Hypoxia 
-.046 
(.10) 
-.090 
(.17) 
-.40 
(.15) 
Resveratrol 
Normoxia 
.069 
(.19) 
.079 
(.18) 
.102 
(.17) 
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Appendix 3.0 The summary of the behavioural results of Chapter 5: the effects of 500 mg resveratrol and placebo on cognitive performance in both hypoxic and 
normoxic conditions. Table displays baseline and change from baseline scores (with SEM values in brackets) for the 3 post-dose battery repetitions after placebo and 500 mg 
resveratrol for 24 healthy, young adults. Table also displays ANOVA F and P values for main effects of treatment (T), oxygen status (OS) the interaction between the two 
(T*OS), repetition (T*R) all three (T*OS*R). *<.05, **<.01 and t= trend (nearing significance). 
 
 
Measure 
 
Treatment 
 Repetition ANOVA 
N Baseline 1 2 3 Effect F P 
 
3’s Correct 
(number) 
Placebo Hypoxia 24 
48.29 
(3.37) 
.92 
(1.34) 
-.58 
(1.11) 
1.08 
(1.40) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.603 
 
5.872 
 
2.344 
 
.628 
 
3.467 
.445 
 
.024* 
 
.107 
 
.436 
 
.040* 
Placebo Normoxia 24 
46.88 
(3.87) 
-.04 
(1.39) 
1.79 
(1.64) 
4.92 
(1.72) 
Resveratrol Hypoxia 24 
49.12 
(4.10) 
-1.58 
(1.26) 
-1.21 
(1.12) 
-.96 
(1.11) 
Resveratrol Normoxia 24 
48.25 
(3.76) 
2.38 
(1.23) 
2.79 
(1.16) 
2.04 
(1.30) 
 
3’s Incorrect 
(number) 
Placebo Hypoxia 24 
2.00 
(.48) 
.71 
(.54) 
.83 
(.45) 
1.04 
(.70) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.015 
 
11.797 
 
1.108 
 
.102 
 
.624 
.904 
 
 .002* 
 
.328 
 
.753 
 
.540 
Placebo Normoxia 24 
1.63 
(.31) 
.13 
(.48) 
-.21 
(.40) 
.00 
(.47) 
Resveratrol Hypoxia 24 
1.63 
(.39) 
.71 
(.41) 
1.00 
(.47) 
1.17 
(.42) 
Resveratrol Normoxia 24 
2.46 
(.45) 
-.83 
(.53) 
-.04 
(.44) 
.25 
(.52) 
 
7’s Correct 
(number) 
Placebo Hypoxia 24 
28.04 
(2.49) 
2.42 
(.70) 
3.21 
(.87) 
2.08 
(1.34) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.016 
 
.473 
 
.306 
 
.002 
 
.388 
.900 
 
.499 
 
.738 
 
.966 
 
.681 
Placebo Normoxia 24 
27.88 
(2.54) 
2.29 
(1.13) 
1.71 
(1.13) 
2.29 
(1.39) 
Resveratrol Hypoxia 24 
27.17 
(2.53) 
2.42 
(1.49) 
2.96 
(1.12) 
1.79 
(2.15) 
Resveratrol Normoxia 24 
29.08 
(3.00) 
1.58 
(.84) 
1.08 
(1.24) 
3.42 
(1.08) 
 
7’s Incorrect 
Placebo Hypoxia 24 
2.29 
(.45) 
-.08 
(.36) 
.29 
(.49) 
.17 
(.44) 
T 
 
.579 
 
.455 
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(number) 
Placebo Normoxia 24 
2.04 
(.38) 
.21 
(.58) 
-.04 
(.34) 
.54 
(.55) 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.109 
 
1.283 
 
.001 
 
2.240 
.745 
 
.279 
 
.973 
 
.137 
Resveratrol Hypoxia 24 
2.54 
(.48) 
-.33 
(.55) 
-.17 
(.58) 
2.04 
(1.85) 
Resveratrol Normoxia 24 
1.58 
(.36) 
.13 
(.51) 
1.38 
(.72) 
.50 
(.40) 
Choice Reaction 
Time % Correct 
Placebo Hypoxia 24 
96.46 
(1.01) 
-.10 
(.68) 
.83 
(.78) 
.42 
(.84) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.326 
 
1.424 
 
.861 
 
.309 
 
.342 
.573 
 
.245 
 
.429 
 
.583 
 
.712 
Placebo Normoxia 24 
96.46 
(.94) 
1.67 
(.76) 
1.67 
(.78) 
.42 
(.78) 
Resveratrol Hypoxia 24 
97.08 
(.65) 
-.31 
(.63) 
-.10 
(.57) 
.94 
(.69) 
Resveratrol Normoxia 24 
97.08 
(.76) 
.83 
(.36) 
.94 
(.49) 
.10 
(.65) 
Choice Reaction 
Time % Correct 
RT (msecs) 
Placebo Hypoxia 24 
428.05 
(17.22) 
-15.02 
(10.65) 
-13.44 
(8.68) 
-1.72 
(14.64) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
4.827 
 
.189 
 
.530 
 
.024 
 
1.581 
.038* 
 
.668 
 
.602 
 
.861 
 
.243 
Placebo Normoxia 24 
430.02 
(19.63) 
-14.80 
(15.29) 
.17 
(12.21) 
-1.56 
(9.51) 
Resveratrol Hypoxia 24 
409.23 
(12.44) 
9.51 
(6.57) 
11.06 
(6.91) 
9.77 
(7.10) 
Resveratrol Normoxia 24 
422.21 
(10.70) 
8.69 
(7.98) 
9.25 
(7.19) 
17.60 
(9.70) 
 
 
RVIP % Correct 
Placebo Hypoxia 23 
72.56 
(12.44) 
.82 
(3.30) 
-.82 
(3.13) 
-6.79 
(3.13) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.108 
 
4.221 
 
1.325 
 
.550 
 
.831 
.746 
 
.052t 
 
.276 
 
.466 
 
.442 
Placebo Normoxia 23 
72.28 
(3.85) 
1.09 
(2.74) 
-.54 
(3.31) 
1.63 
(3.95) 
Resveratrol Hypoxia 23 
78.26 
(2.99) 
-1.90 
(2.79) 
-5.98 
(3.32) 
-8.42 
(3.44) 
Resveratrol Normoxia 23 
70.38 
(3.67) 
6.52 
(2.68) 
-.27 
(2.41) 
1.63 
(2.92) 
 Placebo Hypoxia 23 463.38 14.44 33.34 3.68 
T 
 
1.079 
 
.310 
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RVIP Correct 
RT 
(msecs) 
(12.98) (7.07) (9.43) (9.15)  
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
 
.000 
 
2.781 
 
.109 
 
5.406 
 
.983 
 
.073t 
 
.745 
 
.016* 
Placebo Normoxia 23 
471.36 
(12.72) 
17.58 
(10.21) 
13.89 
(12.06) 
13.03 
(13.45) 
Resveratrol Hypoxia 23 
468.77 
(10.87) 
5.00 
(9.23) 
3.47 
(10.50) 
14.74 
(11.22) 
Resveratrol Normoxia 23 
469.85 
(11.49) 
1.03 
(8.61) 
13.69 
(11.35) 
14.17 
(12.17) 
RVIP Errors 
(number)  
Placebo Hypoxia 23 
1.48 
(.63) 
-.83 
(.55) 
-.52 
(.53) 
-.48 
(.59) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.150 
 
2.225 
 
.058 
 
1.720 
 
1.333 
.871 
 
.437 
 
.398 
 
.203 
 
.274 
Placebo Normoxia 23 
.87 
(.30) 
.39 
(.23) 
.17 
(.20) 
.35 
(.36) 
Resveratrol Hypoxia 23 
1.17 
(.31) 
-.30 
(.24) 
-.13 
(.22) 
.04 
(.24) 
Resveratrol Normoxia 23 
1.13 
(.28) 
-.30 
(.30) 
-.04 
(.29) 
-.04 
(.33) 
 
Stroop % 
Correct 
Placebo Hypoxia 24 
95.63 
(1.18) 
.73 
(.87) 
-.83 
(.98) 
.21 
(.91) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.242 
 
.424 
 
1.426 
 
1.314 
 
.210 
.627 
 
.521 
 
.251 
 
.263 
 
.728 
Placebo Normoxia 24 
95.10 
(1.11) 
1.23 
(.60) 
1.04 
(1.06) 
1.67 
(.70) 
Resveratrol Hypoxia 24 
95.52 
(.96) 
.21 
(.74) 
1.04 
(.58) 
.42 
(.72) 
Resveratrol Normoxia 24 
95.83 
(.87) 
-.63 
(1.58) 
.42 
(.73) 
.63 
(.63) 
 
Stroop % 
Correct 
RT 
(msecs) 
Placebo Hypoxia 24 
669.81 
(30.52) 
-25.41 
(12.06) 
-6.94 
(19.37) 
-44.97 
(14.19) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.732 
 
2.746 
 
.359 
 
.039 
 
3.090 
.401 
 
.111 
 
.654 
 
.845 
 
.055t 
Placebo Normoxia 24 
655.96 
(24.99) 
-23.98 
(14.40) 
-53.95 
(14.54) 
-45.69 
(19.37) 
Resveratrol Hypoxia 24 
640.32 
(20.58) 
5.15 
(9.94) 
-15.00 
(12.37) 
-28.04 
(9.54) 
Resveratrol Normoxia 24 
658.93 
(23.16) 
-20.74 
(19.71) 
-30.79 
(18.90) 
-48.60 
(18.55) 
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Word 
Recognition % 
Correct 
 
Placebo Hypoxia 24 
81.53 
(2.21) 
-4.72 
(2.30) 
-4.45 
(1.93) 
-2.22 
(1.60) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.758 
 
1.507 
 
1.127 
 
.113 
 
.806 
.393 
 
.323 
 
.333 
 
.740 
 
.453 
Placebo Normoxia 24 
81.94 
(2.07) 
-3.33 
(1.82) 
.69 
(2.07) 
-1.11 
(2.37) 
Resveratrol Hypoxia 24 
82.92 
(2.14) 
-1.53 
(1.76) 
-1.67 
(1.95) 
-2.36 
(1.78) 
Resveratrol Normoxia 24 
81.25 
(2.23) 
-.28 
(1.87) 
-.42 
(1.39) 
-.42 
(1.98) 
Word 
Recognition % 
Correct 
RT 
(msecs) 
Placebo Hypoxia 24 
832.57 
(43.30) 
68.03 
(26.16) 
-27.87 
(29.83) 
-18.88 
(38.47) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.223 
 
2.452 
 
.811 
 
.267 
 
.824 
.641 
 
.131 
 
.451 
 
.611 
 
.445 
Placebo Normoxia 24 
878.45 
(44.32) 
-40.41 
(37.20) 
-58.89 
(32.61) 
-71.43 
(32.14) 
Resveratrol Hypoxia 24 
831.21 
(42.02) 
38.46 
(44.03) 
-15.60 
(25.47) 
-4.61 
(28.89) 
Resveratrol Normoxia 24 
843.63 
(2.21) 
-19.93 
(20.63) 
-60.19 
(28.84) 
-23.41 
(27.63) 
 
 
Immediate 
Word Recall 
Correct 
(number) 
Placebo Hypoxia 24 
8.15 
(.52) 
-1.67 
(.44) 
-1.23 
(.57) 
-.42 
(.43) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.125 
 
2.776 
 
3.137 
 
1.757 
 
.389 
.727 
 
.109 
 
.053t 
 
.198 
 
.680 
Placebo Normoxia 24 
7.81 
(.39) 
-.48 
(.44) 
-.04 
(.36) 
.21 
(.45) 
Resveratrol Hypoxia 24 
8.19 
(.49) 
-.52 
(.57) 
-1.23 
(.44) 
-.78 
(.41) 
Resveratrol Normoxia 24 
8.21 
(.36) 
-.46 
(.33) 
-.46 
(.37) 
-.81 
(.28) 
Immediate 
Word Recall 
Incorrect 
(number) 
Placebo Hypoxia 24 
.29 
(.14) 
.00 
(.17) 
.17 
(.19) 
.13 
(.16) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.073 
 
.195 
 
.889 
 
1.061 
 
.177 
.789 
 
.663 
 
.418 
 
.314 
 
.838 
Placebo Normoxia 24 
.29 
(.11) 
-.21 
(.12) 
.08 
(.18) 
-.04 
(.13) 
Resveratrol Hypoxia 24 
.38 
(.17) 
.13 
(.14) 
-.08 
(.08) 
.08 
(.18) 
Resveratrol Normoxia 24 
.21 
(.11) 
-.21 
(.06) 
.13 
(.14) 
.17 
(.13) 
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Delayed Word 
Recall Correct 
(number) 
Placebo Hypoxia 24 
5.94 
(.09) 
-2.54 
(.48) 
-2.54 
(.61) 
-1.44 
(.60) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.106 
 
4.787 
 
1.946 
 
1.192 
 
1.946 
.748 
 
.039* 
 
.410 
 
.286 
 
.154 
Placebo Normoxia 24 
5.78 
(.45) 
-1.17 
(.42) 
-.65 
(.47) 
-.98 
(.54) 
Resveratrol Hypoxia 24 
6.06 
(.46) 
-1.21 
(.55) 
-2.75 
(.45) 
-2.02 
(.62) 
Resveratrol Normoxia 24 
6.17 
(.55) 
-1.56 
(.38) 
-1.23 
(.47) 
-1.40 
(.40) 
Delayed Word 
Recall Incorrect 
(number) 
Placebo Hypoxia 24 
.33 
(.12) 
.42 
(.22) 
.62 
(.24) 
.46 
(.21) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.874 
 
.008 
 
.850 
 
2.552 
 
.952 
.359 
 
.929 
 
.410 
 
.124 
 
.394 
Placebo Normoxia 24 
.50 
(.14) 
-.08 
(.24) 
.42 
(.31) 
.25 
(.30) 
Resveratrol Hypoxia 24 
.75 
(.23) 
-.29 
(.20) 
.13 
(.27) 
.21 
(.23) 
Resveratrol Normoxia 24 
.21 
(.09) 
.13 
(.09) 
.33 
(.17) 
.42 
(.16) 
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Appendix 3.1. The summary of the behavioural results of Chapter 5: the effects of 500 mg resveratrol and placebo on mood in both hypoxic and normoxic conditions. 
Table displays baseline and change from baseline scores (with SEM values in brackets) for the 3 post-dose battery repetitions after placebo and 500 mg resveratrol for 23 
healthy, young adults. Table also displays ANOVA F and P values for main effects of treatment (T), oxygen status (OS) the interaction between the two (T*OS), repetition 
(T*R) all three (T*OS*R). *<.05, **<.01 and t= trend (nearing significance). 
 
 
Measure 
 
Treatment 
 Repetition ANOVA 
N Baseline 1 2 3 Effect F P 
Difficulty 
 
Placebo Hypoxia 24 
39.83 
(4.41) 
3.96 
(2.37) 
9.63 
(2.68) 
8.54 
(3.17) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.031 
 
2.863 
 
.727 
 
1.796 
 
.762 
.862 
 
.104 
 
.539 
 
.193 
 
.483 
Placebo Normoxia 24 
36.88 
(3.52) 
4.71 
(2.56) 
2.67 
(3.40) 
9.79 
(3.57) 
Resveratrol Hypoxia 24 
35.46 
(3.24) 
9.54 
(3.46) 
12.50 
(3.98) 
13.62 
(3.64) 
Resveratrol Normoxia 24 
39.46 
(4.40) 
2.50 
(2.31) 
1.67 
(2.32) 
5.50 
(2.75) 
Mental Fatigue 
 
Placebo Hypoxia 24 
34.71 
(3.58) 
12.79 
(2.59) 
17.02 
(3.28) 
15.54 
(3.96) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.353 
 
25.326 
 
.422 
 
.008 
 
.288 
.904 
 
 <.001* 
 
.663 
 
.930 
 
.834 
Placebo Normoxia 24 
32.50 
(3.86) 
1.21 
(3.52) 
7.13 
(3.47) 
15.54 
(3.95) 
Resveratrol Hypoxia 24 
33.75 
(3.82) 
12.33 
(2.87) 
19.42 
(2.92) 
18.08 
(4.29) 
Resveratrol Normoxia 24 
40.17 
(4.10) 
2.04 
(2.16) 
6.37 
(3.32) 
9.00 
(3.91) 
 
Anxiety 
Placebo Hypoxia 24 
25.54 
(4.16) 
-2.12 
(1.62) 
-3.17 
(2.28) 
-5.00 
(2.81) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.240 
 
.084 
 
2.582 
 
.636 
 
1.564 
.277 
 
.775 
 
.060t 
 
.433 
 
.206 
Placebo Normoxia 24 
16.79 
(2.05) 
-1.79 
(2.13) 
-2.50 
(1.88) 
-2.13 
(1.91) 
Resveratrol Hypoxia 24 
24.21 
(3.38) 
5.33 
(3.05) 
1.75 
(3.22) 
.63 
(3.68) 
Resveratrol Normoxia 24 
22.08 
(3.23) 
-.54 
(1.23) 
1.63 
(3.71) 
-4.17 
(2.04) 
 
 
Placebo Hypoxia 24 
70.38 
(2.61) 
-4.67 
(3.17) 
-4.92 
(2.55) 
-5.58 
(3.32) 
T 
 
3.306 
 
.082t 
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Friendliness 
Placebo Normoxia 24 
69.38 
(3.08) 
-.42 
(2.04) 
-1.33 
(2.17) 
-1.54 
(3.35) 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
2.543 
 
.227 
 
.115 
 
.489 
.124 
 
.820 
 
.737 
 
.636 
Resveratrol Hypoxia 24 
67.25 
(3.06) 
.92 
(2.30) 
-.42 
(2.10) 
-4.13 
(3.65) 
Resveratrol Normoxia 24 
67.50 
(3.06) 
1.46 
(1.00) 
.75 
(1.67) 
1.87 
(1.74) 
Aggression 
Placebo Hypoxia 24 
16.63 
(3.14) 
1.33 
(1.55) 
2.46 
(3.08) 
4.00 
(3.82) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.273 
 
2.836 
 
1.237 
 
.544 
 
.854 
.606 
 
.106 
 
.300 
 
.468 
 
.429 
Placebo Normoxia 24 
12.54 
(1.88) 
.83 
(1.37) 
2.63 
(2.96) 
.04 
(1.87) 
Resveratrol Hypoxia 24 
17.29 
(2.48) 
2.50 
(1.55) 
4.92 
(1.77) 
.42 
(2.06) 
Resveratrol Normoxia 24 
17.00 
(2.71) 
-.12 
(1.43) 
-.58 
(1.70) 
-1.67 
(2.29) 
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Appendix 3.2. The summary of the behavioural Z score analysis of Chapter 5: the effects of 500 mg resveratrol and placebo on overall cognitive domains in both 
hypoxic and normoxic conditions. Table displays change from baseline scores (with SEM values in brackets) for the 3 post-dose battery repetitions after placebo and 500 mg 
resveratrol for 23 healthy, young adults. Table also displays ANOVA F and P values for main effects of treatment (T), oxygen status (OS) the interaction between the two 
(T*OS), repetition (T*R) all three (T*OS*R). *<.05, **<.01 and t= trend (nearing significance). 
 
 
 
Measure 
 
Treatment 
 ANOVA 
1 2 3 Effect F P 
 
 
 
 
Accuracy 
Placebo 
Hypoxia 
-.004 
(.07) 
-.061 
(.08) 
-.107 
(.10) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.451 
 
7.324 
 
.40 
 
.063 
 
.624 
.241 
 
.013* 
 
.961 
 
.958 
 
.540 
Placebo 
Normoxia 
.100 
(.10) 
.114 
(.10) 
.203 
(.10) 
Resveratrol 
Hypoxia 
-.146 
(.07) 
-.122 
(.08) 
-.162 
 (.10) 
Resveratrol 
Normoxia 
.072 
(.19) 
.04 
(.08) 
.073 
(.09) 
 
 
 
 
Speed 
Placebo 
Hypoxia 
-.101 
(.12) 
.145 
(.14) 
-.169 
(.15) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
1.511 
 
.278 
 
1.035 
 
.008 
 
2.498 
.232 
 
.604 
 
.364 
 
.931 
 
.094 
Placebo 
Normoxia 
-.063 
(.17) 
-.103 
(1.16) 
-.107 
(.13) 
Resveratrol 
Hypoxia 
.150 
(.14) 
.061 
(.11) 
.087 
(.10) 
Resveratrol 
Normoxia 
.020 
(.12) 
.050 
(.14) 
.029 
(.16) 
 
 
 
 
Error 
Placebo 
Hypoxia 
-.147 
(.14) 
-.063 
(.14) 
.005 
(.15) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.462 
 
.103 
 
2.752 
 
.823 
 
1.327 
.504 
 
.752 
 
.075t 
 
.374 
 
.276 
Placebo 
Normoxia 
.053 
(.08) 
-.073 
(.08) 
.049 
(.11) 
Resveratrol 
Hypoxia 
-.056 
(.01) 
.021 
(.11) 
.318 
(.20) 
Resveratrol 
Normoxia 
-.197 
(.11) 
.072 
(.10) 
 
.018 
(.12) 
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Secondary 
Memory 
Placebo 
Hypoxia 
-.329 
(.18) 
-.346 
(.21) 
.011 
(.18) 
T 
 
OS 
 
T*R 
 
T*OS 
 
T*OS*R 
.147 
 
3.829 
 
1.954 
 
1.320 
 
.756 
.705 
 
.063t 
 
.154 
 
.263 
 
.476 
Placebo 
Normoxia 
.031 
(.15) 
.295 
(.16) 
.198 
(.19) 
Resveratrol 
Hypoxia 
.102 
(.18) 
-.190 
(.14) 
-.073 
(.17) 
Resveratrol 
Normoxia 
.122 
(.13) 
.115 
(.14) 
.065 
(.13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
233 
 
Appendix 4.0 The summary of the behavioural results of Chapter 6: the effects of 500 mg resveratrol and placebo on cognitive performance. Table displays baseline 
and change from baseline scores (with SEM values in brackets) for the three post-dose battery repetitions after placebo and 500 mg resveratrol for 24 healthy, older adults. 
Table also displays ANOVA F and P values for main effects of treatment (T) and repetition (R) and an interaction between the two (T*R) with *<.05, **<.01 and t= trend 
(nearing significance). 
 
 
Measure 
 
Treatment 
 Task Battery ANOVA 
N Baseline 1 2 3 Effect F P 
3’s Correct 
(number) 
 
Placebo 24 
27.25 
(2.41) 
.92 
(1.04) 
.58 
(1.06) 
1.83 
(1.24) 
R 
 
T 
 
T*R 
3.256 
 
.023 
 
.475 
.048* 
 
.880 
 
.625 Resveratrol 24 
27.25 
(2.08) 
.17 
(1.30) 
.00 
(1.21) 
2.58 
(1.13) 
3’s Incorrect 
(number) 
Placebo 24 
1.50 
(.40) 
.25 
(.71) 
1.00 
(.38) 
.17 
(.39) 
R 
 
T 
 
T*R 
2.322 
 
.490 
 
.691 
.110 
 
.491 
 
.506 Resveratrol 24 
1.25 
(.23) 
.25 
(.79) 
1.13 
(.48) 
.83 
(.47) 
 
7’s Correct 
(number) 
 
Placebo 23 
19.17 
(1.53) 
-.46 
(.71) 
.33 
(1.01) 
1.08 
(.93) 
R 
 
T 
 
T*R 
5.446 
 
.006 
 
.379 
.008** 
 
.939 
 
.687 Resveratrol 23 
19.38 
(1.57) 
-.79 
(.93) 
.92 
(.88) 
1.13 
(.94) 
7’s Incorrect 
(number) 
Placebo 23 
1.67 
(.38) 
.04 
(.48) 
.71 
(.46) 
.04 
(.48) 
R 
 
T 
 
T*R 
.333 
 
.972 
 
1.593 
.718 
 
.334 
 
.214 Resveratrol 23 
1.38 
(.32) 
1.08 
(.56) 
.75 
(.42) 
.92 
(.52) 
CRT % Correct 
 
Placebo 24 
97.71 
(.60) 
.52 
(.54) 
1.15 
(.48) 
.94 
(.58) 
R 
 
T 
 
T*R 
1.144 
 
1.261 
 
.153 
.318 
 
.273 
 
.858 Resveratrol 24 
96.97 
(.89) 
1.46 
(.90) 
1.88 
(.76) 
1.98 
(.92) 
CRT % Correct 
RT (msecs) 
Placebo 24 
507.56 
(20.97) 
-12.40 
(16.64) 
-2.16 
(16.32) 
-17.80 
(14.95) 
R 
 
T 
 
T*R 
2.464 
 
2.474 
 
1.527 
.114 
 
.129 
 
.232 Resveratrol  24 
484.95 
(18.24) 
34.70 
(18.47) 
13.22 
(16.18) 
-4.33 
(11.91) 
RVIP % Correct Placebo 24 
56.77 
(5.16) 
.52 
(2.68) 
6.51 
(2.42) 
8.33 
(2.37) 
R 
 
1.579 
 
.217 
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Resveratrol 24 
63.28 
(5.00) 
-2.86 
(3.19) 
-6.77 
(3.49) 
-2.60 
(2.98) 
T 
 
T*R 
9.514 
 
3.026 
.005** 
 
.058t 
RVIP Correct 
RT 
(msecs) 
Placebo 24 
529.73 
(14.81) 
-28.32 
(23.46) 
-5.73 
(10.40) 
-8.55 
(10.67) 
R 
 
T 
 
T*R 
.026 
 
6.991 
 
1.352 
.935 
 
.015* 
 
.265 Resveratrol 24 
494.05 
(14.72) 
38.72 
(13.69) 
20.59 
(9.59) 
19.23 
(12.42) 
RVIP Errors 
(numbers) 
Placebo 24 
2.08 
(.35) 
.46 
(.56) 
.04 
(.42) 
.08 
(.41) 
R 
 
T 
 
T*R 
.893 
 
.001 
 
.615 
.416 
 
.978 
 
.545 Resveratrol 24 
1.85 
(.47) 
.33 
(.52) 
.33 
(.45) 
-.04 
(.32) 
Stroop % 
Correct 
Placebo 23 
97.72 
(.77) 
.22 
(.86) 
-.22 
(.72) 
-.76 
(1.18) 
R 
 
T 
 
T*R 
.866 
 
.660 
 
.389 
.374 
 
.425 
 
.613 Resveratrol 23 
97.39 
(.68) 
.44 
(.58) 
.87 
(.88) 
-.33 
(1.56) 
Stroop % 
Correct 
RT 
(msecs) 
Placebo 23 
921.34 
(40.53) 
-31.60 
(21.30) 
-60.56 
(24.58) 
-81.33 
(26.26) 
R 
 
T 
 
T*R 
4.180 
 
.161 
 
.201 
.035* 
 
.692 
 
.773 Resveratrol 23 
906.61 
(47.66) 
-28.33 
(26.85) 
-52.61 
(23.64) 
-57.11 
(28.07) 
Word 
Recognition % 
Correct 
Placebo 23 
82.03 
(1.78) 
-5.07 
(2.24) 
-4.93 
(2.00) 
-6.09 
(2.10) 
R 
 
T 
 
T*R 
.556 
 
.077 
 
.710 
.577 
 
.784 
 
.497 Resveratrol 23 
82.03 
(1.63) 
-7.68 
(1.89) 
-4.64 
(1.55) 
-5.65 
(1.81) 
Word 
Recognition RT 
% Correct 
Placebo 23 
993.61 
(68.21) 
37.74 
(37.60) 
33.08 
(50.14) 
-33.26 
(44.91) 
R 
 
T 
 
T*R 
4.541 
 
.390 
 
.482 
.016* 
 
.539 
 
.621 Resveratrol 23 
1008.01 
(56.75) 
22.90 
(40.98) 
-13.74 
(45.78) 
-38.29 
(40.32) 
Immediate 
Word Recall 
Correct 
(number) 
Placebo 24 
6.58 
(.53) 
-1.17 
(.50) 
-.67 
(.43) 
-.44 
(.46) 
R 
 
T 
 
T*R 
1.370 
 
3.397 
 
.528 
.264 
 
.078t 
 
.593 Resveratrol 24 
7.25 
(.45) 
-1.63 
(.44) 
-1.77 
(.35) 
-1.38 
(.50) 
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Immediate 
Word Recall 
Incorrect 
(number) 
Placebo 24 
.58 
(.18) 
.17 
(.28) 
.29 
(.18) 
.21 
(.22) 
R 
 
T 
 
T*R 
.853 
 
3.235 
 
1.304 
.408 
 
.085t 
 
.278 Resveratrol 24 
.33 
(.13) 
.46 
(.29) 
.58 
(.19) 
.96 
(.24) 
Delayed Word 
Recall Correct 
(number) 
Placebo 24 
4.92 
(.55) 
-2.13 
(.44) 
-2.79 
(.50) 
-2.21 
(.52) 
R 
 
T 
 
T*R 
.968 
 
1.492 
 
.376 
.388 
 
.234 
 
.688 Resveratrol 24 
5.60 
(.53) 
-2.81 
(.42) 
-3.04 
(.46) 
-2.85 
(.53) 
Delayed Word 
Recall Incorrect 
(number) 
Placebo 24 
.71 
(.19) 
.87 
(.26) 
2.12 
(.41) 
1.17 
(.37) 
R 
 
T 
 
T*R 
8.021 
 
1.965 
 
2.034 
.001** 
 
.174 
 
.142 Resveratrol 24 
.88 
(.20) 
.46 
(.32) 
1.08 
(.36) 
1.29 
(.48) 
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Appendix 4.1 Summary of the behavioural analysis comparing the younger and the ageing cohort on 
cognitive task performance.  Table displays the average baseline scores for each task outcome from visit 1 (with 
SEM values in brackets) for the 24 healthy, young (18-35 years old) adults of Chapter 5 and the 24 healthy, ageing 
(50-70 years old) adults of Chapter 6. Table also displays t-test T and P values. *<.05, **<.01 and t= trend (nearing 
significance). 
 
   
Measure 
 
Cohort 
Analysis                                       
N Mean (SE) T P 
 
Serial 3 
Correct 
18-35 years 24 41.17 
(3.38) 
 
5.093 
 
>.001** 
50-70 years 24 23.83 
(2.15) 
 
Serial 3 Error 
18-35 years 24 2.21 
(.36) 
 
.385 
 
.702 
50-70 years 24 2.00 
(.41) 
 
Serial 7 
Correct 
18-35 years 24 24.17 
(2.45) 
 
2.086 
 
.044* 
50-70 years 24 18.04 
(1.56) 
 
Serial 7 Error 
18-35 years 24 2.17 
(.20) 
 
.579 
 
.565 
50-70 years 24 1.83 
(1.95) 
CRT 
Correct % 
18-35 years 24 97.60 
(2.90) 
 
.515 
 
.609 
50-70 years 24 97.08 
(4.02) 
CRT Correct 
RT 
18-35 years 24 441.47 
(104.03) 
 
2.102 
 
.041* 
50-70 years 24 501.57 
(93.82) 
RVIP 
Correct % 
18-35 years 24 68.75 
(25.93) 
 
1.364 
 
.179 
50-70 years 24 58.85 
(24.30) 
RVIP Correct 
RT 
18-35 years 24 448.58 
(114.08) 
 
2.047 
 
.046* 
50-70 years 24 504.67 
(70.78) 
RVIP errors 18-35 years 24 2.08 
(3.32) 
 
.771 
 
.445 
50-70 years 24 1.50 
(1.64) 
Stroop 
Correct % 
18-35 years 24 95.83 
(4.87) 
 
.234 
 
.816 
50-70 years 24 95.31 
(9.76) 
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Stroop 
Correct RT 
18-35 years 24 702.65 
(143.02) 
 
4.872 
 
>.001** 
50-70 years 24 962.93 
(219.21) 
Word 
Recognition 
Correct % 
18-35 years 24 81.11 
(10.80) 
 
.554 
 
.582 
50-70 years 24 82.64 
(8.10) 
Word 
Recognition 
Correct RT 
18-35 years 24 865.06 
(212.59) 
 
1.808 
 
.077T 
50-70 years 24 993.08 
(274.14) 
Imm word 
recall correct 
18-35 years 24 7.73 
(.44) 
 
.849 
 
.400 
50-70 years 24 7.17 
(.49) 
Imm word 
recall errors 
18-35 years 24 .25 
(.11) 
 
.731 
 
.468 
50-70 years 24 .38 
(.13) 
Delayed word 
recall correct 
18-35 years 24 5.63 
(.50) 
 
.417 
 
.678 
50-70 years 24 5.92 
(.49) 
Delayed word 
recall errors 
18-35 years 24 .54 
(.13) 
 
.8459 
 
.395 
50-70 years 24 .75 
(.20) 
 
 
